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Abstract 
Intercellular adherens junction (AJ) and tight junction (TJ) proteins (e.g. VE-Cadherin, 
occludin, ZO-1, claudin-5) jointly consolidate the apical surface of adjacent brain 
microvascular endothelial cells (BBMvEC’s) creating the blood-brain barrier (BBB), a 
critical regulator of CNS homeostasis. Junctional disassembly and barrier dysfunction 
are established features of cerebrovascular diseases (e.g. stroke) manifesting 
compromised blood flow, allowing us to hypothesize a pivotal regulatory link between 
BBB phenotype and flow-associated shear stress. In this regard, our research has 
demonstrated that exposure of BBMvEC’s to physiological levels of shear stress in vitro 
can upregulate tight junction protein expression and enhance protein 
immunolocalization at the cell-cell border, in parallel with reduced paracellular solute 
flux.  
For these studies, cultured bovine brain microvascular endothelial cells (BBMvEC’s) 
were exposed to laminar shear stress (0-10 dynes/cm2, 0-24 h) in conjunction with 
targeted inhibition strategies to delineate the intracellular signaling pathways mediating 
adaptation of BBB phenotype to fluid shear stress. 
Initial findings showed that shear-dependent reduction in BBMvEC permeability was 
initially observed after 3-6 h of shear onset (10 dynes/cm2), with more significant 
decreases observed after 12 and 24 h. These responses were temporally mirrored by 
BBMvEC morphological realignment, and were reversed by flow reduction (i.e. to 1 
dynes/cm2, 24 h), the latter flow reduction also attenuated the enhanced cell-cell border 
localization of ZO-1 and reduction in phosphotyrosine (pTyr)-occludin levels induced 
by high shear. 
Furthermore, our studies show that Rac1 activation - possibly by triggering a significant 
reduction in pTyr-occludin levels - is essential to the shear-induced upregulation of BBB 
phenotype. Consistent with the critical nature of pTyr-occludin level, a tyrosine 
phosphatase inhibitor (dephostatin) was found to block shear-induced BBB 
upregulation. In subsequent experiments, the use of molecular strategies to functionally 
block either VE-Cadherin (VE-Cad ∆EXD) or Tiam1 (Tiam-C580), the latter a Rho 
guanine nucleotide exchange factor mediating Rac1 activation, attenuated shear-induced 
BBB upregulation and the associated reduction in pTyr-occludin levels, concomitant 
with a loss of cell-cell border localization of ZO-1 and claudin-5. We also observed that 
RhoA is crucial to the shear-induced regulation of BBB phenotype during the initial 
shear-onset phase, however Rac1 activity is more prominent with regards to maintaining 
shear-induced barrier enhancement in the chronic shear phase.  
In conclusion, the adaptation of BBB phenotype to fluid shear stress is mediated through 
a VE-Cadherin/Tiam1/Rac1 signaling pathway. Collectively, these data confirm the 
existence of a highly novel functional “cross-talk” mechanism between adherens and 
tight junctions. 
 
V 
 
Abbreviations 
ADP Adenosine Diphosphate 
AET Active Efflux Transporter 
AF-6 All-1 fusion partner from chromosome 6 
APTS 8-Aminopyrene-1,3,6-trisulfonic acid trisodium salt 
ARP Actin Related Protein 
ATP Adenosine Triphosphate 
BAEC Bovine Aortic Endothelial Cell 
BBB Blood Brain Barrier 
BBMvEC Bovine Brain Microvascular Endothelial Cell 
bFGF basic Fibroblast Growth Factor 
BSA Bovine Serum Albumin 
cAMP cyclic Adenosine Monophosphate 
CD5 Cadherin-5 
cGMP cyclic Guanosine Monophosphate  
CNS Central Nervous System 
CSF Cerebrospinal Fluid 
CVD Cardiovascular Disease 
DAPI 4',6-diamidino-2-phenylindole  
DEP-1 Density Enhanced-Phosphatase-1 
DH Dbl-Homology 
DMEM Dulbecco’s Modified Eagle Medium 
DMSO Dimethyl Sulfoxide 
DNA Deoxyribonucleic Acid 
EC Endothelial Cell 
EC Extracellular 
ECL Extracellular Loop 
ECM Extracellular Matrix 
EDD Endothelium Dependent Dilation 
EDHF Endothelium Derived Hyperpolarizing Factor 
EDTA Ethylenediaminetetraacetic acid 
VI 
 
E-face Exo-cytoplasmic-face 
EG Endothelial Glycocalyx 
eGFP enhanced Green Fluorescent Protein 
eNOS endothelial Nitric Oxide Synthase 
ERK Extracellular Signal-Regulated Kinase 
ET-1 Endothelin-1 
FACS Fluorescent Activating Cell Sorting 
F-actin Filamentous Actin 
FAK Focal Adhesion Kinase 
FBS Foetal Bovine Serum 
FITC Fluorescein Isothiocyanate 
FRET Fluorescence Resonance Energy Transfer 
GAPDH Glyceraldehyde 3-Phosphate Dehydrogenase 
GDP Guanosine Diphosphate 
GPCR G-Protein Coupled Receptor 
GTP Guanosine Triphosphate 
GUK Guanylate Kinase 
HBMvEC Human Brain Microvascular Endothelial Cell 
HGF Hepatocyte Growth Factor 
HIV Human Immunodeficiency Virus 
HRP Horse Radish Peroxidase 
HUVEC Human Umbilical Vein Endothelial Cell 
IB Immunoblot 
ICAM Intracellular Adhesion Molecule 
IFNγ Interferon Gamma 
IgG Immunoglobulin G 
IL Interleukin 
IP  Immunoprecipitation 
IPTG iso-propyl-β-D-thiolgalactoside  
IQGAP IQ motif containing GTPase-activating protein 1 
JAM Junctional Adhesion Molecule 
VII 
 
LB Luria-Burtani 
LDL Low-Density Lipoprotein 
LPS Lipopolysaccharide 
LSS Laminar Shear Stress 
mAb Monoclonal Antibody 
MAGUK Membrane Associated Guanylate Kinase  
MAPK Mitogen-Activated Protein Kinase 
MDCK Madin Darby Canine Kidney 
MI Myocardial Infarction 
MLC Myosin Light Chain 
MLCK Myosin Light Chain Kinase 
MMP Matrix Metalloproteinases 
mRNA messenger Ribonucleic Acid 
MS Multiple Sclerosis 
NO  Nitric Oxide 
NVU Neurovascular Unit 
PAK p21-activated Kinase 
PBS Phosphate Buffered Saline 
PDGF Platelet Derived Growth Factor 
PECAM-1 Platelet Endothelial Cell Adhesion Molecule-1 
P-face Protoplasmic-face 
P-gp P-glycoprotein 
PH Pleckstrin Homology 
PI  Propidium Iodide 
PI3K Phosphoinisotide 3-OH-Kinsae 
PKA Protein Kinase A 
PKC Protein Kinase C 
PTK Protein Tyrosine Kinase 
PTP  Protein Tyrosine Phosphatase   
PTPµ Protein Tyrosine Phosphatase Receptor type M 
pTyr Phosphotyrosine 
VIII 
 
RhoGAP RhoGTPase Activating Protein 
RhoGDI Rho Guanine Dissociation Inhibitors 
RhoGEF Rho Guanine Nucleotide Exchange Factor 
ROCK Rho-associated Kinase 
ROS  Reactive Oxygen Species 
RTK Receptor Tyrosine Kinase 
S1P Sphingosine-1 Phosphate 
SDS Sodium doecyl sulphate 
SDS PAGE SDS Polyacrylamide gel electrophoresis 
SEM Standard Error of the Mean 
SH2 Src Homology 2 
SH3 Src-homology 3 
SHP2 SH2 containing Phosphotyrosine Phosphatase 
SSB Sample Solubilization Buffer 
SSRE Shear Stress Response Element 
TBS Tris Buffered Saline 
TEE  Transendothelial Exchange 
TEER Transendothelial Electrical Resistance 
TNFα Tumour Necrosis Factor Alpha 
VCAM Vascular Adhesion Molecule 
VE-Cadherin Vascular Endothelial Cadherin 
VEGF  Vascular Endothelial Growth Factor 
VEGFR2 Vascular Endothelial Growth Factor Receptor 2 
VE-PTP Vascular Endothelial Protein Tyrosine Phosphatase 
VM Vasculogenic Mimicry 
VSMC Vascular Smooth Muscle Cell 
WASP Wiskott-Aldrich Syndrome Protein 
WAVE WASP Verpolin Homologous 
ZO-1 Zonula Occludens-1 
  
IX 
 
Units 
cm2 Centimeter Squared 
° Degree Celsius 
U Enzyme Units 
g Grams 
g/mol Grams Per Mole 
h Hours 
kDa Kilo Daltons 
kb Kilobase 
L Liter 
µg Microgram 
µl Microlitre 
µm Micrometre 
mA Milliamps 
mg Milligrams 
ml Millilitre 
mm2 Millimetre Squared 
mM Millimolar 
ms Millisecond 
min Minutes 
M Molar 
ng Nanogram 
nm Nanometre 
OD Optical Density 
rpm Revolution Per Minute 
sec Seconds 
V  Volts 
v/v Volume Per Volume 
w/w Weight Per Volume 
 
X 
 
Publications 
Walsh T.G, Fitzpatrick P, Murphy A, Murphy RP, Cummins PM. Stabilization of brain 
microvascular endothelial barrier function by shear stress: Roles for VE-cadherin, 
Tiam1 and Rac1 signaling in the regulation of tight junction phenotype. J Cell Sci 2010; 
[Submitted]. 
Lieggi NT, Walsh T.G, Colgan OC, Murphy RP, Cahill PA, Cummins PM. Cyclic 
Strain-Induced Barrier Enhancement in Vascular Endothelial Cells Involves Activation 
of Gα-subunit, p38 MAPK, and Rac1 Signalling Mechanisms. Am J Physiol Heart Circ 
Physiol 2010; [In Revision]. 
Fitzpatrick P, Britto M, Walsh T.G, Meade G, Cummins PM, Murphy RP. LASP-1 is 
an important regulator in the molecular complex controlling cell-cell and cell-matrix 
adhesion in the vasculature. J Cell Biol 2010; [In Preparation]. 
Fitzpatrick PA, Guinan AF, Walsh T.G, Murphy RP, Killeen MT, Tobin NP, Pierotti 
AR, Cummins PM. Down-regulation of neprilysin expression in vascular endothelial 
cells by laminar shear stress involves NADPH oxidase-dependent ROS production. Int J 
Biochem Cell Biol 2009;41:2287-2294. 
XI 
 
Presentations 
Walsh T.G, Guinan A.F, Rochfort K.D, Cummins P.M: Stabilization of brain 
microvascular endothelial barrier function by shear stress involves a signaling pathway 
linking adherens and tight junctions via Rac1. University Hospital Zurich, 13th 
International Symposium of the Blood Brain Barrier 2010; Zurich, Switzerland, 
[Abstract/Oral]   
Walsh T.G. Regulation of blood-brain barrier function by shear stress: Hemodynamic 
regulation of Blood Brain Barrier Phenotype: A Cooperative Effort Linking Adherens 
and Tight Junction Complexes. School of Biotechnology: Research Day 2010, Dublin 
City University. [Abstract/Poster] 
Walsh T.G, Fitzpatrick P, Murphy RP, Cummins PM. Roles for VE-Cadherin, Rac1, 
and occludin signalling in the regulation of brain microvascular endothelial permeability 
by blood flow-associated shear stress. University College London Symposium: 
Signalling in the blood-brain and blood-retinal barrier 2009; London, England. 
[Abstract/Poster] 
Walsh T.G. Regulation of blood-brain barrier function by shear stress: Role of Rac1-
GTPase in tight junction assembly and function. School of Biotechnology: Research Day 
2009, Dublin City University. [Abstract/Oral] 
Walsh T.G, Fitzpatrick P, Murphy RP, Cummins PM. Regulation of blood brain barrier 
function by shear stress: role of Rho-GTPases in tight junction assembly and function. 
North American Vascular Biology Organization (NAVBO) Workshop: Biology of 
Signaling in the Cardiovascular System 2008; Hyannis MA, USA. [Abstract/Poster]* 
Fitzpatrick P, Britto M, Walsh T.G, Meade G, Cummins PM, Murphy RP. Cytoskeletal 
re-organization by mechano-transduced LASP-1 regulates cell-matrix and cell-cell 
adhesion through activation of Rac1. North American Vascular Biology Organization 
(NAVBO) Workshop: Biology of Signaling in the Cardiovascular System 2008; Hyannis 
MA, USA. [Abstract/Poster] 
* NAVBO trainee award for best postgraduate abstract.   
XII 
 
List of Figures 
Chapter 1 
Fig 1.1: Human blood vessel.  
Fig. 1.2: Atherosclerotic plaque progression. 
Fig. 1.3: Shear stress and cyclic strain. 
Fig. 1.4: Endothelial mechanosensors.  
Fig. 1.5: Physiological laminar shear vs. disturbed shear. 
Fig. 1.6: Pathways at the blood brain barrier. 
Fig. 1.7: The Neurovascular Unit at the blood brain barrier.  
Fig. 1.8: Tight Proteins of the blood brain barrier. 
Fig. 1.9: Schematic depiction of occludin structure and domains. 
Fig. 1.10: Structure and binding partners of ZO-1. 
Fig. 1.11: Schematic depiction of claudin structure. 
Fig. 1.12: Endothelial adherens junction. 
Fig. 1.13: Schematic of RhoGTPases. 
Fig. 1.14: Regulation of barrier function by Rho and Rac. 
Fig. 1.15: Schematic structure of Tiam1. 
Fig. 1.16: RhoGTPase regulation by RhoGEF’s, RhoGDI’s and RhoGAP’s. 
Fig. 1.17: Schematic depiction of experimental approach. 
Chapter 2 
Fig. 2.1: The Haemocytometer  
Fig. 2.2: ADAM counter microfluidic chip for viable cell counting.  
Fig. 2.3: Orbital Rotation model used in laminar shear stress studies. 
Fig. 2.4: IBIDI flow system for laminar shear studies. 
Fig. 2.5: Transendothelial permeability assay. 
Fig. 2.6: Amaxa nucleofection system. 
Fig. 2.7: Microporation System. 
Fig. 2.8: Wet transfer cassette assembly. 
Fig. 2.9: G-LISA principle. 
XIII 
 
 
Chapter 3 
Fig. 3.1: Characterization of BBMvEC’s. 
Fig. 3.2: Effect of laminar shear stress on BBMvEC and F-actin re-alignment. 
Fig. 3.3: Magnitude-dependent effects of shear stress on BBMvEC permeability and 
morphological realignment. 
Fig. 3.4: Time dependent effects of shear stress on BBMvEC permeability and 
morphological realignment. 
Fig. 3.5: Effect of laminar shear stress on ZO-1 and Claudin-5 localization. 
Fig. 3.6: Effect of laminar shear stress on occludin tyrosine phosphorylation. 
Fig. 3.7: Effect of dephostatin on laminar shear-induced BBMvEC barrier enhancement. 
Fig. 3.8: Effect of flow reduction on the barrier properties of shear-preconditioned 
BBMvEC’s. 
Fig. 3.9: Effect of shear stress on BBMvEC permeability using the “paracellular” 
marker, APTS-dextran. 
Chapter 4 
Fig. 4.1: Assessment of plasmid DNA transfection viability and efficiency via Amaxa 
nucleofection and microporation. 
Fig. 4.2: Effect of laminar shear stress on Rac1 activation. 
Fig. 4.3: Effect of Rac1 inhibition on laminar shear-induced BBMvEC morphological 
and F-actin realignment. 
Fig. 4.4: Effect of Rac1 blockade on laminar shear-induced regulation of BBMvEC 
permeability. 
Fig. 4.5: Effect of Rac1 blockade on laminar shear-induced localization of ZO-1. 
Fig. 4.6: Effect of Rac1 inhibition on laminar shear stress-induced occludin tyrosine 
dephosphorylation. 
Fig. 4.7: Effect of laminar shear stress on RhoA activation. 
Fig. 4.8: Effect ROCK inhibition on shear-induced BBMvEC morphological and F-actin 
realignment. 
XIV 
 
Fig. 4.9: Effect of ROCK inhibition on shear-induced regulation of BBMvEC 
permeability. 
Fig 4.10: Effect of Rho-associated kinase inhibition (ROCK) on shear-induced 
regulation of ZO-1 localization. 
Chapter 5 
Fig. 5.1: Illustration and overexpression of VE-Cad ∆EXD (VE-Cadherin Extracellular 
Domain Deletion) in BBMvEC’s. 
Fig. 5.2: Effect of VE-Cadherin inhibition on laminar shear induced-Rac1 activation. 
Fig. 5.3: Effect of VE-Cadherin inhibition on laminar shear-induced regulation of 
BBMvEC permeability. 
Fig. 5.4: Effect of VE-Cadherin inhibition on laminar shear-induced ZO-1 localization. 
Fig. 5.5: Effect of VE-Cadherin inhibition on laminar shear-induced claudin-5 
localization. 
Fig. 5.6: Effect of VE-Cadherin inhibition on laminar shear-induced occludin tyrosine 
dephosphorylation. 
Fig. 5.7: Illustration and overexpression of Tiam1 C580 (lacking PHn and DHR 
domains) in BBMvEC’s. 
Fig. 5.8: Effect of Tiam1 inhibition on laminar shear-induced Rac1 activation. 
Fig. 5.9: Effect of Tiam1 inhibition on laminar shear-induced cellular realignment. 
Fig. 5.10: Effect of Tiam1 inhibition on laminar shear-induced regulation of BBMvEC 
permeability. 
Fig. 5.11: Effect of Tiam1 inhibition on laminar shear-induced ZO-1 localization. 
Fig. 5.12: Effect of Tiam1 C580 inhibition on laminar shear-induced occludin tyrosine 
dephosphorylation. 
Chapter 6 
Fig. 6.1: Schematic depiction of experimental approach. 
Fig. 6.2: Signaling mechanisms mediating the barrier-stabilizing influence of shear 
stress in BBMvEC’s. 
Fig. 6.3: DIV-BBB model and computer controlled TEER monitoring device. 
Fig. 6.4: Effect of shear stress on HBMvEC re-alignment and ZO-1 localization. 
XV 
 
List of Tables 
Table 2.1: Antibiotic concentrations. 
Table 2.2: SDS-PAGE resolving gel composition 
Table 2.3: SDS-Page stacking gel components. 
Table 2.4: Protein concentrations loaded.   
Table 2.5: Western blot primary and secondary antibody dilutions. 
Table 2.6: Immunocytochemistry primary antibody dilutions. 
 
 
 
XVI 
 
Title Page                 I 
Declaration                II  
Acknowledgements              III 
Abstract               IV 
Abbreviations               V 
Units                IX 
Publications                X 
Presentations               XI 
List of Figures              XII 
List of Tables              XV 
Table of Contents            XVI 
 
Chapter 1: Introduction        
  
1.1 Vascular Endothelium                          2 
          1.1.1      Endothelial Dysfunction             4 
    1.1.2  Atherosclerosis              5 
1.2  Hemodynamics                8 
    1.2.1      Hemodynamics and Vessel Remodeling         10 
    1.2.2      Mechanotransduction            11 
      1.2.2.1  Luminal Mechanosensors         11 
      1.2.2.2  Cell Adhesion Mechanosensors         13 
      1.2.2.3  Cytoskeleton           17 
    1.2.3      Mechanoregulation of Gene Expression         18 
1.3 The Blood Brain Barrier             21 
    1.3.1      Blood Brain Barrier Permeability          22 
      1.3.1.1  Physical Barrier          22 
      1.3.1.2  Enzymatic Barrier          24
      1.3.1.3  Efflux Barrier           24 
    1.3.2      Blood Brain Barrier Heterogeneity          24 
XVII 
 
    1.3.3      The Neurovascular Unit            25 
      1.3.3.1  Astrocytes           26 
      1.3.3.2  Pericytes           27 
      1.3.3.3  Neurons           28 
      1.3.3.4  Extracellular Matrix          28 
    1.3.4      Blood Brain Barrier Disruption           29 
    1.3.5      Regulation of Cerebral Blood Flow          30 
    1.3.6 Shear Stress and the Blood Brain Barrier           31 
1.4 Tight Junctions                    32 
    1.4.1 Occludin              35 
       1.4.1.1  Occludin Function          37 
       1.4.1.2  Occludin Regulation          38 
       1.4.1.3  Occludin Clinical Implications        39 
    1.4.2 ZO-1               40
       1.4.2.1  ZO-1 Function          42 
       1.4.2.2  ZO-1 Regulation          43 
       1.4.2.3  ZO-1 Clinical Implications         43 
    1.4.3 Claudin               45 
       1.4.3.1  Claudin-5 Function           45 
       1.4.3.2  Claudin-5 Regulation          47 
       1.4.3.3  Claudin-5 Clinical Implications        48 
1.5 Adherens Junction              49 
    1.5.1 VE-Cadherin             50 
    1.5.2 VE-Cadherin Function             52
    1.5.3 VE-Cadherin Regulation                      53 
    1.5.4 VE-Cadherin Clinical Implications          55 
1.6 Intracellular Signaling Mechanisms            57 
    1.6.1 RhoGTPases             57 
    1.6.2 RhoGTPase Function            59 
XVIII 
 
      1.6.2.1   RhoA            60 
      1.6.2.2   Rac1 and Cdc42          61
    1.6.3 RhoGTPase Regulation            64 
      1.6.3.1  Rho Guanine Exchange Factors        65 
      1.6.3.2  Rho GTPase Activating Proteins        66 
      1.6.3.3  Rho Guanine Dissociation Inhibitors        67 
    1.6.4 Mechanoregulation of RhoGTPases          68 
1.7 Final Summary and Study Rationale            71 
1.8 Thesis Overview                      72 
 
Chapter 2: Materials and Methods 
2.1  Materials                 74 
2.2  Cell Culture Methods 
    2.2.1  Culture of BBMvEC’s            78 
    2.2.2  Trypsinisation of BBMvEC’s           78 
    2.2.3  Cryogenic Preservation and Recovery of BBMvEC’s        79 
    2.2.4  Cell Counting 
      2.2.4.1   Haemocytometer           80 
      2.2.4.2  ADAM Counter           81 
    2.2.5  Laminar Shear Stress 
      2.2.5.1  Orbital Rotation          82 
      2.2.5.2  IBIDI Flow System           83 
    2.2.6  Transendothelial Permeability Assay 
      2.2.6.1  FITC Dextran            84 
      2.2.6.2  APTS-Dextran           84 
    2.2.7  Treatment with Pharmacological Inhibitors           85 
    2.2.8  FACS Analysis              86 
2.3  Molecular Biology Techniques 
    2.3.1  Plasmid DNA reconstitution             87 
XIX 
 
    2.3.2  Transformation of Competent Cells           87 
    2.3.3  Purification of Plasmid DNA            88 
    2.3.4  Spectrometric Analysis of Plasmid DNA          89 
    2.3.5  Agarose Gel Electrophoresis            90 
2.4  Transfections 
     2.4.1  Plasmid DNA Nucleofection            91 
    2.4.2  Microporation              92 
2.5 Immunodetection Techniques    
  2.5.1 Western Blotting 
   2.5.1.1  Preparation of Whole Cell Lysate         93 
   2.5.1.2   BCA Assay            94 
   2.5.1.3   Immunoprecipitation           94 
   2.5.1.4   Protein Precipitation          95 
   2.5.1.5   SDS-PAGE            96 
   2.5.1.6   Transfer to Nitrocellulose Membrane        98 
   2.5.1.7   Blotting and Chemiluminescence detection         99 
  2.5.2  Immunocytochemistry           101 
 2.6  RhoGTPase GLISA® Activation Assays  
  2.6.1 Lysate Preparation           102 
  2.6.2 GLISA Procedure and Immunodetection        102 
2.7  Statistical Analysis            104 
Chapter 3:  
The effects of laminar shear stress and/or flow cessation on BBMvEC tight 
junction assembly and barrier function. 
3.1 Introduction            106 
3.2 Results             108 
3.3  Discussion             122 
 
XX 
 
Chapter 4:  
The contribution of RhoGTPases, Rac1 and RhoA, to shear-induced 
adaptation of BBMvEC tight junction assembly and barrier function. 
4.1  Introduction             128 
4.2  Results             130 
4.3  Discussion             144 
Chapter 5:  
The role of VE-Cadherin and Tiam1 in shear-induced upregulation 
of BBMvEC tight junction assembly and barrier function. 
5.1  Introduction             151 
5.2  Results             153 
5.3  Discussion             165 
Chapter 6: Final Summary             171 
Bibliography            187 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
 
Chapter 1: 
Introduction 
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1.1 The vascular endothelium 
A basic understanding of the vascular system would describe a network of blood filled 
vessels (arteries, veins and capillaries) supplying oxygen and essential nutrients to every 
tissue throughout the body. Although completely accurate in summation, a more in 
depth understanding from a vascular biologist stand-point would describe a highly 
specialized layer of cells embedded within the lumen of blood vessels, namely the 
endothelium. Originally conceived to be an innate monolayer of cells, endothlelial cells 
(EC’s) are now considered a highly specialized, metabolically active organ exerting 
multifunctional homeostatic effects on the vasculature and surrounding tissues.  The 
term ‘endothelium’ was first coined in 1865 by a Swiss anatomist Wilhelm His, with a 
later definition limiting its presence to the inner cell layer of blood vessels and 
lymphatics. During the 1950’s and 60’s the discovery of the electron microscope proved 
to be an invaluable tool in the structural identification and characterization of EC’s. 
However, the 1970’s and 80’s exposed a new era in cell biology with the first successful 
isolation of EC’s in culture, allowing investigators to influence, in a controlled manner, 
the extracellular environment and thus study endothelial responses in greater detail 
(Aird, 2007). A recent search for the term ‘vascular endothelium’ on PubMed yielded 
92,434 articles, which highlights the surge in research interests toward this exciting field 
of research since the advent of such technologies as cited above.  
Endothelial cells display the same characteristics as other cells in the human body; 
organelles within a cytoplasm, surrounding a nucleus and contained within a cellular 
membrane (Esper et al., 2006). They arise from the mesoderm layer via the 
differentiation of hemangioblasts and or angioblasts (Coultas et al., 2005). Structurally, 
EC’s are flat and realigned in the direction of blood flow with a thickness ranging from 
0.1µm in capillaries to 1µm in the aorta. They typically exist in a quiescent state, i.e. 
non proliferating with an average lifespan of a year (Aird, 2007). The human blood 
vessel (arteries and veins) is depicted in figure 1.1 below 
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Fig. 1.1: Human blood vessel. This image displays the three main layers of a typical 
conduit vessel. EC’s are anchored to a basement extracellular matrix (ECM), rich in 
collagenous and elastic fibers forming the tunica intima layer of the blood vessel. An 
internal elastic lamina separates the tuncia media, a layer composed primarily of 
vascular smooth muscle cells (VSMCs) and elastin collagen fibers. The external elastic 
lamina is separated from the outermost layer, the tunica externa, composed mainly of 
connective tissue attaching the vessel to the underlying tissues. 
(http://www.nicksnowden.net/images/artery-vein). 
 
Primary functions of EC’s include its regulatory effects on vascular tone, blood 
coagulation, wound healing, acute inflammation and leukocyte recruitment, all of which 
are pivotal to vascular homeostasis (Gerritsen, 1987). Maintenance of these functions 
under physiological conditions requires a complex interplay of various ‘blood borne’ 
biochemical and biomechanical stimuli, transduced by the EC, with consequences for 
various aspects of cell function, including proliferation, migration, apoptosis, gene 
expression and permeability. Under physiological conditions the endothelium acts to 
maintain homeostatic balance by presenting an anti-inflammatory, anti-thrombotic and 
anti-coagulative phenotype. The endothelium derived compound nitric oxide (NO) has 
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been one of the most extensively studied molecules with respect to vessel homeostasis. 
Indeed, a Nobel prize was awarded to Robert Furchgott’s group in 1998 for describing 
the L-arginine – NO – cyclic guanosine monophosphate (cGMP) system as the major 
‘player’ regulating endothelium-dependent dilation (EDD), which promotes vascular 
smooth muscle (VSMC) relaxation and resulting vessel dilation (Furchgott and 
Zawadzki, 1980). Apart from acting as a potent vasodilator, NO regulates vascular 
permeability, reduces monocyte adhesion, platelet aggregation, tissue oxidation, 
cytokine expression and favors fibrinolysis (Esper et al., 2006). All these factors 
decrease the risk of atherosclerosis, the most prevalent form of cardiovascular disease 
(CVD), and it is for this reason that NO is considered an anti-atherogenic molecule. 
Other important vasodilators such as prostacyclin, bradykinin and cytochrome P450 2C 
have also been described (Fleming, 2000, Giannotti and Landmesser, 2007). 
Hemodynamic forces are prime candidates involved in the regulation of NO, where 
healthy, atheroprotective laminar flow stimulates NO production (Harrison et al., 2006).                   
 
1.1.1 Endothelial dysfunction 
Pathological conditioning of the endothelium, via altered hemodynamics or 
inflammatory cytokines are known to induce a state referred to as ‘vascular 
dysfunction’, which has the capacity to provoke unfavorable changes in endothelial 
specific functions, at the cell and molecular level with inevitable consequences for 
disease. It may even be argued that the endothelium plays a part in most if not all 
diseases, either as a primary determinant of pathophysiology or a ‘victim of collateral 
damage’ (Aird, 2005). CVD is a generic diagnostic for a range of diseases that affects 
the heart and blood vessels, and includes atherosclerosis, myocardial infarction (MI), 
stroke, hypertension, peripheral vascular disease, aneurysm and coronary artery disease. 
According to the respective Heart Foundations, it is estimated that CVD accounts for 
36% (2005) of all deaths in Ireland and 34% (2006) in the United States. Atherosclerosis 
(arterial disease) is the most prevalent class of CVD that is diffusely localized 
throughout the vascular tree. As a prototypical model of endothelial dysfunction its 
pathophysiology is described in more detail below. It is a disease related to activation of 
the immunological system that responds to chronic levels of inflammation. The 
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‘classical’ risk factors for atherosclerosis include hyper-cholesterolemia, hypertension, 
diabetes, smoking and a sedentary lifestyle, while so called new risk factors include 
hyper-homocysteinemia, lipoprotein Lp(a), infections by Chlamydia pneumonia and 
Helicobacter Pylori, all of which contribute to an atherogenic cascade of 
cytokine/adhesion molecule production and ablation of NO production (Esper et al., 
2006, Tobin et al., 2008).  
 
Although the vasculature is exposed to various ‘systemic’ risk factors for disease, 
atherosclerotic plaques tend to form at hemodynamically vulnerable points within the 
vascular bed (curvatures or branch points), highlighting the importance of blood flow to 
endothelial health and disease. Shear stress hemodynamic forces (discussed properly in 
section 1.2) are imposed directly on the endothelium and modulate their structure and 
function through a series of mechanotransduction mechanisms.  Low endothelial shear 
stress and/or oscillatory flow play a crucial role in the initiation of atherosclerosis 
(Chatzizisis et al., 2008, Cunningham and Gotlieb, 2005). A recent study by Chatzizisis 
et al., demonstrated that low levels of shear stress (non-physiological levels) determines 
the location and complexity (high risk plaque content) of coronary atherosclerotic 
plaque development and progression (Chatzizisis et al., 2008). Indeed the earliest 
detectable manifest of atherosclerosis is a decreased NO response to hemodynamic 
stimuli or pharmacological stimulation (Hunt, 2002).  
 
1.1.2 Atherosclerosis 
Although multi-factorial in its progression, a brief synopsis of atherosclerosis 
development would describe a modulation of the mechanotransduction process leading 
to alterations in expression of inflammatory cytokines, tumor necrosis factor (TNF-α), 
interleukin-1 (IL-1), IL-6 and vascular adhesion molecules recruiting leukocytes 
(monocytes) to the endothelium, concomitant with a reduction in NO production (Esper 
et al., 2006). Migration of monocytes into the sub-endothelial layer ensues, leading to 
their activation and transformation into macrophages, which digest oxidized low-density 
lipoprotein (LDL-ox) cholesterol molecules forming foam cells. Foam cells, the 
principal component of ‘fatty streaks’ are the first step of atheromatous plaque 
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formation, which may undergo programmed death (apoptosis) releasing stored lipids, 
thus creating a lipid/necrotic core in the sub-endothelial layer of intima. As this lipid 
core expands, its thrombogenicity is enhanced and is separated only from the circulating 
blood by a fibrous cap, formed by an abundance of ECM proteins (collagen and 
laminin). These proteins are produced by VSMC’s, which normally act to regulate 
vascular tone, but undergo phenotypic change, migrate to the intima and counteract the 
developing lipid core. To the detriment of VSMC’s, inflammatory cytokines such as 
interferon gamma (IFN-γ) act to inhibit collagen synthesis and macrophages secrete 
matrix metalloproteinases (MMP’s), which degrade components of the fibrous cap 
(Hunt, 2002). This plaque formation is associated with ‘remodeling’ of the vessel wall, 
and can have two possible fates;1): The plaques expands until it occludes the vessel, 
leading to irreversible ischemia or 2):The plaque ruptures, releasing its thrombotic 
content, and the resulting intravascular thrombosis could lead to MI or stroke. Figure 1.2 
below shows the logical progression of atherosclerotic plaque formation within the 
vessel wall.   
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Fig. 1.2: Atherosclerotic plaque progression. (A) represents a healthy, atherosclerotic 
resistant area of the vasculature exposed to undisturbed laminar flow. (B-D) depicts the 
initiation of atherosclerotic plaque development, progression through to rupture in a 
branched area of the vasculature where flow patterns are disturbed (Hahn and Schwartz, 
2009).   
 
Physiological levels of shear stress are critical in maintaining vascular function, 
including thromboresistance, barrier function and vascular homeostasis. Continuous 
exposure to these forces, especially in straight sections of the arteries promotes the 
establishment of essential physiological characteristics of the vessel wall promoting an 
anti-atherogenic phenotype (Cunningham and Gotlieb, 2005). Thus, shear stress is 
critically vital in regulating the normal vessel physiology as-well as the pathobiology of 
vascular dysfunction through multifaceted mechanisms that promote atherogenesis. 
Crucially however, as alterations in blood flow (low/disturbed shear stress) are 
inevitable due to the complex spatial architecture of the vasculature, individuals with 
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elevated levels of CVD risk factors will be at a heightened risk for priming these 
‘hotspots’ in the vasculature for endothelial cell activation, and thus initiate the 
atherosclerotic cascade described above. 
 
1.2 Hemodynamics 
With regards to extracellular stimuli regulating endothelial function, blood borne 
hemodynamic forces are of utmost importance and dramatically influence endothelial 
cell properties and function. These forces are fundamental to the development and 
physiology of the vasculature but a dysregulation significantly contributes to human 
disease. Two prominent hemodynamic forces exist, both of which exert physical 
(mechanical) stimulation of endothelial receptors (mechanosensors) with the ability to 
convert these stimuli into intracellular signalling cascades with downstream 
consequences for cellular functions (see figure 1.3). Cyclic strain is the circumferential 
force/wall tension generated by blood pressure causing a physical stretch in the vessel 
wall and is sensed by both endothelial and VSMC’s (Lehoux et al., 2006). It is defined 
by Laplace’s Law, which describes wall tension as a function of vessel radius and blood 
pressure (Laplace, 1899).  
 
Where T = wall tension (force per unit length of the vessel), P = blood pressure, r = 
vessel radius and h = thickness of the vascular wall. Cyclic strain is most prominent on 
the arterial side of the vasculature, in larger vessels such as the aorta, but less significant 
on the venous side. More importantly though, this hemodynamic force has the capacity 
to regulate a number of endothelial functions essential to vessel homeostasis, including 
permeability (Collins et al., 2006),  migration (Von Offenberg Sweeney et al., 2005) and 
apoptosis (Haga et al., 2003).  
 
Shear stress describes the frictional force of the blood against the vessel wall sensed 
principally by endothelial cells and is experienced more uniformly throughout the 
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vasculature. Laminar shear stress describes the undisturbed, unidirectional flow of blood 
in a vessel that is generally atheroprotective and essential for endothelial physiology. By 
comparison, disturbed/oscillatory shear, which predominates at complex vessel 
geometries in the vasculature promotes differential gene expression to induce a pro-
atherogenic phenotype (Davies, 2009). Shear stress is proportional to the viscosity and 
velocity of blood flow and inversely proportional to the vessel radius.  
 
Where, τ = shear stress (dynes/cm2); µ = viscosity, Q = flow rate and R = vessel radius. 
(Lehoux and Tedgui, 2003). Physiological ranges of shear stress typically fluctuate 
between 10-20 dynes/cm2 depending on the specific area within the vasculature (Deli et 
al., 2005). Not only is this force critical to controlling vascular physiology, it is also a 
key factor responsible for induction of the vascular plexus, and thus the cardiovascular 
system during embryonic development (Hahn and Schwartz, 2009).   
 
 
Fig. 1.3: Shear stress and cyclic strain. Schematic of hemodynamic forces within the 
vasculature; (A) laminar shear stress and (B) cyclic strain. Arrows in red indicate the 
direction of blood flow.    
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1.2.1 Hemodynamics and vessel remodeling 
Blood vessels are highly dynamic, elastic structures that rapidly respond to changes in 
their internal environment, i.e. blood flow. Fluctuations in shear stress/cyclic strain 
evoke transient changes in vessel diameter to accommodate changes in blood flow and 
thus preserve the initial ‘baseline’ level of hemodynamic force. This response is 
mediated by endothelial release of potent vasodilators, such as NO, prostacyclin and 
endothelium-derived hyperpolarizing factor (EDHF) and arachidonic acid, which induce 
VSMC hyperpolarization and opening of potassium ion channels. This mechanism 
blocks the influx of calcium ions (Ca2+) through voltage dependent calcium channels 
which naturally occurs in a depolarized state, thus inhibiting myosin mediated VSMC 
contraction, allowing the vessel to dilate  (Vanhoutte et al., 1995, Haddy et al., 2006). 
This endothelial dependent response to blood flow occurs over seconds to minutes. On 
the contrary, sustained levels of aberrant hemodynamics (e.g. hypertension) have the 
ability to induce profound genotypic and phenotypic alterations in the vessel wall. This 
adaptive, structural process involves remodeling of VMSC’s which causes thickening of 
the vasculature, allowing the vessel to resist these elevated forces. However over an 
extended period of time, this remodeling will ultimately compromise vessel elasticity 
and thus reduce the vessels ability to adapt to any further change in pressure (Hahn and 
Schwartz, 2009). Non-physiological conditioning of the vasculature as observed with 
hypertension can result in shearing rates greater than 40 dynes/cm2 (Resnick et al., 
2003). Wall stretch-associated hypertension, along with other aforementioned classical 
CV risk factors has been shown to enhance atherosclerotic plaque progression through 
the production of reactive oxygen species (ROS) and activation of pro-inflammatory 
genes (Chobanian and Alexander, 1996). Induction of vascular dysfunction is an early 
manifestation of CVD, defined as an impaired flow-mediated dilation through an artery 
bed. High resolution brachial artery ultrasound is a non invasive technique employed to 
assess endothelial dependent dilation in response to flow and thus used as an indicator of 
vascular function.  
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1.2.2 Mechanotransduction   
Mechanotransduction describes the process by which EC’s detect physical/mechanical 
stimuli generated by blood flow and transduce them into an intracellular signalling 
cascade(s) with downstream consequences for cellular functions. Differentiating 
between physiological or pathological hemodynamic stimuli is a host of membrane 
bound mechanosensors (receptors) which includes luminal based membrane proteins, 
cell-cell and cell-matrix adhesion proteins and the cytoskeleton (Deli et al., 2005, Tzima 
et al., 2005). Mechanotransduction of blood flow is a complex process that involves 
rapid and almost simultaneous activation of multiple mechanosensors on the luminal, 
lateral and subluminal surface of EC’s. This suggests that a coordinated effort amongst 
receptors is fundamental to the initiation of cellular responses and that there is no single 
shear stress receptor. Shear stress is the principal hemodynamic stimulus influencing 
EC’s at the blood brain barrier (BBB) and thus the responsivity of various 
mechanosensors will be discussed within this context (Desai et al., 2002). The 
mechanosensors discussed below are among the commonly studied receptors in vascular 
mechanobiology. A schematic representation is presented in figure 1.4  
     
1.2.2.1  Luminal mechanosensors 
Ion channels 
Several ion channels have been identified in vascular EC’s, of which some have been 
shown to shear responsive. They exist as membrane bound protein complexes that 
regulate ion transport across the membrane, establishing small voltage gradients. The 
P2X purinoceptors and transient receptor potential are shear-sensitive Ca2+- permeable 
cation channels mediating Ca2+ influx. Intracellular Ca2+ rapidly increases within 1 min 
of shear application and subsides by 5 min (Ando et al., 1988). Significant to these 
responses, P2X4 (subtype of P2X) gene knock-out mouse models show a blunted 
vasodilatory response to increases in blood flow and have elevated blood pressure 
compared to wild type controls (Yamamoto et al., 2006) . Furthermore, studies have 
shown that shear stress activates an inward rectifying K+ current, inducing 
hyperpolarization of the plasma membrane, compared to activation of chloride ion 
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channels, which cause membrane depolarization. Blockade of shear-induced K+ current 
inhibited the induction of NO suggesting its importance in shear responsiveness and 
vascular function (Uematsu et al., 1995). Changes in membrane fluidity or tension under 
flow have been proposed as mechanisms facilitating regulation of these 
mechanosensitive channels as high plasma membrane levels of cholesterol inhibit their 
responses to flow (Fang et al., 2005).   
 
G-proteins and G-protein coupled receptors  
G-proteins are aptly named because of their ability to bind the guanine nucleotides, 
guanosine diphosphate (GDP) and guanosine triphosphate (GTP). They are 
heterotrimers consisting of Gα, Gβ and Gγ subunits and associate with transmembrane 
G-protein coupled receptors (GPCR). GPCR’s contain extracellular loops facilitating 
ligand binding and a cytoplasmic tail which interacts with the heterotrimeric G-proteins. 
The Gα subunit sequesters GDP in its binding site, but upon ligand binding with the 
GPCR, an allosteric change takes place triggering GDP release and GTP binding to Gα. 
This promotes dissociation of Gα from Gβγ, both acting on specific downstream 
effectors (Wieland and Mittmann, 2003). Gudi et al.. showed that G-protein activation 
occurs 1 sec following shear onset, while inhibition of G-proteins using antisense Gαq 
oligonucleotides blocked shear induced Ras-GTPase activity (Gudi et al., 1996, Gudi et 
al., 2003). Furthermore pretreatment of EC’s with pertussis toxin inhibited shear-
mediated extracellular signal regulated kinases (ERK) 1/2 activation (Jo et al., 1997). 
However, the precise nature of shear-induced G-protein activation is contradictory. 
Reports from in-vitro studies seems to suggest ligand independence, as Frangos et al.. 
have shown that G-proteins reconstituted in liposome’s are activated in response to 
shear (White and Frangos, 2007), while genetic deletion of kinin in mice (precursor of 
bradykinin) blocked responses to flow (Bergaya et al., 2001). Thus further clarification 
on the precise roles of G-proteins and GPCR’s as mechanotransducers are required.              
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Endothelial glycocalyx 
The luminal surface of EC’s is coated with a dense layer of proteoglycan projections 
anchored to the plasma membrane, which constitute the endothelial glycocalyx (EG). 
The EG consists of heparan sulfate, chondroitin/dermatan sulfate and hyaluronic acid, 
all of which are modified by plasma proteins, enzymes, growth factors and cytokines 
(Weinbaum et al., 2007). More recent developments have suggested a role of the EG in 
force transmission of shear stress to the actin cytoskeleton, possibly through direct 
associations with the cytoskeleton or signalling molecules that dock with the core 
proteins of the glycocalyx (Ando and Yamamoto, 2009). Florian et al. using selective 
cleavage of heparin sulfate proteoglycans, was able to abrogate shear-induced NO 
production (Florian et al., 2003) and further work by Yao and colleagues identified a 
role for the proteoglycan in flow-induced EC realignment (Yao et al., 2007). 
Interestingly, cleavage of chondroitin with chondroitinase did not inhibit NO production 
in aortic EC’s in response to flow. However, studies involving cleavage of glycocalyx 
proteoglycans may also affect the interaction of integrins with their cognate ECM 
ligand(s) along the basolateral surface; molecules which have also been strongly 
implicated in flow responses (see section 1.2.2.2), therefore calling into question the 
feasibility of the EG in  apical mechanotransduction (Hahn and Schwartz, 2009). Further 
work is required to determine the precise contribution of the EG to 
mechanotransduction.              
 
 
1.2.2.2 Cell adhesion mechanosensors 
The sensing of hemodynamic forces by cell-cell and cell-matrix adhesion components 
has been well documented. Tzima et al. have previously characterized an intracellular 
mechanosensory complex consisting of 3 laterally located transmembrane receptors 
comprising the platelet endothelial cell adhesion molecule-1 (PECAM-1), vascular 
endothelial (VE)-Cadherin and vascular endothelial growth factor receptor 2 (VEGFR2). 
This complex was found to mediate a host of intracellular responses to flow but required 
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each receptor component to elicit a functional response. The proposed sequential 
participation of each receptor is discussed below (Tzima et al., 2005). 
 
PECAM-1, a 130kDa glycoprotein abundantly expressed in EC’s can also be found in 
circulating platelets and leukocytes. It contains 6 extracellular immunoglobulin (IgG) 
domain-like loops which participate in homophilic interaction with neighboring cells, an 
intracellular domain which interacts with the actin cytoskeleton, and is crucial to the 
transendothelial migration of leukocytes (Vaporciyan et al., 1993, Nakada et al., 2000). 
More recent investigations have shifted towards a putative role for this molecule in 
mechanosensing. Within seconds of flow onset, PECAM-1 is tyrosine phosphorylated, 
allowing the binding of the tyrosine phosphatase SHP-2. This association initiates a Ras 
GTPase signalling pathway which leads to ERK activation (Osawa et al., 2002), a 
response that appears to be independent of other early shear stress responses such as ion 
channels, as alterations in intracellular Ca2+ or K+ concentrations had no effects on 
PECAM-1 phosphorylation (Fujiwara, 2006). Furthermore, studies using magnetic 
beads coated with antibodies for different adhesion receptors have concluded that 
PECAM-1 is a direct mechanotransducer of mechanical force within this adhesion 
complex (Osawa et al., 2002, Tzima et al., 2005).  Mechanical stimulation of PECAM-1 
has been implicated in activating a Src family kinase, which is the earliest known 
intracellular signalling event in this particular pathway (Tzima et al., 2005).  
 
Downstream of PECAM-1 activation, VE-cadherin (discussed in section 1.5) functions 
as an adaptor molecule within this mechanosensory complex. The adherens junction has 
previously been implicated in the adaptation of EC’s to long term shear stress (Noria et 
al., 1999, Schnittler et al., 1997) but its role in mechanosensing was first elucidated by 
Shay-Salit et.al.(Shay-Salit et al., 2002) Following flow onset, a mutli-member complex 
is formed consisting of VE-Cadherin, β-catenin and VEFR2, which associates with the 
endothelial cytoskeleton. This complex is essential for shear-induced responses as EC’s 
null for VE-Cadherin lacked the acute shear-mediated phosphorylation of Akt and p38, 
and more chronic induction of shear stress response element (SSRE) genes (Shay-Salit 
et al., 2002). It was suggested however that participation of VE-Cadherin in shear-
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dependent signalling was shown to occur independently of cell-cell adhesion, as a 
blocking antibody of VE-Cadherin extracellular domains had no effect on flow 
stimulated WOW-1 binding, an active form of the shear responsive integrin αvβ3 
(Tzima et al., 2005).  
   
VEGFR2/Flk-1 is a receptor tyrosine kinase (RTK), for which its extracellular ligand 
VEGF is one of the main inducers of endothelial proliferation and permeability. 
Approximately 20 different RTK’s have been identified, which exist as monomeric 
transmembrane receptors exhibiting a high affinity for many polypeptide growth factors, 
cytokines and hormones. Ligand binding triggers tyrosine phosphorylation, which 
creates binding sites for a Src Homology 2 (SH2) and phosphotyrosine binding domain-
containing proteins to regulate effector proteins controlling various cellular activities 
(Pawson, 1994, Zwick et al., 2001). Shear stress and cyclic strain have also been 
implicated in their activation, as exposure to hemodynamic forces results in the 
activation and phosphorylation of the platelet-derived growth factor receptor-α (PDGF) 
(Hu et al., 1998). Moreover, VEGFR2 shows a rapid, Src-dependent, ligand-independent 
activation in response to flow facilitating the association of the adaptor protein Shc, a 
SH2 domain containing adaptor protein (Chen et al., 1999). Blocking Shc attenuates the 
shear-induced activation of ERK and c-Jun N-terminal kinase and the consequent gene 
transcription mediated by the binding of the transcription factor activator protein-1 to 
the 12-O-tetradecanoylphorbol-13-actetate responsive element (TRE). Shear-dependent 
activation of VEGFR2 in a ligand-independent manner causes the recruitment of 
phosphoinisotide 3-OH-kinsae (PI3K) and the consequent activation of Akt and 
endothelial nitric oxide synthase (eNOS) (Jin et al., 2003). Interestingly, flow-mediated 
activation of VEGFR2 was absent in PECAM -/- and VE-Cadherin -/- EC’s, confirming 
its downstream role in signalling within this mechanosensory complex (Tzima et al., 
2005).            
 
To summarize the proposed signalling complex, following flow onset, PECAM-1 acting 
as a mechanotransducer is tyrosine phosphorylated which leads to the activation of Src. 
Through association with VE-Cadherin/β-catenin as an adaptor, VEGFR2 is brought 
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into proximity with PECAM-1 which facilitates its transactivation by Src to initiate 
cellular processes described above. Indeed, ectopic plasmid expression of PECAM-1, 
VE-Cadherin and VEGFR2 in COS-7 African monkey cells would only allow cellular 
alignment to flow when all 3 plasmids were present (Tzima et al., 2005).    
 
Integrins 
Integrins comprise a family of 20 transmembrane proteins, which exist as heterodimers 
consisting of α and β subunits. They are topically expressed on the basolateral surface of 
EC’s where their extracellular domains mediate cell-matrix adhesion via specific ECM 
ligands such as fibronectin, vitronectin and collagen. The cytoplasmic domain associates 
with various molecules forming focal adhesions, comprising signalling molecules such 
as focal adhesion kinase (FAK), C-src, adaptor molecules Shc and Grb2, and actin 
binding proteins talin and α-actinin, thus establishing a link with the actin cytoskeleton 
(Sastry and Horwitz, 1993). Integrins are unique structures in the sense that they can 
mediate ‘inside out’ signalling, where intracellular signals affect their binding affinity to 
ECM ligands, and ‘outside in’ signalling whereby extracellular signals drive integrin-
mediated intracellular signalling cascades. They are highly sensitive to hemodynamic 
force, and their subsequent activation has been shown to be essential to flow-mediated 
NO release (Muller et al., 1997), cellular realignment (Tzima et al., 2005), I-kappa-B 
(IkB) release (Bhullar et al., 1998) and ERK 1/2 activation (Takahashi and Berk, 1996). 
In the context of the mechanosensory complex described above, shear induced integrin 
activation was shown to occur downstream of VEGFR2-mediated PI3K activation. 
Wang et al.  however has shown that shear induced VEGFR2 activation is attenuated by 
blockade of integrins; suggesting bi-directional signalling within this mechanosensing 
network (Wang et al., 2002). Interestingly the specificity of the integrin-matrix 
interaction is also an important determinant of the flow-mediated intracellular response. 
For example, flow triggers activation of the MAP kinase p38 on EC matrices coated 
with collagen and not fibronectin, whereas flow induces activation of the transcription 
regulator nuclear factor-kappa-B (NF-κB) on fibronectin but not collagen or laminin 
(Orr et al., 2005). Although discrepancies in the literature exist, the functional relevance 
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of integrins in shear-mediated cellular processes is undoubted, but requires a precise 
control over the extracellular environment these molecules are exposed to.  
 
1.2.2.3 The cytoskeleton 
The cytoskeleton describes a cellular scaffold that is essential to a number of cellular 
processes responding to spatially organised signalling mechanisms, which determines 
cell shape and mediates cell growth and differentiation. It consists of 3 types of protein 
filaments; actin microfilaments, vimentin intermediate filaments and tubulin 
microtubules. With a growing number of endothelial receptors implicated in shear-
mediated signalling events, some of which are not directly exposed to flow, raised the 
possibility that a common structure could tie these receptors together. The endothelial 
cytoskeleton became the natural candidate, based on its ability to sense and transmit 
mechanical force and associate directly or indirectly to the mechanosensors described 
above (Helmke and Davies, 2002). Indeed spatio-temporal analysis of vimentin 
following flow onset shows a displacement of these structures to lateral and basal 
structures, suggesting transmission of force to these sites, therefore consistent with 
models of cell-cell or cell-matrix adhesion mediating mechanotransduction (Helmke et 
al., 2001). Furthermore disruption of the actin cytoskeleton by drugs was sufficient to 
abrogate shear stress mediated signalling and changes in gene expression (Malek et al., 
1999, Hutcheson and Griffith, 1996, Imberti et al., 2000).  
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Fig. 1.4: Endothelial mechanosensors. This figure schematically shows the cellular 
localization of the aforementioned mechanosensors described in section 1.2.2 (Hahn and 
Schwartz, 2009).  
 
1.2.3 Mechanoregulation of endothelial gene expression 
Hemodynamic forces profoundly influence gene expression with the capacity to evoke 
phenotypic changes essential to physiology or pathophysiology. Based on a series of 
studies assessing shear-dependent changes in endothelial gene expression, the specificity 
of the response is highly dependent on the shear rate, location in the vasculature and the 
time course of exposure to shear stimulus. Shear-responsive genes possess a short 
nucleotide sequence termed shear stress response elements (SSRE), which, following 
transcriptional factor binding, activate/repress gene expression. The first of such SSRE 
was identified by Resnick et al. in the promoter region of the PDGF-B gene containing a 
nucleotide sequence of GAGACC, with a later study by Khachigian and colleagues 
attributing the NF-κB/p50-p65 heterodimer as the transcriptional factor regulating this 
response (Resnick et al., 1993, Khachigian et al., 1995). Through the exploitation of 
gene array technology, hundreds of genes have been shown to be regulated by laminar 
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shear stress and chronic exposure (24 h) of shear suppressed more genes than it induced 
(Resnick et al., 2003). The transcription factor kruppel-like factor 2 has been shown to 
regulate up to a third of shear-activated genes and has been suggested to underpin the 
molecular basis of the healthy state of flow exposed to EC’s (Parmar et al., 2006, 
Garcia-Cardena and Gimbrone, 2006).     
 
Interestingly, the early onset of physiological levels of laminar shear stress (0-60 min) 
triggers the activation of multiple signalling pathways, which favour the induction of 
genes consistent with a pro-inflammatory, pro-coagulant, atherosclerotic phenotype, 
thus transiently mimicking pathways evoked by turbulent/oscillatory shear flow 
patterns. Alteration in gene expression during this immediate laminar shear phase 
includes an upregulation of intracellular adhesion molecule (ICAM-1), vascular 
adhesion molecule (VCAM-1), and E-selectin concomitant with enhanced levels of 
monocyte adhesion (Walpola et al., 1995, Chappell et al., 1998), increase in ROS 
activity (McNally et al., 2003, De Keulenaer et al., 1998), while levels of eNOS are 
downregulated (Wilcox et al., 1997). However within 1-3 hr of exposure to laminar flow 
conditions, the activity of this pro-inflammatory cascade decreases substantially to 
below baseline levels, while induction is sustained under non-physiological flow 
conditions such as oscillatory flow. This suggests that the main difference between 
atheroprotective laminar flow and athero-promoting disturbed flow is the ability of EC’s 
to temporally adapt to the laminar flow stimulus and downregulate relevant pathways 
influencing gene expression (see figure 1.5 below) (Hahn and Schwartz, 2009).  
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Fig. 1.5: Physiological laminar shear vs. disturbed shear. This figure depicts a 
branch point (bifurcation) in a blood vessel, which is a common site for atherosclerotic 
plaque progression. Possible endothelial cell fates at specific sites in the vessel are 
presented in two colour coded boxes (red/blue) depending on the hemodynamic stimuli 
experienced at this particular point (Hahn and Schwartz, 2009).  
 
As described above, a wealth of knowledge exists about various mechanosensors 
implicated in coupling hemodynamic force to biochemical activity. The complexity of 
understanding these mechanisms is compounded by the fact that a great deal of interplay 
among mechanosensors seems to exist. Furthermore, adhesion sites and intercellular 
junctions are rich in various kinases, phosphatases and adaptor molecules necessary to 
elicit biochemical mechanotransduction processes. As such, the diversity of endothelial 
functions is reflected by this variety of mechanosensing mechanisms, suggesting that a 
single mechanism for coordinated mechanotransduction in EC’s is unlikely.  
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1.3 The blood brain barrier  
Despite the global localization of the EC’s throughout the body, their specific 
function(s) can vary considerably depending on the specific vascular bed (Bouis et al., 
2001). They are highly heterogeneous in nature, and thus have important implications 
for strategies in basic research, diagnostics and therapeutics. This premise certainly 
holds true for the dense network of EC’s located within the cerebrovascular capillaries, 
which form the ‘Blood-Brain-Barrier’ (BBB). The BBB is an extremely selective barrier 
to the passage of blood-borne solutes to the central nervous system (CNS) by acting as a 
‘physical barrier’ due to the presence of complex tight junction proteins between 
adjacent EC’s regulating paracellular transport and specific transport systems on the 
luminal and abluminal membranes controlling transcellular traffic (Abbott et al., 2006).  
 
The initial characterization of the BBB dates back to the 1880’s as work by Paul Ehrlich 
found that cationic vital dyes were quickly taken up by all organs of the body following 
intravascular injection with the exception of the brain and spinal cord (Ehrlich, 1904). 
Although initially interpreted as a freak occurrence, work by Edwin E. Goldman showed 
soon after that intracranial injection of the very same dyes exclusively stained CNS 
tissue while all other organs remained unstained (Goldmann, 1913). The concept of the 
BBB was born, however the term ‘BBB’ was first coined by Lewandowsky who 
demonstrated that neurotoxic compounds only exerted aberrant effects on brain function 
following intracranial injection compared to intravenous administration. The precise 
location of the barrier remained unknown for 70 years, until Reese and co-workers using 
electron microscopy, tracked the barrier to be situated in the EC’s of brain capillaries 
(Brightman and Reese, 1969, Reese and Karnovsky, 1967). Two other barriers within 
the CNS exist; the choroid plexus epithelium between blood and the ventricular 
cerebrospinal fluid (CSF), and the arachnoid epithelium between the blood and the 
subarachnoid CSF. However, individual neurons may be millimeters or centimeters 
from a CSF compartment whereas individual neurons are rarely more than 8-20µm from 
brain capillaries. Hence out of all the CNS barriers, the BBB exhibits the utmost control 
over the immediate microenvironment of the CNS (Schlageter et al., 1999).  
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1.3.1 Blood brain barrier permeability 
As alluded to earlier, the endothelium performs a variety of functions central to 
homeostasis of the vessel wall and the underlying tissue. Specific to the BBB, regulation 
of vascular permeability is a dominant, non-stagnant function involving coordinated 
interaction of adjacent brain EC’s and the surrounding neurovascular unit (NVU). 
Permeability can be described as the sum of many mechanisms that increase or decrease 
barrier function (Mehta and Malik, 2006). Different vascular beds have unique barrier 
characteristics which are essential to appropriate functioning of the underlying 
interstitium. The arteries and capillaries of the BBB elicit a relatively impermeable 
barrier, whereas regions within post-capillary venules are often cited as having ‘leaky 
barriers’ (Simionescu et al., 1975, Simionescu et al., 1976) and the adhesion of platelets 
and leukocytes is more probable here (del Zoppo, 2008). Brain capillary EC’s are the 
primary constituent forming the BBB, which display barrier properties that significantly 
impede the movement of virtually all blood borne solutes to the brain, with the 
exception of those that are small and lipophilic. Three distinctive barrier functions 
within the BBB, have been described and their roles are categorized below (Pardridge, 
2002). 
 
1.3.1.1 Physical barrier 
The flux of molecular traffic from blood to CNS occurs via two distinctive pathways. 
The transcellular pathway describes molecular movement through the cell membrane 
and is mediated by processes such as passive diffusion (O2 and CO2), active transport of 
glucose and various amino acids, and receptor/absorption mediated transport of larger 
molecules such as insulin or leptin (Ballabh et al., 2004). This transport mechanism is 
severely restrictive at the BBB as EC’s display minimal pinocytosis to minimize non-
specific transport into the CNS (Brightman, 1977). The paracellular pathway describes 
the movement of substances between adjacent endothlelial cells (gate function), a 
pathway within the BBB that is tightly controlled by a series of opposing tight and 
adherens junctional complexes limiting paracellular flux of ions, hydrophilic molecules 
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and hormones. Furthermore these tight junction protein complexes (see section 1.4) also 
have a valuable role (fence function) by separating the apical and basolateral domains of 
the cell membrane so the endothelium can take on the polarized (apical – basal) 
properties that are also common in certain epithelia (Abbott et al., 2006). The overall 
thickness of the brain endothlelial cell is about 200-300nm, but this extremely thin 
barrier has been described as having some of the most restrictive barrier properties of 
any biological membrane (Oldendorf, 1971). Figure 1.6 below highlights the different 
pathways present at the BBB. 
 
 
Fig. 1.6: Pathways at the blood brain barrier. A schematic representation of EC’s at 
the BBB and the mechanisms of molecular traffic across the barrier. A) The paracellular 
pathway, regulated by tight junction proteins, which controls the penetration of water 
soluble molecules. B) The transcellular pathway regulates solute flux through B (i) the 
cell membrane, B (ii) active transporters, B (iii) receptor mediated endocytosis and B 
(iv) absorptive mediated transcytosis (Abbott et al., 2006). 
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1.3.1.2 Enzymatic/Metabolic barrier 
The BBB possess a diverse range of enzymes capable of neutralizing many drugs or 
nutrients that attempt to pass the endothelial barrier.  This includes a variety of 
ectoenzymes such as peptidases and nucleotidases capable of metabolizing peptides and 
ATP respectively, while intracellular enzymes such as monoamine oxidase and 
cytochrome P450 can block many neuroactive and toxic compounds (el-Bacha and 
Minn, 1999).  These enzymes act in concert with the physical barrier properties of the 
tight junctions to restrict unwelcome entry of blood-borne solutes into the CNS. This 
enzymatic barrier also plays a role in regulating the polarity between the luminal and 
abluminal surfaces of brain endothelial cells that contribute to barrier function. Enzymes 
involved in establishing these properties are the γ-glutamyl transpeptidase and alkaline 
phosphatases on the luminal surface and the Na+-K+ ATPase and sodium-dependent 
neutral amino acid transporter associated with the subluminal surface (Abbott, 2005).    
 
1.3.1.3 Efflux barrier  
Another essential function of the BBB is the controlled removal of waste products and 
any potentially harmfully compounds from the brain into the blood stream. Even if 
certain drugs cross the endothelium via free diffusion and influx in the CNS, they can be 
followed by immediate active efflux back into the blood if the drug is a substrate for one 
of the many different active efflux transporters (AET). P-glycoprotein (P-gp) is the 
classic AET present at the BBB which has a broad substrate specificity for many 
xenobiotics compounds (Zhou, 2008). Multidrug resistance proteins (MRP-1), brain 
multidrug resistance protein (ABCG2/BCRP) and the organic anion-transporting 
polypeptide (OATP2) represent other commonly cited AET at the BBB (Deli et al., 
2005).  
 
1.3.2 Heterogeneity at the blood brain barrier 
The microvasculature within the BBB shows the most extreme form of phenotypic 
differentiation of any vascular bed within the body, with an upregulation and/ or down 
regulation of certain factors that are poorly expressed or absent from peripheral 
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endothelium (Abbott, 2005). Examples of this include the lack of fenestrations in 
neuronal endothelium, which are small pores between EC’s (common in capillaries of 
the glomerulus) and are replaced by tight junction complexes. These tight junctions are 
more complex and extensive in the brain and thus seal the intercellular cleft more 
effectively. The tightness of these junctions is such that they even restrict the movement 
of small ions such as Na+ and Cl- and exhibit transendothelial electrical resistance 
(TEER) values (an index of paracellular barrier integrity) between 1000-2000 ohm (Ώ) 
cm2 compared to 2-20 Ώ cm2 in peripheral capillaries (Rubin and Staddon, 1999, Abbott 
et al., 2006). It is believed that BBB EC’s contain 5-6 times more mitochondria per 
capillary section compared to rat skeletal tissue, enhancing the energy potential required 
for the active transport of nutrients to the brain (Persidsky et al., 2006b). The 
anticoagulant factor thrombomodulin, which is expressed by vessels surrounding all 
organs with the exception of the brain (Ishii et al., 1986), as is the anticoagulant tissue 
factor pathway inhibitor predominantly expressed in microvascular endothelium but is 
lowest in the brain (Osterud et al., 1995). Even though there is a definite diversity of 
factors present at the BBB interface, EC’s of this origin are not conformed to 
predetermined phenotype, but are induced by a variety of factors from the local 
environment. This local input from surrounding structures hold the key to this unique 
heterogeneity, as the endothelium is exposed to paracrine/endocrine influences from 
different cell types, along with varying degrees of biomechanical stresses.  
 
1.3.3 The Neurovascular Unit 
The NVU describes the interaction of microvascular endothelium with neural and glial 
tissue. Figure 1.7 below illustrates the close interactions of the four components of the 
NVU, namely astrocytes, pericytes, neurons and the basal lamina with their putative 
roles in establishing BBB characteristics as described.  
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Fig. 1.7: The Neurovascular Unit at the Blood Brain Barrier.  The BBB is formed by 
cerebral capillary endothelial cells, which are anchored to a basal lamina of ECM 
proteins and surrounded by astrocytic end feet processes. Pericytes are also in close 
proximity, while astrocytes provide the cellular link to neurons (Abbott et al., 2006). 
 
1.3.3.1 Astrocytes  
Astrocytes are a subtype of glial cells, i.e. non neuronal cells that comprise 
approximately 90% of brain mass and are categorized into divisions based on their 
structure and location. Fibrous astrocytes posses a star like morphology and are 
predominantly found in the white matter, while protoplasmic astrocytes reside in the 
grey matter containing a branched architecture enveloping neuronal processes. The third 
type, are the Bergmann glia, contained within the Purkinje layer of the cerebellar cortex 
containing two types of processes: thick processes which connect to Purkinje neurons 
and thin processes which project out of the cortex ultimately contacting blood vessels 
(Gee and Keller, 2005). One of the primary functions of astrocytes is to maintain 
extracellular K+ ion levels as a result of their release from signalling neurons, and thus 
regulate an optimal environment for neuronal signalling (Ransom and Sontheimer, 
1995).  Importantly though, astrocytes envelop 99% of the BBB endothelium and this 
close cell-cell association led to the suggestion that they could mediate specific features 
of the BBB barrier phenotype. Indeed there is overwhelming evidence from in-vitro 
studies suggesting that the co-culture of brain EC’s with astrocytes can induce/restore 
common BBB features, including tighter barriers as shown by increases in TEER 
(Colgan et al., 2008, Willis et al., 2004b, Willis et al., 2004a), the expression and 
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polarized localization of AET’s including P-gp (Schinkel, 1999), and specialized 
enzymes systems (Haseloff et al., 2005). Astrocytes secrete a variety of chemical 
mediators which act in paracrine fashion to induce specific effects on the endothelium. 
These include transforming growth factor-β, glial derived neurotrophic factor, basic 
fibroblast growth factor (bFGF) and angiopoietin 1, which have been shown to induce 
an increased localization of Claudin-1 and ZO-1 to cell-cell junctions, key proteins 
involved in the regulation of paracellular permeability. Although astrocytes have been 
shown to induce a range of characteristics in brain endothlelial cells it is unlikely that 
they are sufficient to induce the broad spectrum of BBB properties seen as astrocytes are 
present in circumventricular organs where capillaries have leaky barriers (Engelhardt, 
2005).  
    
1.3.3.2 Perictyes  
“Peri’ meaning around and “cyto” cell reflects the anatomical description of the location 
of pericytes at the abluminal side of the microvessel. For the large part, they are 
separated from brain EC’s by the basal lamina of ECM proteins, however cellular 
projections do invaginate through the lamina to cover approximately 20-30% of the 
microvascular circumference (Frank et al., 1987). Morphologically, pericytes contain a 
spherical cell body with a prominent nucleus and many cytoplasmic processes (Farrell et 
al., 1987). Pericytes have a close physical association with the endothelium as they share 
a common basal membrane and communication between them via gap junctions has 
been shown in-vitro (Lai and Kuo, 2005). Pericytes significantly contribute to the 
development, maintenance and regulation of the BBB and it has also been suggested that 
they help regulate the endothelial-astrocyte interaction (Ramsauer et al., 2002). As with 
astrocytes, co-culture models of brain EC’s and pericytes have been shown to induce 
tighter paracellular barriers as monitored by TEER and water soluble fluorescein tracer 
studies (Deli et al., 2005). These finding may in part be reflected by the fact that 
pericyte derived angiopoietin-1 has been shown to enhance occludin gene expression in 
brain EC’s, which would contribute to tight junction assembly at the paracellular 
junction (Hori et al., 2004). Furthermore under hypoxic conditions, an event associated 
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with BBB disruption, pericytes were shown to migrate away from the microvessel 
further implicating their role in barrier stabilization (Gonul et al., 2002).  
1.3.3.3 Neurons 
Whether or not neurons play a role in the development of the BBB phenotype is yet to 
be determined, however a wealth of evidence exists showing their critical importance in 
the regulation of cerebral blood flow and thus BBB function (Hawkins and Davis, 
2005). Neuronal tissue exhibits a constant, dynamic demand on the local cerebral 
microvasculature to meet their metabolic needs, and this close relationship between 
brain activity and blood flow has been demonstrated by neuroimaging although the 
exact signalling mechanisms are unknown (Paemeleire, 2002). Brain EC’s and/or 
associated astrocytes are innervated by a variety of neuronal projections, namely 
noradrenergic, serotonergic, cholinergic and GABA-ergic neurons (Persidsky et al., 
2006b). Chemically induced loss of noradrenergic stimulation of the microvasculature 
was associated with an enhanced vulnerability of the BBB to hypertension (Ben-
Menachem et al., 1982), as was a loss of cholinergic innervation (as observed in 
Alzheimer’s) associated with impaired cerebrovascular function (Tong and Hamel, 
1999). Moreover a study by Lee et al. showed a selective increase in BBB permeability 
rather than an anatomical disruption in response to intra-cerebral hemorrhage implying 
that communication between neurons and the vasculature may not just simply regulate 
cerebrovascular blood flow, but BBB permeability too (Lee et al., 1999).   
 
1.3.3.4 Extracellular matrix (ECM)  
The ECM through the expression of matrix proteins such as laminin, collagen IV and 
fibronectin serves as an anchor (basal lamina) for the endothelium and aforementioned 
members of the NVU. Brain endothelium expresses specific integrin and dystrogylcan 
receptor family members, which have been shown to be essential for organ development 
and physiological functioning of the CNS. For example deletion of the  α6, αV or β6 
integrin subunits results in embryonic or perinatal lethality or in the case of the latter 
two receptors, cerebral hemorrhage (Georges-Labouesse et al., 1996). These receptors 
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regulate cellular activities in a variety of ways including transducing extracellular 
stimuli to intracellular signals, forming a transmembrane link between the basal lamina 
and the cell cytoskeleton (Del Zoppo et al., 2006). With respect to BBB function, these 
matrices have been shown to influence the expression of tight junction proteins, 
suggesting a plausible role for the ECM in maintenance of paracellular permeability 
(Savettieri et al., 2000). A study by Rosenberg et al. was able to show that the ECM is 
strongly associated with the BBB permeability as a bacterial collagenase induced severe 
disruption of the basal lamina and opened the BBB (Rosenberg et al., 1993). Moreover 
Rascher and colleagues (2002) demonstrated that in response to a glioblastoma, BBB 
breakdown is reflected by changes in the molecular composition of both tight junction 
proteins and the basal lamina component agrin (Rascher et al., 2002).           
  
This concept of the NVU provides a framework for understanding the development, 
physiology and pathology of the BBB. An understanding of these factors is therefore 
crucial to the design and undertaking of any in-vitro based systems to mimic the in situ 
microenvironment of the BBB. Recently a triple co-culture in-vitro model incorporating 
freshly isolated primary brain EC’s, astrocytes and pericytes was established. This 
model elicited a characterizational profile of common BBB markers (Occludin, Claudin-
5, ZO-1) with typical junctional localization and TEER values of approximately 400 
Ώcm2 (Nakagawa et al., 2009). Therefore, this in-vitro model represents an ideal 
candidate for research on BBB physiology and pathology, and to test novel compounds 
for CNS drug delivery.    
 
1.3.4 Blood brain barrier disruption  
As discussed earlier, under physiological conditions the BBB is relatively impermeable. 
Conversely BBB dysfunction is characterized by disassembly of intercellular junctional 
complexes and has been implicated in a number of neurological diseases, including 
inflammation (uncontrolled leukocyte extravasation and cytokine production), infection 
(meningitis), neoplasia (metastatic brain tumors) and neurodegeneration (multiple 
sclerosis and Alzheimer’s Disease) (Weiss et al., 2008). In some incidences, the increase 
in BBB permeability can be a consequence of the pathology, as is the case with ischemic 
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stroke (Ilzecka, 1996) and a brain trauma (Morganti-Kossmann et al., 2002), whereas in 
the case of multiple sclerosis (MS), BBB opening is speculated to be the precipitating 
event (Hawkins and Davis, 2005). The vasoactive peptides bradykinin and histamine, 
along with the polyunsaturated fatty acid, arachidonic acid, and the neurotransmitter 
serotonin have been cited as classical inflammatory mediators of BBB permeability 
modulation (Abbott, 2000). Other humoral agents serving as permeabilizing factors 
include glutamate, aspartate, taurine, ATP, endothelin-1 (ET-1), TNF-α, IL-1 (Abbott, 
2000, Abbott, 2004, Chen et al., 2000, Kustova et al., 1999, Magistretti et al., 1999).  
Interestingly, these BBB-modulating agents can be released by the endothelium itself, 
albeit in response to inflammatory cytokines, and thus in autocrine fashion act on 
associated endothlelial receptors, e.g. ET-1 acts on ETa receptors. Also, cells of the 
surrounding NVU can interact with activated macrophages, which amplify the 
inflammatory responses leading to BBB alterations (Persidsky et al., 1999) or enhanced 
monocyte transmigration (Persidsky et al., 2006a). Although two possible pathways of 
molecular flux across the BBB exist, alterations in the tight and adherens junction 
complexes regulating paracellular permeability mechanisms are continually associated 
with various CNS disorders (Huber et al., 2001). Moreover the BBB has often been 
described as the rate limiting step in the development of drugs targeting neurological 
disorders of the brain. Thus, understanding the assembly and interactions of these 
junctional complexes will provide valuable insights into possible mechanisms for 
treatment of such disorders.       
 
1.3.5 Regulation of cerebral blood flow 
Being such a dynamic, non-stagnant organ, the brain requires a continuous supply of 
blood to ensure essential neuronal function and eliminate any risk of irreversible damage 
to its constituents, as observed with flow cessation during cerebral ischemia. Organs 
such as the kidney or liver are more tolerant to ischemia whereas the brain must 
incorporate specific defence mechanisms to compensate and sustain appropriate levels 
of cerebral perfusion.  An integrated effort between the NVU and cerebral blood vessels 
crucially regulate this process. Three lines of defence have been proposed. 
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1. Via neural influence over the cardiovascular system, the brain controls the 
distribution of blood flow. This hierarchical control can counteract any deficits 
in cerebral perfusion by redirecting blood flow from peripheral regions to the 
cerebral circulation. 
2. In response to fluctuations in arterial blood pressure, cerebrovascular 
autoregulation ensues to stabilize the cerebral perfusion rate. Under low arterial 
pressure the cerebral arteries vasodilate, compared to vasoconstriction when the 
arterial pressure increases, both of which impact to maintain downstream flow 
rates within the cerebral capillaries and venules 
3. The brain can also induce functional hyperaemia which causes an increase in 
blood flow to a specific region within the brain based on activity within that 
region, insuring adequate delivery of essential nutrients/gases to that area, but 
also removing any metabolic waste (Iadecola, 2004). 
These defence mechanisms are essential to CNS homeostasis. Any aberrant conditioning 
of factors regulating these processes i.e. vascular dysfunction will therefore have 
detrimental consequences for the CNS. 
 
1.3.6 Shear stress and the BBB 
Vascular endothelial sensitivity to blood flow was first observed more than 150 years 
ago by the famous pathologist Virchow, who noted profound changes in endothelial 
morphology along the arterial tree, which correlated with flow patterns. Indeed the 
hallmark of the endothelial response to prolonged exposure of laminar shear stress 
results in their elongation and realignment in the direction of flow (Dewey et al., 1981, 
Galbraith et al., 1998). This is an important adaptive response which alters the way in 
which the shear acts on the endothelium (Hahn and Schwartz, 2009). Furthermore, 
physiological levels of laminar shear stress can suppress EC apoptosis (Dimmeler et al., 
1997), decrease EC rates of proliferation (Akimoto et al., 2000), enhance levels of 
migration in response to wound healing (Sprague et al., 1997), regulate EC permeability 
(Siddharthan et al., 2007), repress anti-inflammatory mediators and activate various 
antioxidants to control ROS levels (Berk et al., 2001).     
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Rates of shear stress in the cerebral microvasculature range between 3-20 dynes/cm2 
(Desai et al., 2002). Interestingly, levels of cyclic strain are barely detectable in 
microvascular beds making shear stress the primary hemodynamic force influencing 
EC’s at the BBB. Similar to EC’s of non-neuronal origin, shear-induced stimulation of 
BBB endothelium can release a variety of protective vasoactive substances including 
NO, cyclooxygenase-2, adenosine and EDHF which induce vasodilation (Busse and 
Fleming, 2003).  
 
Stannes and colleagues demonstrated that shear stress acting in tandem with glial-
derived factors was essential for the induction and maintenance of the BBB (Stanness et 
al., 1997). Furthermore, recent experiments using the HCMEC/D3 cell line (human 
immortalized brain microvascular endothelial cell line) showed that physiological levels 
of flow maintained permeability characteristics of the BBB in the absence of co-culture 
with abluminal astrocytes, strengthening the functional relevance of physiological flow 
for BBB maintenance (Cucullo et al., 2008). Consistent with these findings, loss of flow 
alone (independent of hypoxia-hypoglycemia) contributed to BBB failure by enhancing 
leukocyte-mediated inflammatory mechanisms (Krizanac-Bengez et al., 2006). 
Moreover, Colgan et al. showed that biochemical changes in tight junction proteins were 
responsible for shear-induced upregulation of BBB function, thus offering a potential 
cellular mechanism for the physiological regulation of BBB function in response to flow 
(Colgan et al., 2007). Signalling mechanisms linking shear stress to changes in tight 
junction assembly at the BBB are notably lacking from literature, however could be of 
real therapeutic significance in pathologies eliciting compromised BBB function.  
         
1.4 Tight junctions 
A series of junctional complexes constitute most known barrier systems, namely tight 
junctions, adherens junctions, gap junctions and desmosomes. Out of all these junctions, 
endothelial tight junctions (zonula occludens) have been described as having the highest 
degree of complexity within the cardiovascular system (Nagy et al., 1984). By 
definition, tight junctions are domains of occluded intercellular clefts as first evidenced 
by initial studies using freeze fracture electron microscopy (Schulze and Firth, 1993, 
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Brightman and Reese, 1969). In general, tight junctions perform two distinctive 
functions; first they contribute to maintaining cell polarity and second, they seal 
adjacent EC’s preventing uncontrolled molecular flux (Schnittler, 1998). The assembly 
of the tight junction barrier during morphogenesis/tissue repair is a multistage process, 
initially involving the establishment of cell-cell contact by adherens junctions, the lateral 
extension of these contacts and the subsequent recruitment of transmembrane tight 
junction proteins to the intercellular cleft, forming the paracellular barrier (Fanning and 
Anderson, 2009). A study by Gumbiner and Simons first supported this notion, as they 
found that blocking antibodies against E-Cadherin, an essential component of adherens 
junction in epithelial cells, was a prerequisite for tight junction formation (Gumbiner 
and Simons, 1986). As the strands of the tight junction proteins become longer and 
interconnected, i.e. complex, the outer leaflets of adjacent membranes within junctional 
contacts become fused, forming “membrane kisses” (Kniesel et al., 1996).  
 
There are two key parameters that determine the functional quality of the tight junction: 
the intricacy of the strands and their association with the protoplasmic fracture face (P-
face) of the plasma membrane or with the exo-cytoplasmic fracture face (E-face) 
(Wolburg and Lippoldt, 2002, Engelhardt, 2005). In non-neuronal EC’s, tight junctions 
predominantly associate with the E-face of the plasma membrane, whereas P-face 
associations prevail at the BBB. This P-face association was considered to correlate with 
barrier function and become a morphological criterion of endothelial barrier properties 
in mammals and is hypothesized that this particle distribution is the result of 
cytoplasmic anchoring of tight junction proteins, which differs in BBB and non-BBB 
endothelia (Wolburg et al., 1994). The basic molecular equipment of the tight junction is 
similar to those found between epithelial cells, however components of the adherens and 
tight junction intermingle in endothlelial rather than epithelial cells (Schulze and Firth, 
1993). Specific to the BBB, tight junctions are the rate limiting step in the paracellular 
flux of solutes between endothlelial cells and are the most apically located of the 
intercellular junctions (see figure 1.8) (Huber et al., 2001). Tight junctions are composed 
of an intricate series of transmembrane and cytoplasmic accessory proteins linked to the 
actin cytoskeleton that from the paracellular seal.  
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Fig. 1.8: Tight Proteins of the Blood Brain Barrier. Schematic figure of the proposed 
associations of the key, well known proteins of the tight junction complex at the BBB 
(Huber et al., 2001)).  
 
 
As demonstrated in figure 1.8, there are three integral transmembrane proteins forming 
the tight junction complex. Occludin, a 60-65 kilodalton (kDa) protein was the first of 
these to be identified (Furuse et al., 1993), with a key role in the regulation of barrier 
tightness (discussed further in section 1.4.1). To date, 24 mammalian isoforms of the 
claudin family have been identified, with molecular weight ranges between 20-27 kDa 
and are vital in the assembly of junctional complex (discussed further in section 1.4.3) 
(Krause et al., 2008). The junctional adhesion molecules (JAM’s) are members of the 
Immunoglobulin superfamily, of which 3 isoforms have been identified; JAM-A, JAM-
B and JAM-C. Their predominant function besides tight junction maintenance is to 
facilitate leukocyte extravasation, in association with the platelet endothelial cellular 
adhesion molecule 1 (PECAM-1) (Huber et al., 2001). These transmembrane proteins 
are anchored to the actin cytoskeleton by a complex of cytoplasmic accessory proteins, 
which provide structural support adjacent to the junctional cell membrane. The zonula 
occludens proteins (ZO-1, ZO-2 and ZO-3) belong to family of proteins known as 
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MAGUKs (membrane-associated guanylate kinase like proteins), which serve as 
recognition sites for tight junction placement and a support structure for signal 
transduction proteins (discussed further in section 1.4.2) (Haskins et al., 1998). AF6 
(All-1 fusion partner from chromosome 6) interacts with JAM via N-terminus 
interaction with ZO-1 and serves as a scaffold protein regulating cell-cell contacts 
(Yamamoto et al., 1997). Cingulin, a 140 kDa  myosin-like protein, existing as a dimer 
intertwined in a “coiled-coil”, has been shown to interact with ZO-1, -2, -3, myosin, 
JAM and AF6, and links the tight junction cytoplasmic accessory complex to the 
cytoskeleton (Cordenonsi et al., 1999). The 7H6 antigen is a phosphoprotein, which has 
been shown to play a role in the regulation of paracellular permeability to ions and 
macromolecules (Satoh et al., 1996). Vinculin is another actin binding phosphoprotein, 
which facilitates the interaction of the tight junction with the actin cytoskeleton, and its 
activation by specific kinases can trigger disassembly of the complex (Harhaj and 
Antonetti, 2004).   
 
Many signalling pathways have been implicated in the regulation of permeability 
through modification of tight junctions, including G-proteins (Granderath et al., 1999), 
serine-, threonine-, tyrosine-kinases (Collins et al., 2006), cyclic adenosine 
monophosphate (cAMP) levels (Wolburg et al., 1994), aswell as proteases and cytokines 
(Adamson et al., 1999). These mediators can act at the level of the tight junction or 
through modulation of cytoskeletal elements. Furthermore, the importance of 
cytoskeletal integrity in-vivo was demonstrated by infusions of cytochalasin D, an 
inhibitor of actin polymerization, which led to increased blood brain barrier permeability 
(Nag, 1995).  
 
1.4.1 Occludin 
In 1993, Furuse et al. using chick liver raised 3 monoclonal antibodies specific for a 65 
kDa protein in rats. It was assigned the name occludin derived from the Latin word 
“occlude” and became the first transmembrane tight junction protein to be identified. 
This anti-chick antibody failed to detect occludin in mammalian tissues and it wasn’t 
until 1996 that the protein was first detected in humans (Ando-Akatsuka et al., 1996). 
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Based on amino acid sequencing, there is a 90% homology between human, murine and 
canine occludin, however only a 50% homology exists between avian and marsupial 
structures. Structurally occludin is a tetraspanning membrane protein, consequently 
possessing two extracellular loops that form homophilic interactions with occludin from 
adjacent EC’s, a cytoplasmic COOH- and NH2- terminus, and can be divided into 5 
separate domains (A-E). The COOH terminus is strongly concentrated with charged 
amino acids and the extracellular (EC) domains are rich in tyrosine and glycine residues 
(see figure 1.9 below) (Feldman et al., 2005). The human occludin gene was mapped to 
chromosome band 5q.13.1, and the possibility of several alternatively spliced products 
was noted due to the existence of several occludin mRNA bands in Northern blots 
(Saitou et al., 1997). Mankertz et al. identified 4 alternately spliced mRNA transcripts, 
of which two expressed translated occludin proteins that resulted in altered distribution 
patterns of occludin and a loss of co-localization with ZO-1. These splice variants 
lacked the 4th transmembrane domain, thus highlighting the significance of the region in 
targeting occludin to the tight junction (Mankertz et al., 2002). 
 
Fig. 1.9: Schematic depiction of occludin structure and domains. Adapted from 
(Feldman et al., 2005). 
 
37 
 
1.4.1.1 Occludin function 
The function of occludin was initially investigated following transfection of chick 
occludin complementary DNA (cDNA) in Madin-Darby Canine Kidney (MDCK) cells 
using a Lac-inducible vector. Following induction of occludin expression by iso-propyl-
β-D-thiolgalactoside (IPTG), TEER values across MDCK monolayers increased 
progressively and were 30-40% greater than control levels at 31 hours post induction 
(McCarthy et al., 1996). Expression of occludin correlates with barrier function, as 
arterial EC’s express 18-fold greater occludin protein levels than venous EC’s and form 
a tighter barrier (Kevil et al., 1998). Moreover occludin expression is most prominent at 
the BBB. The N-terminus of occludin (domain A) has been shown to be functionally 
relevant to the regulation of barrier function. Studies using NH2 truncated mutants of 
occludin exhibited alterations in transendothelial electrical resistance (TEER) values and 
gaps were shown to appear in the P-face associated tight junction strands. It was 
postulated that the N-terminally truncated mutant was unable to oligomerize with other 
tight junction proteins, thus explaining the gaps between the strands (Bamforth et al., 
1999). Wong and Gumbiner used peptide mimics of the two EC domains (B and D) of 
occludin, termed Occ-1 (corresponding to domain B) and Occ-2 (domain D) to decipher 
their roles in the junctional seal. Occ-2 appeared to have the most significant effect as it 
not only disrupted the integrity of the tight junction barrier, it also reduced the 
localization of occludin to the junction complex (Wong and Gumbiner, 1997). 
Subsequent work by Medina and colleagues confirmed these findings using truncated 
constructs of the relevant EC domains and found occludin present at the basolateral 
surface and not at the tight junction (Medina et al., 2000).  
 
The COOH terminus is also believed to perform essential roles in correct tight junction 
assembly. This region binds with ZO-1 within its coiled-coil domain, although 
conflicting data concerning specific roles of the COOH terminus in trafficking of 
occludin to the junctional complex exist. Work by Furuse et al. showed that this region 
is required for ZO-1/ZO-2 binding, and that it is necessary for occludin to localize at the 
tight junction (Furuse et al., 1994). However experiments by Balda et al. using stable 
MDCK-II lines expressing either full-length or COOH terminally truncated chicken 
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occludin showed that the COOH-terminal cytoplasmic domain is not essential for 
trafficking of occludin to the tight junction. Both mutants did induce an increase in 
TEER, but overexpression of occludin also increased paracellular permeability (Balda et 
al., 1996). It was postulated that the interaction of occludin with ZO-1 is necessary for 
occludin to function with the junctional complex. With continued overexpression of 
occludin, saturation of the cellular pool of ZO-1 may of occurred, and the unbound 
occludin was able to form pores within the tight junction (McCarthy et al., 1996).     
 
1.4.1.2 Regulation of occludin 
A host of signal transduction pathways appear to be able to modulate occludin behavior 
and thus tight junction assembly. Phosphorylation seems to be the key mechanism, thus 
placing a great emphasis on the role of specific kinases and phosphatases regulating the 
functional activity of occludin. Work by Sakakibara and colleagues initially discovered 
that occludin was highly phosphorylated in MDCK cells exhibiting high levels of 
TEER, with phosphospecific sites identified to be predominantly on serine, and to a 
lesser extent threonine residues (Sakakibara et al., 1997). Moreover findings by Clarke 
et al. found an increase in permeability in LLC-PK1 epithelial cells concomitant with a 
dephosphorylation of occludin threonine residues as a result of protein kinase C (PKC) 
activation (Clarke et al., 2000). PKC is a serine/threonine kinase, and the detection of 
dephosphorylated occludin at threonine residues would suggest PKC is not acting 
directly on occludin, but further upstream in a signalling cascade. The role of 
phosphorylation of tyrosine residues of occludin also appears crucial in regulating 
barrier function. Indeed published findings from our laboratory has shown the cyclic 
strain-induced tight junction organization of bovine aortic endothelial cells (BAEC’s) 
involved a significant tyrosine dephosphorylation of occludin (Collins et al., 2006). 
Other investigations support this response, including work by Wachtel et al. who 
showed that inhibition of tyrosine phosphatases with phenylarsine oxide and 
pervanadate induced proteolysis of occludin in human umbilical vein endothelial cells 
(HUVEC’s) (Wachtel et al., 1999). Furthermore oxidative stress-induced tyrosine 
phosphorylation of occludin disrupted the occludin-ZO-1 association at the tight 
junction complex (Rao et al., 2002). Consistent with this focal ischemia in cerebral 
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capillaries lead to an increase in occludin tyrosine phosphorylation levels via a Src 
dependent mechanism (Takenaga et al., 2009).  
 
The coiled-coil domain is also believed to function as a target site that can interact with 
specific regulatory proteins, including c-Yes (non-receptor tyrosine kinase), the p85 
regulatory subunit of PI3K, protein kinase C-ζ and the gap junction protein connexin 26 
(Feldman et al., 2005). Some of the cell-signalling mediators identified in regulating 
occludin include members of the small GTPases, namely RhoA and Rac1,which through 
constitutively active mutants induced disorganization of occludin at the tight junction 
(Jou et al., 1998). The protease rMCP-II, which is a chymotrypsin like enzyme 
decreased immunostaining of occludin at the junction in MDCK monolayers 
(Scudamore et al., 1998). The cytokine hepatocyte growth factor (HGF), had been 
shown to decrease expressional levels of occludin in human vascular endothelial cells, 
concomitant with a decrease in TEER (Jiang et al., 1999). Low levels of the 
hemodynamic force, laminar shear stress was also shown to decrease both endothelial 
cell occludin mRNA and protein expression in porcine arterial endothelial cells (Conklin 
et al., 2002). Thus occludin can be regulated by a variety of extracellular and 
intracellular signalling mechanisms, and it appears that the downstream consequence of 
either serine/threonine phosphorylation and/or tyrosine dephosphorylation of occludin 
are critical to maintaining tight junction assembly. Moreover, it appears that various 
kinases and phosphatases work in a coordinate manner to regulate these post-
translational changes. 
 
1.4.1.3 Clinical implications 
Disturbances in the physiological regulation of occludin, with respect to 
phosphorylation changes and altered distribution or expression patterns are often evident 
during early manifestations in human disease. Microvessels of human brain tumors are 
consistently known for their ability to down-regulate occludin levels, and the resulting 
tight junction ‘leakiness’ has been attributed to the formation of cerebral edema (Davies, 
2002, Papadopoulos et al., 2001). Similarly, occludin localization patterns and 
expression are altered with increasing grades of prostate cancer, which was associated 
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with loss of cell polarity (Busch et al., 2002). With respect to diabetes, elevated levels of 
vascular endothelial growth factor (VEGF) in diabetic rats was believed to be the 
mechanism which significantly reduced occludin expression and altered the occludin 
phosphorylation state, a result which correlated with an increased permeability to 
macromolecules at the blood retinal barrier (Antonetti et al., 1998, Barber and Antonetti, 
2003). Furthermore, alterations in the homeostatic occludin profile are observed in 
various disease conditions including inflammation (Burgel et al., 2002, Kucharzik et al., 
2001), human immunodeficiency virus (HIV) encephalitis (Dallasta et al., 1999), MS 
(Minagar et al., 2003) and even aging (Mooradian et al., 2003). In summary occludin 
represents an excellent therapeutic strategy for controlling junctional barriers, but 
requires a more in-depth understanding about the specific cellular/molecular 
mechanisms regulating its role in disease/physiology.    
 
1.4.2 Zonula Occludens 
Tight junctions consist of several cytoplasmic accessory proteins, of which the zonula 
occludens 1 (ZO-1) protein has been the most extensively studied. ZO-1, with a 
molecular weight of 210-225 kDa was the first tight junction protein to be identified and 
was later found to co-precipitate with other polypeptides of this plaque, namely ZO-2 
(160 kDa) and ZO-3 (130 kDa) (Stevenson et al., 1986, Jesaitis and Goodenough, 1994). 
ZO-1 is ubiquitously expressed at both the tight and adherens junctions of endothelial 
and epithelial cells, but can also be found in cells lacking tight junctions, such as 
fibroblasts and cardiac myocytes through its interactions with the cadherin superfamily 
(Itoh et al., 1993).  
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Fig. 1.10: Structure and binding partners of ZO-1. The N terminal portion of ZO-1 
contains 3 PDZ domains, a basic domain (+), Src homology region 3(SH3), and a 
catalytically inactive guanylate kinase (GUK) homologue. The C-terminal half contains 
an acidic region (-), an alternatively spliced α motif and proline rich terminal domain 
(structure adapted from (Gonzalez-Mariscal et al., 2003). 
 
When full length cDNA of  ZO-1 was sequenced, the protein was identified as a 
member of the family of membrane associated guanylate kinase proteins, termed 
MAGUK, that shared sequence homology to the tumor suppressor protein disc large 
(Dlg) of septate junctions in Drosophila and the postsynaptic density protein 
PSD95/SAP-90 of synaptic densities in neurons (Willott et al., 1993). Proteins in this 
family are recognized by having structurally conserved PDZ, SH3 and GUK domains 
(see figure 1.10 above). ZO-1 contains 3 PDZ domains, which enable protein-protein 
interactions. These modules are approximately 80-90 amino acids long, enable protein-
protein interactions via recognition of a short peptide motif in the target protein and play 
a crucial role in the spatial clustering and anchoring of transmembrane proteins within 
specific subcellular domains (Gonzalez-Mariscal et al., 2000). With ZO-1, PDZ1 at the 
COOH terminal binds with the transmembrane protein claudin, PDZ2 associates with 
ZO-2 and -3 through dimerization of their respective PDZ domains, while PDZ2 and 3 
interacts with JAM (Gonzalez-Mariscal et al., 2003). The SH3 domain mediates 
interactions with cytoskeletal elements and signalling proteins such as the ZO-1 
associated kinase (ZAK), which is a serine/threonine kinase that phosphorylates residues 
between the SH3 and GUK domain. Occludin lacks a PDZ binding consensus on its C-
terminus and binds to ZO-1 via a portion of the GUK and acidic domain (Furuse et al., 
1994, Fanning et al., 1998), a domain on occludin that has also has been implicated in its 
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trafficking to the tight junction. ZO-1 has a proline rich C-terminus which favors 
associations to actin binding proteins or the actin cytoskeleton. The C-terminus also 
contains a variably expressed α motif arising from post-transcriptional modifications 
due to alternative RNA splicing. This α+ isoform (80 amino acid sequence) is 
predominantly expressed in epithelial cells, while the α- isoform is more specific to 
endothelial cells (Willott et al., 1992).         
1.4.2.1 ZO-1 function 
Besides it role as a hub facilitating protein-protein interactions, ZO-1 is also crucial in 
the assembly of tight junction complexes via the trafficking of tight junction proteins to 
the apical sub-membrane domain and bridging their connection to the cortical based 
actin cytoskeleton (Fanning and Anderson, 2009). ZO-1 has also been implicated in the 
assembly of the adherens junction complex, a process mediating cell-cell adhesion, 
which occurs prior to the establishment of the tight junction complex. Studies have 
shown that ZO-1 co-localized with adherens junction proteins such as α-catenin, 
AVCRF (armadillo repeat member of the catenin family) and afadin before associating 
with the tight junction complex. (Kausalya et al., 2004, Yamamoto et al., 1997). The 
notion of ZO-1-mediated cell-cell adhesion also holds true for non endothelial/epithelial 
cells such as fibroblasts where ZO proteins are active components in adherens junction 
formation. Thus the accepted hypothesis is that ZO proteins use the direct interaction 
with adherens junction proteins as a positional signal during initial cell-cell adhesion 
and thus recruit tight junction proteins into an apical complex that becomes separated 
from the adherens junction (Fanning and Anderson, 2009).  
 
With respect to functional consequences of ZO-1 exhaustion, work by Umeda and 
colleagues showed that depletion of ZO-1 and ZO-2 in a mammary epithelial cell line 
completely abrogated tight junction assembly and more recently work by Fanning et al. 
have revealed a novel role for the acidic/U6 motif in the correct cellular localization of 
tight junction proteins, as a mutant of ZO-1 (lacking the U6 motif) induced ectopic 
displacement of tight junctional proteins, ZO-1, occludin and claudin on the lateral cell 
membrane (Umeda et al., 2006, Fanning et al., 2007). Moreover, targeted disruption of 
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ZO-1 in mice results in embryonic lethality that is correlated with the disruption of the 
paracellular barrier and the structure of cell junctions (Katsuno et al., 2008). Besides 
junctional regulation, a role for ZO-1 in the regulation of cell-cell cycle has also been 
well documented (Gottardi et al., 1996, Balda and Matter, 2000). In sub-confluent 
epithelial cells, ZO-1 localizes in the nucleus, as compared to the edge of cells in 
wounded monolayers indicating its nuclear localization in relation to the immaturity of 
the cell contact. A Y-box transcription factor ZONAB binds with the SH3 domain of 
ZO-1, and co-localizes with it at the tight junction and the nucleus suggesting a role for 
ZO-1 in regulating gene expression. Thus, it is apparent that ZO-1 is a multifunctional 
protein involved in establishing and recruiting junctional components, but is also 
implicated in cell cycle progression.          
 
1.4.2.2 ZO-1 regulation 
Like occludin, ZO-1 is a phosphoprotein that can be subjected to post-translational 
modifications regulating its biological function. The effect of specific phosphorylation 
changes of ZO-1 on physiology of the tight junction remains somewhat controversial. 
For the main part, tyrosine phosphorylation of ZO-1 seems to be associated with a 
weakening of the junctional barrier, as treatment with the non-receptor tyrosine kinase 
Src (Takeda and Tsukita, 1995), vascular endothelial growth factor (VEGF) (Antonetti 
et al., 1999), and tyrosine phosphatase inhibitors (Staddon et al., 1995) significantly 
increased paracellular permeability. Interestingly though, during tight junction 
reassembly following ATP repletion, ZO-1, -2 and -3 become tyrosine phosphorylated, 
however only in the latter two were significant changes detected (Tsukamoto and 
Nigam, 1999). Inconsistencies in studies that assessed serine/threonine phosphorylation 
of ZO-1 in parallel with assays of permeability are also prevalent. Reports have shown 
that inhibition of serine/threonine phosphatases with okadaic acid reduced levels of 
TEER and immunostaining of ZO-1 at cell borders in mammary epithelial cells, which 
was consistent with the finding of Ward and colleagues using MDCK cells in response 
to epidermal growth factor treatment (Ward et al., 2002, Singer et al., 1994). 
Conversely, the activation of PKC (serine/threonine kinase) through the activator 1,2-
dioctanoylglycerol induced the junctional localization of ZO-1 and development of 
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TEER, which were consistent with published findings from our laboratory by Collins et 
al. showing that cyclic strain-induced regulation of tight junction assembly and barrier 
function involves phosphorylation of ZO-1 on serine and threonine residues (Balda et 
al., 1993, Collins et al., 2006). Collectively, these results reveal that ZO phosphorylation 
plays a vital role in junctional remodeling and permeability regulation and differences in 
responses may be reflected due to variation in applied stimulants and differences in cell 
lines used.  
 
1.4.2.3 ZO-1 clinical implications     
Studies have shown that under inflammatory conditions such as those accompanied with 
MS, increases in the infiltration of leukocytes lead to the breakdown of ZO-1 and 
occludin, which is accompanied by re-organization of the actin cytoskeleton. The 
inflammatory cytokines TNF-α and IL-1 have been described as key inflammatory 
mediators of the alterations of BBB permeability in animal models of MS (Minagar and 
Alexander, 2003, Forster et al., 2007). Also, the pro-inflammatory transcription factor, 
nuclear factor-kappa B (NF-κB) has been shown to specifically down regulate ZO-1 
gene expression and re-distribution of the protein away from the intercellular junctions, 
concomitant with an increase in Caco-2 tight junction permeability (Ma et al., 2004). 
Heightened levels of VEGF, as observed in diabetic retinopathy have been shown to 
regulate post-translational modifications of ZO-1 (and occludin), which as described in 
section (1.4.1.3) are capable of modulating paracellular permeability (Harhaj et al., 
2006). The expression profile of ZO-1 also appears to be down-regulated/abnormal in 
liver metastases (Erin et al., 2009) and gastric carcinoma (Ohtani et al., 2009). Based on 
the information above, strategies targeting ZO-1 could potentially enhance tight junction 
assembly in disease states, possibly via restoration of its expression profile or re-
localization to the junctional membrane but a greater understanding of the multitude of 
factors regulating ZO-1 is still required.    
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1.4.3 Claudin 
Claudin is derived from the Latin claudere, meaning to close, thus alluding to a potential 
function for this pivotal tight junction protein. In 1998, work by Furuse and co-workers 
purified two peptides and sequenced full-length cDNAs from chick liver, revealing 
related proteins of 211 and 230 residues which were named claudin-1 and -2 (Furuse et 
al., 1998a). Currently 24 different isoforms of claudin have been identified in humans 
but they lack sequence homology to occludin (Krause et al., 2008). Like occludin, 
claudin possesses a tetraspan membrane topology, with two extracellular loops and a 
cytoplasmic C- and N- terminus (See figure 1.11 below).  
 
Fig. 1.11: Schematic depiction of claudin structure. The N-terminus and first EC loop 
are well conserved among claudins. The second EC loop is much shorter and less 
characterized while the C-terminus contains variable sequences amongst isoforms with 
the exception of the YV motif which is highly conserved. (structure adapted from 
(Turksen and Troy, 2004).   
 
1.4.3.1 Claudin function 
Interest in identifying other markers regulating paracellular barrier tightness stemmed 
from findings whereby tight junctions still formed in occludin knockout mice, although 
these mice did develop a variety of abnormalities in tissues requiring tight junctions 
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(Saitou et al., 1998). Experiments by Furuse and co-workers first established a 
functional role for claudins in tight junction formation. Transfection of claudins1-3 into 
mouse L fibroblasts (which don’t express tight junctions) induced the establishment of 
intra-membranous strands as observed in freeze fracture replica’s, findings which were 
similar to work by Morita and colleagues with claudin-5 performed shortly after  
(Furuse et al., 1998b, Morita et al., 1999). Not only are claudins pivotal to the formation 
of tight junctions, they also play an important role in maintaining the barrier properties 
of the cell-cell contact, thus sealing the intercellular cleft for solute flux. Work by Inai et 
al. showed that overexpression of claudin-1 in MDCK cells increased TEER values four 
fold, concomitant with a reduced flux of fluorescently labelled dextran versus control 
cells (Inai et al., 1999)  
 
Claudin expression profile varies substantially within different tissues, thus highlighting 
potential divergence in the contribution of claudin isoforms to barrier properties. For 
example claudins-2, -7, -10, -15 and -16 have been described as ‘pore’ forming claudins 
regulating paracellular cation permeability whereas claudins -4, -5, -8, -11, -14 and -19 
selectively inhibit cation flux through the tight junction (Krause et al., 2008). The first 
extracellular loop (ECL1) of claudin appears pivotal in determining the sealing and pore 
forming potential of the claudin strand, which is dependent on the specific charge 
present on amino acids residues. For example replacement of basic by acidic residues in 
claudin-4 ECL1 increases cation permeability (Hou et al., 2005). Less is known about 
the ECL2 but it is believed to be essential for claudin-claudin interactions between 
adjacent cells (Piontek et al., 2008). Moreover, Furuse et al. demonstrated that the 
introduction of claudin-2 into MDCK I cells (normally expressing claudin-1 and -4), 
decreased TEER values 20 fold to levels characteristic of those observed in MDCK II 
cells (normally expressing claudin-2), whereas introduction of claudin-3 into MCDK I 
cells showed no shift in TEER values (Furuse et al., 2001). This suggests that the co-
existence of various isoforms in certain tissues determine the degree of barrier tightness 
within the tight junction. The cysteine residues contained within a signature motif in 
ECL1 are thought to form an intramolecular disulfide bond, thus stabilizing the 
conformation of the loop (Findley and Koval, 2009). The C-terminus contains a YV 
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motif which enable interactions with the PDZ1 domain of ZO-1, -2 and -3. Claudins can 
still however be targeted to the tight junction in the absence of this ZO binding motif, 
but it formed aberrant tight junction strands suggesting that the localization or retention 
of claudin at the apical tight junction requires interactions with ZO-1 (Kobayashi et al., 
2002).  To date, claudins-1, -3, -5 and -12 have been shown to be expressed in capillary 
EC’s of the BBB, of which none are described as pore forming claudins, thus 
contributing to the stringent control over paracellular flux within the CNS.  
 
1.4.3.2 Claudin regulation 
Phosphorylation changes in claudin drastically regulate the barrier properties at the tight 
junction complex. A host of multiple kinases and phosphatases have been shown to 
regulate claudin. The serine/threonine phosphatase PP2A was shown to decrease 
claudin-1 phosphorylation in MDCK cells, an event which correlated with an increase in 
paracellular permeability (Nunbhakdi-Craig et al., 2002). Protein kinase A (PKA)-
mediated threonine phosphorylation of claudin-3 in ovarian cancer cells was shown to 
induce its cytoplasmic localization and barrier dysfunction (D'Souza et al., 2005), whilst 
PKA was shown to be necessary for claudin-16 assembly and function in MDCK cells 
via serine phosphorylation. Palmitoylation on cysteine residues is another type of post-
translational modification that increases the hydophobicity of claudin, and thus it’s 
integration into the tight junction complex (Van Itallie et al., 2005). Specific to 
signalling at the BBB, the secondary messenger cAMP was shown to not only enhance 
claudin-5 expression, but also phosphorylate (via PKA) claudin-5 and enhance its 
immunoreactivity along cell borders, suggesting a promotional role in tight junction 
assembly (Ishizaki et al., 2003). Interestingly though, other PKC isoforms (PKC-α and 
ζ) have been shown to phosphorylate claudin-5 under inflammatory conditions, leading 
to the disappearance of claudin-5 from the cell membrane. PKC-α also induced an 
increase in paracellular permeability, a mechanism which was found to be dependent of 
RhoA (see section 1.6.2.1), a RhoGTPase known to drive actin based cell contractility 
(Stamatovic et al., 2006). For the most part, post-translational modifications at the 
cytoplasmic C-terminus of claudin are the dominant target sites for 
kinases/phosphatases, with the resulting effect on barrier function highly dependent on 
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the specific upstream signalling mediators and the specific residues phosphorylated 
(Fujibe et al., 2004, Yamauchi et al., 2004, Tanaka et al., 2005).  
 
1.4.3.3 Claudin clinical implications 
Several pathological conditions are capable of modulating tight junction assembly via 
alterations in claudin physiology. Bacterial toxins such as cytotoxic necrotizing factor-1, 
and the gram negative bacterium Helicobacter pylori, have both been shown to cause 
claudin internalization, with a resulting increase in epithelial permeability (Fedwick et 
al., 2005, Hopkins et al., 2003). Clostridium perfringens enterotoxin exposure was also 
shown to specifically interact with ECL2 of claudin-3 and -4, thus blocking tight 
junction reformation, in addition to its endocytotic capabilities (Fujita et al., 2000). 
Prasad and colleagues showed that the inflammatory cytokine TNF-α can downregulate 
claudin-2 and-3 expression in crypt epithelial cells with a resulting increase in 
paracellular permeability. Paradoxically in the same set of experiments, the cytokine 
interleukin (IL)-13 enhanced claudin-2 expression, but increased permeability 
suggesting a different mechanism of action to TNF-α (Prasad et al., 2005). Mutations in 
four claudin genes have also been reported, of which a mutation in the claudin-19 gene 
(highly expressed in the renal tubules and retina) has been linked to families affected by 
severe hypomagnesemia, renal failure and ocular abnormalities (Konrad et al., 2006). At 
the BBB, HIV infected cells are capable of modulating BBB structures via the release of 
the Tat protein, which has been shown to decrease expression of claudins-1 and -5, 
along with inducing the cellular redistribution of claudin-5 immunoreactivity (Andras et 
al., 2003). This mechanism could therefore facilitate HIV trafficking into the brain. 
Moreover, Wolburg and colleagues demonstrated that claudin-3 is a central component 
determining the integrity of the BBB in vivo, as its localization is selectively lost during 
pathological conditions such as tumors (glioblastoma multiforme) or during 
inflammation (autoimmune encephalomyelitis) (Wolburg et al., 2003). These findings 
make claudin an ideal target for therapy-based interventions, however a greater 
understanding of signalling mechanisms regulating claudin in 
physiology/pathophysiology need to be deciphered.   
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1.5 Adherens junctions  
Adherens junctions are a dynamic complex present at cell-cell borders between adjacent 
endothelial and epithelial cells. In EC’s they exist as intermingled complexes with tight 
junction proteins, compared to spatially distinctive complexes in epithelial monolayers. 
Unlike tight junction complexes, which are more renowned for their ‘sealing properties’, 
the associated proteins of the adherens junction have been implicated in a wide variety 
of cellular functions and changes in their composition or function can therefore have 
more complex effects on overall vascular homeostasis (Dejana et al., 2008). Adherens 
junction establishment has been shown to precede the development of tight junctions 
during initial cell-cell contact, which is followed by tight junction organization once the 
adherens junction has been stabilized (Dejana, 2004).  Adherens junctions are formed by 
members of the cadherin superfamily of adhesion proteins, of which there are different 
subtypes. Most is known about the classic cadherins, of which epithelial (E) – cadherin 
(type I classical cadherin) is most commonly associated with epithelial cells whereas 
vascular endothelial (VE) – cadherin (type II classical cadherin) is a vascular specific 
cadherin. The cytoplasmic tail of VE-Cadherin (as with many other cadherins) interacts 
with other adherens junction proteins, namely the catenins, comprising p120-catenin, β-
catenin, and α-catenin (see figure 1.12 below). Catenin is the Greek for ‘link’, and its 
members were named as such because of their roles in linking cadherins to the actin 
cytoskeleton (Gumbiner, 2005). Also important in adherens junction assembly is nectin, 
a cell-cell adhesion molecule of the IgG superfamily, which is recruited to the cell-cell 
complex through its interaction with the actin binding protein afadin, which has also 
been implicated in the organization of tight junctions through interactions with ZO-1 
and JAM (Takahashi et al., 1999, Fukuhara et al., 2002).   
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Fig. 1.12: Endothelial adherens junction. VE-Cadherin is presented as a cis 
homodimer exhibiting homophilic interaction with neighboring VE-Cadherin via 
extracellular (EC) domains. The core cadherin-catenin complex and its proposed 
mechanism of contact with the actin cytoskeleton are also presented. Nectin is linked to 
the actin cytoskeleton via afadin (AF6). Figure adapted from (Wallez and Huber, 2008, 
Gumbiner, 2005). 
 
1.5.1 VE-Cadherin 
In 1990 Heimark and colleagues produced a monoclonal antibody (mAb) (Ec6C10), 
which reacted with a specific cell surface antigen present in confluent monolayers of 
bovine aortic endothelial cells, and not MDCK monolayers. This molecule was found to 
mediate intercellular adhesion in a calcium-dependent manner, a feature which had 
already been shown to be a requirement of cadherin family cell adhesion molecules in 
certain epithelia (Heimark et al., 1990). The biological and biochemical characteristics 
of this novel endothelial-specific cadherin were further characterized in 1992 by 
Lampugnani and colleagues using the 7B4 mAb, who noted an exclusive staining 
pattern localized to cell borders of human endothelium in vitro and in situ, and found no 
cross reactivity with other cell types such as fibroblasts, SMC’s or circulating blood 
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cells. The cDNA was sequenced and found to be identical to cadherin-5 (CD5), a 
recently characterized cadherin family member by Suzuki et al. CD5 displayed 
significant homology with previously described cadherin sequences including a highly 
conserved cytoplasmic tail (Suzuki et al., 1991, Lampugnani et al., 1992). It was 
subsequently renamed VE-Cadherin and may also be referred to as CDH5, CD144 or 
7B4 (Breviario et al., 1995). 
 
VE-Cadherin with a molecular weight of 140 kDa, is a single pass transmembrane 
protein exhibiting cis and trans homophilic interactions via five homologous 
extracellular domains (EC1-5) in a Ca2+-dependent manner. Binding of Ca2+ is essential 
for the correct conformational organization of EC domains (Halbleib and Nelson, 2006). 
Dimerization/trimerization of VE-Cadherin in cis occurs through interactions of EC4, 
while VE-Cadherin dimers interact in trans through their EC1 domain (as shown in 
figure 1.12) (Hewat et al., 2007). Once homophilic engagement occurs, the EC domains 
develop additional forces, therefore tightening the adhesive contacts between adjacent 
cells. However this mechanism can also be dissociated in response to a shift in the 
cellular environment (Gavard, 2009). VE-Cadherin’s cytoplasmic domains associate 
with the catenin family members of the adherens junction. Each catenin member has 
unique roles in stabilizing the association of VE-Cadherin between adjacent cells and 
with the actin cytoskeleton. The VE-Cadherin proximal cytoplasmic tail contains a 
binding site for p120 catenin, with a distal binding region for β-catenin towards the C-
terminus. In contrast to this, α-catenin does not bind directly to VE-Cadherin, but binds 
to β-catenin and bridges the cadherin-catenin complex to the actin cytoskeleton either 
through direct binding to actin filaments or indirectly through actin binding proteins 
such as α-actinin or vinculin (Dejana et al., 2008, Vestweber, 2008). The exact 
molecular basis of this interaction is still a matter of debate as recent investigations 
showed that α-catenin cannot bind to both β-catenin and actin simultaneously with the 
binding preference appearing to be dependent on the oligomeric state of α-catenin as 
either a monomer or homodimer (Weis and Nelson, 2006). Furthermore, numerous 
protein kinases including Src, c-Src tyrosine kinase and proline rich tyrosine kinase 2, 
and phosphatases including vascular endothelial protein tyrosine phosphatase (VE-PTP), 
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protein tyrosine phosphatase receptor type M (PTPµ) and the density-enhanced 
phosphatase-1 (DEP1) may directly/indirectly associate with the adherens junction 
complex in response to various conditions suggesting their active participation in VE-
Cadherin/catenin function and regulation.      
 
1.5.2 VE-Cadherin-catenin function 
The adherens junction complex performs multiple functions in endothelial biology. 
Based on its distinctive junctional localization within confluent endothelial monolayers 
it would be prudent to implicate its involvement in some aspect of barrier function. 
Indeed the first evidence for the role of VE-Cadherin in-vivo demonstrated its functional 
participation in the regulation of vascular permeability and leukocyte transmigration. 
Blocking antibodies targeting specific EC domains of VE-Cadherin were able to affect 
adhesion and clustering of the protein, inducing significant increases in vascular 
permeability (Gotsch et al., 1997). Mice deficient in VE-Cadherin die as a result of 
severe vascular defects, which are characterized by defective capacities in sprouting 
angiogenesis suggesting a putative role for VE-Cadherin in vascular morphogenesis 
(Gory-Faure et al., 1999). Carmeliet and colleagues further analyzed VE-Cadherin 
function using mice with partially truncated cytoplasmic VE-Cadherin at the β-catenin 
binding site. Interestingly, C-terminal truncation of VE-Cadherin reduced complex 
formation with the VEGFR-2,  β-catenin and PI3K and abolished cell survival signals 
transmitted by VEGF-A to Akt (serine/threonine) kinase, thus unveiling VE-Cadherin as 
mediator of pro-survival signals (Carmeliet et al., 1999).  
 
Moreover, VE-Cadherin has been determined to be an essential molecule in the contact 
inhibition of EC cell proliferation as a result of junctional stabilization (Caveda et al., 
1996, Grazia Lampugnani et al., 2003). A number of possible mechanisms have been 
attributed to explain this phenomenon, with Pierce and colleagues suggesting that VE-
Cadherin docking at the plasma membrane sequesters β-catenin at the cadherin-catenin 
complex, effectively blocking its capacity to translocate into the nucleus and regulate 
genes involved in cell proliferation via the Tcf/Lef transcription factor (Pierce et al., 
53 
 
2003). Another explanation suggests that VE-Cadherin binding to VEFGR-2 provokes a 
dramatic tyrosine phosphorylation of VEGFR2, thereby attenuating mitogen-activated 
protein kinase (MAPK) activation and its subsequent role in cellular proliferation 
(Grazia Lampugnani et al., 2003). Furthermore, VE-Cadherin expression in VE-
Cadherin null (-/-) EC’s was found to augment the activation of Rac1, a small 
RhoGTPase family member, which had functional consequences for the organization of 
the actin cytoskeleton (Lampugnani et al., 2002). Dynamic remodeling of the actin 
cytoskeleton occurs under conditions of blood flow-associated shear stress, which 
profoundly influences EC realignment and elongation in the direction of flow (Masuda 
and Fujiwara, 1993, Colgan et al., 2007, Hahn and Schwartz, 2009). This effect is 
abrogated under flow conditions in COS-7 cells (VE-Cadherin -/- cell line) but can be 
restored following transfection of a plasmid encoding VE-Cadherin. In view of this, VE-
Cadherin has been shown to be a crucial receptor in the mechanosensing of blood flow-
associated shear stress within the vasculature, where it acts as an adaptor molecule in a 
mechanosensory complex with PECAM-1 and the VEGFR-2, regulating various 
intracellular signalling cascades (as discussed in section 1.2.2.2) (Tzima et al., 2005).  
 
Finally, a significant role for VE-Cadherin in regulating expression of claudin-5 was 
recently demonstrated by Taddei and colleagues. This suggests a mechanism of “cross-
talk” between adherens and tight junctions through which VE-Cadherin acts as a 
hierarchy in organization of cell-cell junctions, and thus may also further explain why 
VE-Cadherin inhibition induces increases in permeability (Taddei et al., 2008). Thus 
VE-Cadherin exhibits several essential functions in vascular homeostasis through its 
ability to develop and organize cellular junctions, control signal transduction pathways 
with implications for proliferation, cell survival and gene transcription, and regulate 
vascular permeability.  
 
1.5.3 VE-Cadherin-catenin regulation 
As described above, VE-Cadherin can act as a receptor mediating ‘outside-in’ 
signalling, a function analogous to integrins expressed basolaterally, which can drive 
various cellular processes. Interestingly, VE-Cadherin engagement upon cell-cell 
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contact also initiates a complex intracellular ‘inside-out’ signalling cascade that acts as a 
cue for regulating VE-Cadherin assembly. Studies using fluorescence resonance energy 
transfer (FRET) probes revealed that cell-cell contact is a prerequisite for activation of 
Rap1, a small GTPase belonging to the Ras family of proteins. Docking of the adaptor 
molecule MAGUK inverted domain structure (MAGI-1) with β-catenin following 
homophilic engagement has been shown to activate Rap1, which enhances cortical actin 
cytoskeleton accumulation at the cell borders, thereby stabilizing the adherens junction 
and reducing cell permeability (Sakurai et al., 2006, Mochizuki et al., 2001). 
Furthermore, p120 catenin has been shown to be of vital significance for VE-Cadherin 
retention at the adherens junction. Binding of p120 catenin within a highly conserved 
juxtamembrane domain of VE-Cadherin not only stabilizes its membrane insertion, but 
also prevents the cadherin from been internalized, degraded and may even facilitate the 
recycling of internalized cadherin back to the membrane (Xiao et al., 2003, Xiao et al., 
2005).  
 
Similar to tight junctions, phosphorylation of the adherens junction complex drastically 
influences complex integrity. A wealth of knowledge exist about multiple intracellular 
and extracellular signalling mediators that are directly or indirectly associated with VE-
Cadherin, with the capacity to affect endothelial permeability. For the most part, in-vitro 
experiments have suggested that tyrosine phosphorylation of VE-Cadherin or catenin 
family members have detrimental consequences for barrier function. Exposure of 
endothelial monolayers to some of the classical permeability inducing agents such as 
TNF-α (Angelini et al., 2006), histamine (Andriopoulou et al., 1999) and VEGF (Esser 
et al., 1998) induce the tyrosine phosphorylation of VE-Cadherin, β-catenin and p120 
catenin, causing cadherin-catenin dissociation and possible internalization. Common 
intracellular signalling mediators of such effects include the family members of the 
RhoGTPases, Rho or Rac, which may act indirectly, while the tyrosine kinase Src has 
been shown to interact directly with the cytoplasmic domain of VE-Cadherin (Wallez et 
al., 2007). Moreover, tyrosine phosphorylation of residue Y731 was identified as 
specific mediator of ICAM-induced leukocyte diapedesis, as overexpression of a 
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tyrosine-phenylalanine point mutant blocked transendothelial migration (Allingham et 
al., 2007, Turowski et al., 2008).       
 
Adherens junction phosphatases have been shown to enhance barrier characteristics and 
stabilize the junction complex. VE-PTP is an endothelial-specific phosphatase that 
associates directly with the EC domains of VE-Cadherin. Treatment with VE-PTP 
following VEGF stimulation dephosphorylated VE-Cadherin leading to an increase in 
barrier function (Wallez and Huber, 2008). Similarly, it has been shown that docking of 
neutrophils to the apical surface of EC’s triggered the dissociation of VE-PTP from VE-
Cadherin, thus implicating its involvement in neutrophil transmigration (Vestweber, 
2008). Other phosphatases such as DEP-1 (Grazia Lampugnani et al., 2003), PTPµ (Sui 
et al., 2005) and SH2 - containing phosphotyrosine phosphatase (SHP2) (Ukropec et al., 
2000) may interact with and dephosphorylate VE-Cadherin and thus enhance barrier 
properties.         
 
Finally, VE-Cadherin itself is highly susceptible to enzymatic lysis, thus adding further 
explanation as to possible causes for heightened vascular permeability or leukocyte 
diapedesis. Exposure to various metalloproteases, elastase, cathepsin, or trypsin cleaves 
VE-Cadherin EC domains in cultured cells (Dejana et al., 2008).Thus both intracellular 
signalling processes and VE-Cadherin itself regulate the interaction/assembly of the 
cadherin-catenin junctional complex, uncovering a reciprocal signalling relationship. 
This has functional consequences for the membrane trafficking, internalization, 
degradation and post-translational modifications of VE-Cadherin with inevitable 
implications for barrier integrity. A more in-depth analysis, particularly from the in vivo 
situation will potentially shed more light on specific regulatory targets.  
 
1.5.4 VE-Cadherin-catenin clinical implications 
Due to the diverse range of endothelial functions regulated by the cadherin-catenin 
complex, it is not surprising that pathological conditioning of the endothelium with 
resulting increases in vascular permeability may precipitate via perturbations in the 
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homeostatic regulation of the adherens junction complex. Most severely, VE-Cadherin 
knockout mice are embryonic lethal, exhibiting a severely altered vascular phenotype 
compared to claudin-5 knockout mice which develop normally but die shortly after birth 
due to defective BBB functioning. With respect to specific diseases, alterations in the 
cell surface expression of VE-Cadherin is adversely regulated under conditions of 
inflammation (Alexander et al., 2000), diabetes (Navaratna et al., 2007) and viral 
infection (Dewi et al., 2008), with the latter two studies showing concomitant increases 
in vascular permeability. Anti-permeability factors which enhance VE-Cadherin 
membrane stabilization include angiopoietin-1, cAMP-elevating GPCR agonists, 
sphingosine 1 phosphate (S1P) and fibroblast growth factor, and therefore have direct 
implications as therapeutics targeting aberrant vascular leakiness (Gavard, 2009). 
Endothelial cell-cell adhesion is also compromised in tumor endothelium as large 
intercellular gaps are often present suggesting that VE-Cadherin function is altered, 
which is consistent with observations in epithelial-derived tumors (Hashizume et al., 
2000, Berx and Van Roy, 2001). Interestingly and somewhat paradoxically though, VE-
Cadherin was found to be expressed by highly aggressive melanoma tumor cells which 
were capable of inducing ‘vasculogenic mimicry’ (VM), i.e. the ability of tumor cells to 
form tubular-like structures (blood vessels) independent of angiogenesis (Hendrix et al., 
2001). Based on its cell-cell adhesion functions, it is postulated that VE-Cadherin 
facilitates the connection of the VM channel to the host’s blood vessel, thus acquiring 
essential growth factors for tumor survival, growth and metastasis. This phenotype has 
also been observed in several other malignant tumor types such as breast cancer, liver 
cancer, glioma and prostate cancer (Zhang et al., 2007). Therapeutic strategies targeting 
VE-Cadherin in this manner have been exploited through the use of antibodies against 
various epitopes of VE-Cadherin. Of particular significance was the mAb E4G10, which 
selectively blocked tumor growth in mice but did not affect normal blood vessels (Liao 
et al., 2002). Thus, exploiting knowledge on the functional regulation of VE-Cadherin 
and the catenin complex has real therapeutic value in a wide variety of clinical settings.   
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1.6 Intracellular signalling mechanisms 
 
Amongst a plethora of intracellular mediators facilitating the transmission of circulatory 
conditions (both humoral and mechanical) with consequences for endothelial cell 
function is the Ras superfamily of small guanosine tripohosphatases (GTPases). The Ras 
superfamily comprises 5 family members, namely, the Ras, Rho, Ran, Rab and Arf 
GTPases, classified as such on the basis of structure and function. A total of 150 
superfamily members have been identified in humans. They exist as monomeric G-
proteins with molecular masses ranging between 20-30 kDa. The Ras sarcoma (Ras) 
genes were first identified as oncogenes of sarcoma viruses and are the earliest 
discovered members of the Ras family of GTPases, which control gene expression and 
regulate cell proliferation, differentiation and survival. The Ras like proteins in brain 
(Rab) family of GTPases and ADP-ribosylation factor (Arf) GTPases are involved in 
intracellular vesicular transport and trafficking of proteins between different organelles. 
The Ras like nuclear (Ran) protein is the most abundant GTPase in the cell which 
regulates nucleocytoplasmic transport of RNA and protein during cell cycle (G1-S-G2 
phases) and microtubule organization during the metaphase (Matozaki et al., 2000, 
Wennerberg et al., 2005). The Ras like homologous (Rho) proteins are of particular 
interest to this thesis and are discussed in greater detail in section 1.6.1 below. 
 
1.6.1 RhoGTPases 
The RhoGTPases represents an intriguing family of signalling molecules, which are 
pivotal regulators of several signalling cascades activated by an array of receptor types, 
including mechanosensors (Tzima et al., 2001, Tzima et al., 2002). To date, 23 members 
of the Rho family of GTPases have been identified. They have being implicated in many 
signalling pathways in the vasculature regulating barrier function, inflammation, 
leukocyte extravasation and oxidative stress as well as smooth muscle cell contraction, 
migration, proliferation and differentiation. The relationship between RhoGTPases and 
endothelial function in physiology or pathology has been the subject of intensive 
investigation over the past decade and thus, their participation is discussed herein. 
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RhoGTPases, similar to other GTPase families function as molecular switches to initiate 
or terminate specific cell processes through their ability to bind to activate numerous 
downstream effectors leading to diverse signalling pathways. Each GTPase possesses a 
set of conserved G-box GTP/GDP binding motifs which exhibit a high binding affinity 
for GDP and GTP (see figure 1.13 below). 
 
In response to upstream stimuli, the GTPase switches from an inactive (GDP-bound) to 
an active (GTP-bound) state, to induce conformational changes necessary to facilitate 
downstream effector binding within the core effector domain. Interestingly, the two 
nucleotide bound states have relatively similar conformations but contain pronounced 
differences at the switch I and II domains, allowing the effectors to ‘sense’ the 
nucleotide status of the small GTPase (Bishop and Hall, 2000). Another important 
structural feature of the majority of RhoGTPases is that they contain a C-terminal 
CAAX (Cysteine-Aliphatic-Aliphatic-X any amino acid) motif. This serves as a 
recognition sequence for farnesyltransferase and geranylgeranyltransferase I, which 
post-translationally modify the GTPase through the covalent attachment of an 
isoprenoid lipid, thus enhancing GTPase hydrophobicity and membrane insertion (Cox 
and Der, 2002). The principal regulatory processes that facilitate the switch between the 
active and inactive conformations are discussed in section 1.6.3.  
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Fig. 1.13: Schematic of RhoGTPases. RhoGTPases contain a conserved structure and 
biochemistry with 5 G (GDP/GTP-binding) motifs, an effector domain for binding 
downstream targets controlled by conformational changes in switch domains (I and II). 
The hypervariable region differs between RhoGTPases and can contain a polybasic 
region and/or sites for palmitoylation. The CAAX box is important for membrane 
localization and is prenylated on the cysteine residue. Adapted from Ridley 2006.  
 
1.6.2 RhoGTPase function 
As mentioned earlier, RhoGTPases have been implicated in a range of endothelial 
functions. Of specific interest to this report however are their roles in regulating cell-cell 
adhesion and cytoskeletal dynamics. Detriments in adherens and tight junction 
assembly, and alterations in actin cytoskeleton-mediated associations with these 
intercellular junctions pose a genuine threat to physiology of the paracellular pathway. 
Moreover, there is ample evidence suggesting that the actin cytoskeleton is simply more 
than a structural component of junctional complexes, but dynamic changes in its 
expression and localization in response to spatially regulated cues are critically 
modulators of tight junction integrity and BBB permeability (Mark and Davis, 2002, 
Gloor et al., 2001, Vorbrodt and Dobrogowska, 2003). Unraveling the participation of 
RhoGTPases as regulators of endothelial barrier function will help clarify the cell and 
molecular processes behind BBB pathologies exhibiting leaky barriers.  
 
From an endothelial perspective, RhoA, Rac1 and Cdc42 represent the three most 
extensively studied family members of RhoGTPases, and thus will be the subject of this 
discussion. Early work on the functions of these RhoGTPases in fibroblasts noted 
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dramatic capabilities of these signalling molecules to influence actin cytoskeletal 
dynamics; findings that were subsequently confirmed in EC’s (Wojciak-Stothard et al., 
1998). RhoA was first shown to promote the formation of stress fibers, contractile 
actomyosin bundles and focal adhesions, whereas Rac1 and Cdc42 were shown to 
induce the formation of lamellipodia and filopodia, respectively (Nobes and Hall, 1995). 
Lamellipodia are sheet-like protrusions of branching actin filaments commonly found at 
the leading edge of migrating cells while filopodia describe spike-like membrane 
protrusions containing parallel bundles of actin filaments.  
 
1.6.2.1 RhoA 
RhoA mediates its biological effects through a number of effector proteins including 
citron kinase, rhotekin, diaphanous related formins 1-2, and the more extensively 
studied Rho-associated kinase (ROCK). RhoA has been generally documented to 
promote barrier instability through its influence over actin cytoskeletal properties. In 
response to barrier destabilizing compounds such as thrombin, endothelin-1 and 
lipopolysaccharide (LPS), RhoA-GTP binds to ROCK to phosphorylate myosin light 
chain (MLC) via myosin light chain kinase (MCLK). ROCK can also enhance this 
process by inactivating myosin light chain phosphatase, an enzyme that 
dephosphorylates MLC. These changes in MLC enhance stress fiber formation and 
allow the myosin molecule to change conformation and interact with actin to induce 
actin-myosin contractility (Wojciak-Stothard and Ridley, 2002). This force generation is 
proposed to dissemble the intercellular junction complexes by physically ‘tugging’ 
trans-homophilic junctional proteins apart and enhance paracellular permeability (Sun et 
al., 2006, Birukova et al., 2004, Wojciak-Stothard et al., 2001a). Consistent with these 
findings is that inhibition of ROCK reduced baseline permeability of both post-capillary 
venules in-vivo and using microvascular EC’s in-vitro (Adamson et al., 2002, Baumer et 
al., 2008).  
 
RhoA activity has also been shown to be downregulated as endothelial monolayers 
reach confluence and the paracellular gap is sealed. Critical to this process is the binding 
of p120 catenin to the newly established adherens junction complex, which activates 
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p190RhoGAP (a regulator of RhoA activity) and inactivates RhoA (Wildenberg et al., 
2006). More specific to the BBB, RhoA-mediated signalling has been associated with 
HIV infected monocyte infiltration across the BBB and in tight junction disassembly. 
Pretreatment with a ROCK inhibitor (Y-27632) was able to abrogate the monocyte 
induced post-translational modifications of tight junction proteins occludin and claudin-
5, and the concomitant reduction in TEER (Persidsky et al., 2006a). Further experiments 
by Yamamoto and colleagues showed that ROCK could directly associate with both 
occludin and claudin-5 in brain microvascular EC’s at phosphospecific residues, which 
paralleled with BBB dysfunction (Yamamoto et al., 2008). It is possible that the tight 
junction-associated RhoA activator GEF-H1/Lfc induced such profound responses. 
Although the majority of the literature points to the deleterious effects of RhoA on 
endothelial permeability, it has an important functional role in paracellular-mediated 
leukocyte extravasation to subendothelial sites of acute inflammation, however it would 
serve to the detriment of the tissue under a chronically inflamed state.   
 
1.6.2.2 Rac1 and Cdc42 
By contrast, Rac1 and Cdc42 are more renowned to antagonize the effects of RhoA and 
promote barrier-enhancing/stabilizing effects. Through the use of the pharmacological 
inhibitor NSC23766 and lethal toxin (LT) (block Rac1 and Cdc42 activity, respectively), 
microvascular endothelial barrier function was severely weakened, findings which were 
consistent with a report using dominant negative Rac1 mutants in macrovascular 
endothelium (Wojciak-Stothard et al., 2005, Baumer et al., 2009, Baumer et al., 2008). 
Both Rac1 and Cdc42 can target similar and/or diverse downstream effectors which 
regulate actin bundles and are thought to be associated with adherens and tight 
junctions. This includes the actin-binding protein cortactin, which has been heavily 
implicated in cortical actin assembly and reorganization and serves to strengthen 
endothelial barrier properties by stabilizing junctional proteins. (Dudek et al., 2004, 
Jacobson et al., 2006). Cortactin can bind directly to ZO-1 and may guide the spatial 
organization of actin within the tight junction. Another mechanism for stabilizing 
cortical actin fibers involves Rac1- and Cdc42-induced activation of LIM kinase via 
downstream effectors p21-activated kinase (PAK) 1-3, which directly phosphorylates 
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the actin-severing and depolymerizing protein cofilin, thereby inactivating it and 
stabilizing the actin filament arrays at the cell peripheries. Rac1 and Cdc42 can also 
stimulate actin polymerization via the actin-binding Arp (actin-related protein) 2/3 
complex, albeit through diverse pathways. Cdc42 binds directly to the Wiskott-Aldrich 
syndrome protein (WASP) target, which directly binds to and activates Arp2/3, whereas 
Rac1 indirectly binds to the multi protein WASP Verpolin homologous (WAVE) 
complex via its targets Sra1 or IRSp53 to induce Arp2/3-associated actin nucleation 
(Ridley, 2006). Interestingly WASP-mediated stimulation of actin polymerization has 
been shown to be regulated by protein-protein interactions via the SH3 domain of 
cortactin, thus offering another mechanism for the accumulation of cortical actin.  
Besides cytoskeletal dynamics, both Rac1 and Cdc42 are activated where junctional 
complexes are formed. A possible explanation for the relevance of this suggests; 
following VE-cadherin engagement, p120 catenin binding activates Rac1 and Cdc42, 
which bind to IQGAP (IQ motif containing GTPase-activating protein 1), thus retaining 
the GTPases in their active state. This facilitates the release of β-catenin from IQGAP to 
associate with α-catenin, which cross links with the cortical actin cytoskeleton and 
stabilizes the adherens junction (Beckers et al., 2010). At the tight junction, levels of 
ZO-1 were reduced following overexpression of a dominant negative Rac1 mutant as the 
localization pattern to cell borders was more fragmented (Wojciak-Stothard et al., 
2001b). Moreover, a recent report by Schlegel et al. showed that claudin-5 staining at 
cell borders was reduced by LPS exposure (in-vivo and in-vitro) and this effect was 
dependent on the inactivation of Rac1 as opposed to activation of RhoA (Schlegel et al., 
2009). The precise mechanism(s) of how Rac1/Cdc42 exerts its barrier-stabilizing 
effects on the tight junction remain elusive. The more obvious route would suggest 
direct modulation of cortical actin dynamics. However it is tempting to speculate the 
presence of upstream regulators (similar to GEF-H1/Lfc for RhoA) and/or downstream 
effectors embedded within the core plaque of proteins at the tight junction. Data is 
currently lacking in EC’s but one such mechanism has been proposed in tight junctions 
of epithelial cells, where the scaffold protein angiomotin binds RICH1 (a regulator of 
Cdc42) suppressing its GTPase activity, thus allowing Cdc42-mediated barrier 
protection (Wells et al., 2006).  
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The information presented above depicts the generally well-accepted viewpoint that 
Rac1/Cdc42 serves to strengthen the intercellular junction whereas RhoA opposes these 
activities and is detrimental to endothelial permeability (see figure 1.14 below) however 
some controversy remains as to the precise roles of RhoGTPases in endothelial 
permeability regulation. A recent report by Amerongen et al. demonstrated that basal 
activity of Rho kinase was required for barrier maintenance and was required to sustain 
a basal tension necessary to enhance the affinity between the intercellular junctions and 
the cortical actin cytoskeleton (van Nieuw Amerongen et al., 2007). Furthermore, 
overexpression of a constitutively active Rac1 enhances breakdown of intercellular 
junctions consistent with reports which demonstrated that Rac1 activation mediated 
VEGF-induced tyrosine phosphorylation of occludin and VE-Cadherin causing 
hyperpermeability (Peng et al., 2009, Monaghan-Benson and Burridge, 2009). Thus, a 
subtle context-dependent balance in the regulation and relative ratios of the 
RhoGTPases appears essential for junctional integrity as excessively high GTP levels of 
one RhoGTPase can affect the activity of the other, thus altering their relative ratios 
affecting cellular physiology and endothelial permeability. Moreover, the specificity of 
the upstream stimulus acting on a particular RhoGTPase appears crucial in determining 
the specificity of the downstream effector(s) and cellular response.      
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Fig. 1.14: Regulation of barrier function by Rho and Rac. This figure presents 
mechanisms of RhoGTPase (Rho/Rac) activation and alludes to the generally well 
accepted view that Rho activity is detrimental to barrier function and Rac enhances 
barrier integrity via alterations in intercellular junctions (Wojciak-Stothard and Ridley, 
2002).  
 
 
1.6.3 RhoGTPase regulation  
To appreciate the role of the RhoGTPases in health and disease it will be essential to 
understand how they are regulated. The cycling of RhoGTPases between their active 
and inactive forms is finely tuned by three primary regulators, which are discussed 
below. It is however, important to note that a functional cross-talk between RhoGTPases 
exists, i.e. activation of one GTPase can have consequences for another, thus adding 
further complexity to RhoGTPase regulation. A hierarchical activation linking RhoA, 
Rac1 and Cdc42 was first demonstrated in Swiss 3T3 fibroblasts following agonist 
treatment, which activated Cdc42 inducing a rapid activation of Rac1 leading to RhoA 
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activation and subsequent actin stress fiber assembly (Kjoller and Hall, 1999). From an 
endothelial perspective, intensive effort has focused on the RhoA-Rac1 relationship 
where studies have shown that HGF-induced activation of Rac1 blocked the thrombin-
induced activation of RhoA by interfering with p115RhoGEF (an activator of RhoA), 
while similarly cAMP-associated Rac1 activation also blocked thrombin-mediated 
RhoA activity (Birukova et al., 2007, Baumer et al., 2009). In view of this, EC’s 
exposed to hypoxic conditions were shown to inactivate Rac1, which was followed by 
activation of RhoA; however the mechanism(s) underlying this sequential response 
needs to be clarified (Wojciak-Stothard et al., 2005). Furthermore, other small GTPases 
of different family members have been shown to influence the activity of RhoA, Rac1 
and Cdc42, convoluting the regulation process even further (Matozaki et al., 2000). 
Understanding the coordinated regulation of these signalling molecules will constitute 
the next frontier in the study of RhoGTPases.  
 
1.6.3.1 Rho guanine nucleotide exchange factors (RhoGEF’s) 
RhoGEF’s are essential components driving RhoGTPase-mediated cellular behaviours 
in response to upstream stimuli. They catalyze the exchange of GDP for GTP in the 
switch region of the GTPase, which propagates specific downstream effector activation. 
RhoGEF’s are generally large proteins (> 1000 amino acids) with multiple domains that 
facilitate protein-protein and protein-lipid interactions. This includes a Dbl homology 
(DH), SH2, SH3 and pleckstrin homology (PH) domains (Cerione and Zheng, 1996). 
The DH domain confers GEF specificity towards their GTPase substrate and catalyses 
the GDP-GTP exchange reaction. The PH domain interacts with phospholipids, 
facilitating RhoGEF interaction upon membrane association and subsequent GTPase 
activation to the membrane. Indeed, activation of Rac1 was induced by membrane 
localization of the cytosolic RhoGEF Tiam1 (Michiels et al., 1997). This particular 
interaction is of specific interest to this thesis and is depicted in figure 1.15 below. 
Certain RhoGEF’s (p115RhoGEF, PDZ-RhoGEF) also contain a regulator of G-protein 
signalling (RGS) domain, which forms a molecular complex with the Gα12/13 subunit of 
GPCR’s enhancing the activation of RhoA (Hart et al., 1998, Siderovski and Willard, 
2005). Furthermore, RhoGEF’s can be regulated by phosphorylation via PKC isoforms 
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(Mehta and Malik, 2006), FAK (Chikumi et al., 2002) and RTK’s via Src (Schiller, 
2006). To date, 83 GEF’s have been identified in the human genome, some of which are 
RhoGTPase specific while others activate multiple RhoGTPases.  Given the fact that 
there are over 50 known effector targets for Rho, Rac and Cdc42 (Hall, 2005), the 
specificity of the upstream stimulus (i.e. RhoGEF) is essential for determining the 
specificity of the downstream effector target of the RhoGTPase.   
 
Fig. 1.15: Schematic structure of Tiam1. The specific domains indicated herein are 
from the N-terminus onwards: myr: myristoylation site; P: PEST sequence; PHn: N-
terminal PH (pleckstrin homology) domain; CC: coiled coil region; Ex: extended 
structure; RBD: Ras binding domain; PDZ: PSD-95/DlgA/ZO-1 domain; DH: Dbl 
homology domain and PHc;C-terminal PH domain. Rac1 interacts with the DH domain 
of Tiam1 (Mertens et al., 2003).   
 
1.6.3.2 RhoGTPase activating proteins (RhoGAP’s) 
Contrary to what their name implies, RhoGTPases have a relatively low intrinsic 
GTPase activity. RhoGAP’s represent a family (70 known members in mammals) of 
regulatory proteins that bind to active GTPases and enhance the GTP hydrolysis, 
thereby inactivating the protein and terminating the signalling event. The expression of 
most RhoGAP’s is ubiquitous; however one of them, p73RhoGAP has a preferential 
vascular expression which was crucial to angiogenesis (Hori et al., 2004). Similar to 
RhoGEF’s, RhoGAP’s can act on a single RhoGTPase, while others have preferential 
activity towards multiple proteins, thus explaining why RhoGTPase activities may 
simultaneously augment or diminish. Independent of their GAP activity, RhoGAP’s 
molecular structure presents multiple functional domains to act as scaffold molecules 
mediating cross-talk between other GTPases and integrate signals from different 
pathways thereby specifying downstream signalling (Tcherkezian and Lamarche-Vane, 
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2007). RhoGAP activities appear to be regulated by different mechanisms including 
phosphorylation (Roof et al., 1998) and proteolytic degradation (Jenna et al., 2002).         
 
1.6.3.3 Rho guanine dissociation inhibitors (RhoGDI’s) 
In a resting cell, the majority of RhoGTPases are cytosolic and complexed in their GDP-
bound conformation despite the fact the GTP is more abundant in the cell. Sequestering 
of RhoGTPases in this conformation is finely regulated by RhoGDI’s which have two 
structurally distinct regions. Their N-terminal flexible domain specifically interacts with 
the switch domains of the RhoGTPase to lock it in their inactive conformation while the 
C-terminal accommodates the isoprenyl moiety of the GTPase into its hydrophobic 
pocket, regulating cytosol/membrane partitioning (Dovas and Couchman, 2005). There 
are currently three RhoGDI’s known; RhoGDI-1(α) which is ubiquitously expressed, 
RhoGDI-2(β) is expressed in hematopoietic cells and RhoGDI-3(γ) is preferentially 
expressed in organs (Beckers et al., 2010). In-vivo and in-vitro findings have shown that 
RhoGDI-1 binds to RhoA, Rac1 and Cdc42, although the mechanisms regulating the 
formation of stable, cytosolic RhoGDI complexes remain largely unknown. The 
dissociation of RhoGTPases from RhoGDI’s however appears to be regulated by an 
array of factors including phosphorylation by PKCα (Mehta et al., 2001), PAK 
(DerMardirossian et al., 2004) and via protein-protein interaction with the ERM 
(Ezrin/Radixin/Moesin) family of proteins (Takahashi et al., 1997). Figure 1.16 below 
summarizes the mechanism of RhoGTPase regulation.  
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Fig. 1.16: RhoGTPase regulation by RhoGEF’s, RhoGDI’s and RhoGAP’s. 
RhoGTPases are retained in their inactive GDP form by RhoGDI’s. RhoGEF’s facilitate 
the exchange of GDP for GTP following activation by upstream agonists, leading to 
downstream effector signalling. RhoGAP’s accelerate the hydrolysis of GTP and 
accumulation of the inactive GDP-bound form.   
 
1.6.3.4  Mechanoregulation of RhoGTPases 
EC’s exposed to laminar shear stress and cyclic stretch exhibit distinct patterns of 
cytoskeletal remodeling and changes in morphology. Amongst an array of possible 
intracellular signalling mechanisms mediating such effects, the RhoGTPases represent 
likely candidates based on their undoubted ability to influence cytoskeletal dynamics. 
Indeed, studies have shown that following flow onset, RhoA and Rac1 are both 
transiently activated in a sequential manner that appears to control the functional 
response, i.e. cellular/cytoskeletal realignment. RhoA is initially activated (peaks within 
5 mins) leading to stress fiber formation and cell contraction. This facilitates cell 
depolarization allowing EC’s to elongate more efficiently in the direction of the shear 
stress. The elongation process requires activation of Rac (within 15 mins) at the leading 
edge of the EC and subsequent deactivation of RhoA to allow optimal extension of 
membrane protrusions (Wojciak-Stothard and Ridley, 2003). Cdc42 is also activated in 
similar time pattern to Rac1 but there are conflicting reports as to whether or not its 
activation is essential to shear induced alignment (Li et al., 1999, Tzima, 2006).  
69 
 
Interestingly the expression of constitutively active (and dominant negative) mutants of 
Rho and Rac abolished the cytoskeletal reorientation of EC’s in response to sustained 
shear stress. In the case of EC’s expressing V12Rac1 (constitutively active Rac1), high 
levels of Rac1 activity were detected but lacked the spatial polarization towards the 
downstream edge of the cell following flow onset. Thus, although RhoA and Rac1 
activation is a prerequisite for shear-induced morphological realignment, a precise 
temporal fine tuning of their relative GTP ratios and spatial organization will dictate the 
efficiency of their signal propagation and cellular responses. Moreover, these signalling 
mediators have been extensively linked to flow induced enhancements of endothelial 
permeability under physiological conditions, predominantly through their coordinated 
influences of the cortical actin cytoskeleton (Tzima et al., 2002, Birukova et al., 2008, 
Wojciak-Stothard and Ridley, 2002). Recent work by Miyazaki et al. demonstrated that 
disturbed flow conditions, which are associated with intercellular junction disassembly 
triggered an over-activation of RhoA (for 60mins) (Miyazaki et al., 2010). Although the 
authors didn’t address Rac1 activity under similar conditions, it is possible that the 
aberrant RhoA signalling pattern ablated the characteristic Rac1 activation necessary to 
elicit a barrier-enhancing response. Furthermore, this is consistent with the notion that 
RhoA signalling is the common facilitator mediating permeability enhancement in 
response to upstream signalling.   
 
The vast majority of these studies have however been performed in EC’s of 
macrovascular origin where the magnitude of hemodynamic loading can vary 
drastically; therefore further studies will need to be performed in areas of the 
microvasculature such as the BBB to confirm to the roles of these signalling molecules. 
Although a role for integrins in force mediated changes in GTPase activity has been 
established (Tzima et al., 2002, Tzima et al., 2001), the contribution of intercellular 
junctions to force-dependent changes in these signalling molecules remains to be 
investigated. Understanding the mechanisms of mechanotransduction and involvement 
of RhoGTPases in the regulation of endothelial permeability will be essential to 
identifying key regulatory molecules or targets for drug therapies in diseases exhibiting 
vascular leakage. Future efforts must attempt to tie specific upstream signalling 
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mediators such as RhoGEF’s/GDI’s/GAP’s to flow-mediated activation of RhoGTPases 
to further unravel the molecular mechanisms involved.                 
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1.7 Summary and study rationale 
The vascular endothelium represents a dynamic, heterogenic interface between blood 
constituents and the underlying interstitium, performing multifunctional roles in human 
health and disease. More specifically, the capillary endothelium of the cerebral 
microvasculature constitutes the BBB, a physical and metabolic barrier regulating 
blood-borne solute flux into the brain interstitial fluid (ISF). Disruption of this barrier is 
associated with multiple disease states; however the physiological characteristics of the 
BBB are the rate-limiting step in drug delivery. The burden of the physical barrier is 
borne primarily at the level of the tight junction; a series of transmembrane (occludin 
and claudin-5) and cytoplasmic (ZO-1) proteins that effectively seal the paracellular 
pathway. Acting in tandem with this complex is the adherens junction, comprising VE-
Cadherin and catenins (α-, β-, p120-), which coordinate and regulate junctional 
assembly. Crucial to the regulation of these intercellular junctional complexes and thus, 
BBB permeability are the surrounding cells forming the NVU (astrocytes, pericytes, 
neurons and ECM components) and blood-borne hemodynamic forces, namely laminar 
shear stress. Indeed the latter component alone is of genuine physiological relevance 
considering the fact that EC’s are continuously subjected to these forces in-situ. 
Moreover, altered shear stress is one of the contributing vascular causes of stroke and its 
microvascular consequences during cerebral ischemia.   
 
The purpose of this study is to build on previous published findings from our laboratory 
assessing the effects of laminar shear stress on tight junction assembly and barrier 
function, and further examine the role of shear reduction (flow cessation) on these 
indices. It will primarily encompass elucidation of the signalling mechanism(s) 
pertaining to shear-dependent stabilization of barrier function within an in-vitro, 
monoculture model of the BBB. Clarification of how the BBB is regulated in 
physiology or pathology will further enhance our knowledge and thus serve as a 
platform to identify or develop novel therapeutic strategies targeting neurological 
diseases eliciting comprised barrier function.    
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1.8 Thesis Overview 
The research data presented herein describes the physiological regulation of the tight 
junction complex in bovine brain microvascular endothelial cells (BBMvEC’s) 
responding to laminar shear stress and various intracellular signalling intermediates. 
Tight junction assembly is assessed by the localization patterns of ZO-1 and claudin-5 
and post-translational modifications of occludin in response to shear stress and various 
molecular/pharmacological knockout strategies. Permeability studies involving tracer 
fluorophores (FITC/APTS-dextran) were monitored in parallel to deduce if there is a 
direct association between shear induced tight junctional changes and endothelial barrier 
function, and furthermore to assess possible signalling intermediates pertaining to such 
effects. The findings are presented in the following manner.         
 
Chapter 3: To monitor the effects of laminar shear stress and/or flow cessation on 
BBMvEC tight junction assembly and barrier function. 
 
Chapter 4: To examine the contribution of RhoGTPases, Rac1 and RhoA, to shear-
induced adaptation of BBMvEC tight junction assembly and barrier 
function. 
 
Chapter 5: To assess the role of VE-Cadherin and Tiam1 in shear-induced upregulation 
of BBMvEC tight junction assembly and barrier function. 
 
See figure 1.16 below for a schematic depiction of the experimental approached uses in 
this thesis. 
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Fig. 1.17: Schematic depiction of experimental approach. Primary bovine brain 
microvascular endothelial cells (BBMvEC’s) were subjected to different experimental 
paradigms; pathological shear conditions (blue) and physiological shear (red), and 
monitored for structural changes in morphology, functional alterations in permeability 
and biochemical changes in tight junction proteins. Various molecular and 
pharmacological inhibition strategies (green) were incorporated to assess potential 
involvement under physiological conditions.   
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Chapter 2:  
Materials and Methods 
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2.1 Materials: 
Acros Organics (NJ, USA) 
Formaldehyde (37%). 
 
Aktiengeselischaft and Company (Numbrecht, Germany) 
1.5 mL micro tube with safety cap, 10, 200 and 1000 µL pipette tips, 15 and 50 mL 
falcon tubes, 2, 5, 10 and 25 mL serological pipettes, 6 and 24-well tissue culture plates, 
T-25 tissue culture flasks, T-75 tissue culture flasks, cell scrapers, 58 cm2 tissue culture 
dishes.   
 
Amaxa (Köln Germany) 
Basic endothelial nucleofector kit. 
 
Barloworld-Scientific (London, UK) 
White flat-bottomed 96-well plates. 
 
Becton Dickinson (NJ, USA) 
FACS sheath fluid, FACS rinse, FACS clean, FACS tubes. 
 
Bio-Rad, Hercules (CA, USA) 
Thick mini trans-blot filter paper, Precision plus protein marker. 
 
Calbiochem (San Diego, CA) 
Dephostatin: Tyrosine phosphatase inhibitor, NSC23766: Rac-1 inhibitor, Y-
27632:Rho-kinase inhibitor. 
 
Cell Applications (San Francisco, USA) 
Bovine brain microvascular endothelial cells (BBMvECs). 
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Cell Systems Inc (Kirkland, WA, USA) 
Primary human brain microvascular endothelial cells (HBMvECs), CSC complete 
growth media, CSC attachment factor. 
 
Cell Signalling Technology Inc (MA, USA) 
HRP-conjugated anti-Rabbit IgG 2° antibody. 
 
Cytoskeleton Inc (CO, USA) 
Rac1 and RhoA G-LISA® activation assay kit, Mouse anti-Rac1 monoclonal antibody. 
 
DAKO (CA, USA) 
Rabbit anti-Von Willebrand Factor polyclonal antibody, Fluorescent mounting media. 
 
Eppendorf (Cambridge, UK) 
UVette: UV-disposable cuvettes. 
 
GE-Healthcare (Buckinghamshire, UK) 
HRP-conjugated anti-mouse IgG 2° antibody, ECL Hyperfilm, Protein-G Sepharose 
Beads. 
 
Gibco (Scotland, UK) 
Fetal calf serum. 
 
Invitrogen (CA, USA) 
Alexa Fluor 488 F(ab’)2 fragment of goat anti-mouse IgG (H+L), Alexa Fluor 488 
F(ab’)2 fragment of goat anti-rabbit IgG (H+L), Alexa Fluor® 546 rhodamine phalloidin, 
DH5α E-coli competent cells, SyberSafe®.  
 
Millipore (MA, USA) 
bFGF – Recombinant human basic fibroblast growth factor, Millicell hanging cell 
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culture transwell inserts (6 well format, 0.4 µm pore size, 24 mm filter diameter). 
 
Nalgene Nunc (NY, USA) 
Cryogenic vials, Cryo freezing container 
 
Pall Life Science (NY, USA) 
Acrodisc 32 mm syringe filter with 0.2 µm super membrane, Nitrocellulose transfer 
membrane 
 
Pierce Biotechnology (IL, USA) 
BCA protein assay kit, Supersignal West Pico chemiluminescent substrate 
 
Qiagen (West Sussex, UK) 
HiSpeed Midi-prep kit. 
 
Roche Diagnostics (Basal, Switzerland) 
Protease and phosphatase inhibitor cocktail. 
 
Santa Cruz Biotechnology (CA, USA) 
Rabbit anti-GAPDH polyclonal antibody, Rabbit anti-Tiam1 polyclonal antibody. 
 
Sigma Chemical Company (Dorset, UK) 
2-mercaptoethanol, Acetic acid, Acetone, Ammonium Persulfate, ATPS (8-
Aminopyrene-1,3,6-trisulfonic acid trisodium salt), Ampicillin (disodium salt), Agarose, 
Bovine serum albumin, Bromophenol blue, Citric acid, DAPI, Dextran, DMEM – High 
glucose D5796, EDTA, EGTA, FITC-dextran (40kDa), Forskolin, Glycerol, Glycine, 
Heparin, HEPES, Hydrochloric acid, Isopropanol, Kanamycin sulphate, LB agar, LB 
broth, Lauryl sulfate, PBS tablets, Penicillin-Streptomycin (100X), Ponceau S solution, 
Potassium chloride, Potassium phosphate, Potassium hydroxide, Sodium chloride, 
Sodium cyanborohydride, Sodium deoxycholate, Sodium orthovanadate, Sodium 
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phosphate-dibasic anhydrous, Sodium phosphate-monobasic anhydrous, TEMED, 
Thrombin, Triton X-100, Trizma Base, Trypsin-EDTA (10X), Tween 20. 
 
 
Thermo Fisher Scientific (Leicestershire, UK) 
Buffer solution pH 4 (phthalate), Buffer solution pH 7 (phosphate), Buffer solution pH 
10 (borate). 
 
VWR international Ltd (West Sussex, UK) 
Methanol.  
 
Zymed Laboratories (CA, USA) 
Mouse anti-Occludin monoclonal antibody, Mouse anti-ZO-1 monoclonal antibody, 
Mouse anti-phosphotyrosine monoclonal PY-Plus™ antibody, Mouse anti-Claudin-5 
monoclonal antibody.  
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2.2 Cell culture methods 
All cell culture procedures were undertaken in a clean and sterile environment using a 
Bio Air 2000 MAC laminar flow cabinet. Cells were monitored daily for growth and 
morphology characteristics using an Olympus CK30 and/or Nikon Eclipse TS100 phase-
contrast microscope. 
 
2.2.1  Culture of bovine brain microvascular endothelial cells (BBMvEC’s) 
BBMvEC’s are an adherent cell line that forms a contact-inhibited monolayer upon 
confluency with distinct cobblestone morphology. Cryopreserved passage two 
BBMvEC’s were acquired from Cell Applications Inc., (Cat No. B840-05) California, 
USA. The cell line was tested free from bacteria, mycoplasma or fungal contaminants 
prior to shipping. Cells were characterized as endothelial by positive Dil-Ac-LDL 
uptake. BBMvEC’s were routinely grown in high glucose DMEM supplemented with 
10% foetal bovine serum (FBS), 3 µg/ml heparin, 3 ng/ml human recombinant basic 
fibroblast growth factor (bFGF), 100 U/ml penicillin and 100 µg/ml streptomycin. 
BBMvEC’s were cultured in T25, T75 and 58 cm2 culture flasks/dishes along with 6 and 
24-well plates. Cells between passages 5-12 were used for experimental purposes, and 
were maintained in a humidified atmosphere of 5% CO2/95% air at 37°C. 
 
2.2.2  Trypsinisation of BBMvEC’s 
As BBMvEC’s are an adherent cell line, trypsinisation was necessary for sub-culturing. 
BBMvEC’s were passaged at approximately 70-90% confluency. The trypsinisation 
process involved pre-equilibrating sterile phosphate buffered saline (PBS), 
trypsin/ethylenediamene tetracetic acid (5% v/v Trp/EDTA in PBS) and growth medium 
to 37°C. Using a sterile pipette, growth medium was aspirated from the culture flask and 
cells were washed with 4-6 mls of PBS for 30 sec to remove α-macroglobulin and other 
trypsin inhibitors present in the culture medium. Following removal, an appropriate 
volume of trypsin-EDTA was added to the cells and incubated for 2-3 mins at 37°C until 
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the cells were rounded but not detached. At this point the dish was gently tapped on the 
side to facilitate cellular detachment from the growth surface and subsequently an equal 
volume of culture media was added to prevent further trypsinisation. Cells were then 
removed from suspension by centrifugation at 700 rpm for 5 min at room temperature. 
The trypsin/growth medium was removed with the resulting cell pellet resuspended in 
growth or freeze media, and either counted for experimental procedures, split at a 1:4 
ratio or cryopreserved.           
2.2.3  Cryogenic preservation and recovery of BBMvEC’s 
For long term storage, BBMvEC’s were preserved in a liquid nitrogen cryo-freezer unit 
(Taylor-Wharton, Al, USA). Following trypsinisation, cells were centrifuged at 700 rpm 
for 5 min at room temperature and the supernatant was removed.  The resulting pellet 
was resuspended in an appropriate volume of freeze media; high glucose DMEM 
supplemented with 20% v/v FBS, 10% Dimethyl sulfoxide (DMSO), 3 µg/mL Heparin 
and 3 ng/mL bFGF, 100 U/ml Penicillin, 100 ug/ml Streptomycin and transferred in 1 
mL aliquots to Nalgene cryovials and frozen in a -800C freezer at a rate of -10C/min 
using a Mr. Freeze® cryo-freezing container.  Following this procedure, cryovials were 
transferred to the liquid nitrogen cyro-freezer unit until required. 
 
For recovery of cells, cryovials were heated rapidly in a 370C water bath and added to a 
culture flask containing an appropriate volume of culture media pre-equilibrated at 37°C 
to dilute the DMSO.  After 24 h, the media was removed, the cells were washed with 
sterile PBS and fresh culture media was added. 
 
2.2.4  Cell counting 
For efficient cell growth, BBMvEC’s were seeded at precise numbers and densities to 
ensure consistency between experimental procedures. To achieve this, cell counts were 
performed using a Neubauer chamber haemocytometer and cell viability was assessed 
using trypan blue staining. This was incorporated for all experimental procedures with 
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the exception of seeding for transendothelial permeability assays, which utilized the 
Advanced Detection and Accurate Measurement (ADAM) counter.  
 
2.2.4.1  Haemocytometer 
For this procedure, the center chamber of the haemocytometer was mounted with a 
square coverslip until the Newton rings were visible.  Approximately 20 µl of trypan 
blue was added to 100 µl of cell suspension and the haemocytometer chamber was filled 
by capillary action. Cells were visualized and counted in the four grids (G1-4) using a 
4x objective under a phase-contrast microscope where viable cells excluded the trypan 
blue whilst non-viable (dead) cells stained blue. Viable cells touching the right and top 
corner were counted while those touching the left and bottom corner were excluded 
(Figure 2.1). The total number of cells in the all grids (G1-4) was divided by four to give 
the average count per 1 mm2. The number of viable cells was calculated according to the 
equation: 
Avg. cell no. x 1.2 (dilution factor) x 1x104 (conversion factor) = Viable cells/mL 
            
 
Fig. 2.1: The Haemocytometer  
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2.2.4.2 ADAM Counter 
The ADAM Counter (Digital Bio, Korea) utilizes laser excitation and sensitive 
fluorescent optics connected to a charge coupled device (CCD) detection system to 
accurately measure viable cell suspension densities based on propidium iodide (PI) 
staining. Approximately 20 µl of cell suspension is mixed with 20 µl of solution T 
(containing PI and lysis buffer) and transferred (~30 µl) by capillary action into the ‘T’ 
channel of a microfluidic chip, giving a total cell count. Similarly 20 µl of cell 
suspension is mixed with 20 µl of solution N (containing PI, no lysis buffer), transferred 
to the ‘N’ channel giving a total non-viable cell count. The microfluidic chip is 
transferred to the ADAM counter and the results are calculated. Each N/T channel 
contains 22 grids, which are automatically counted, averaged and the resulting cell 
density of ‘N’ is subtracted from ‘T’ giving a viable cell count/ml of cell suspension 
(Figure 2.2). 
 
 
Fig. 2.2: ADAM counter microfluidic chip for viable cell counting.  
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2.2.5  Laminar shear stress studies 
2.2.5.1 Laminar shear stress by orbital rotation 
BBMVEC’s were seeded at 1x105 cells/well of a 6-well plate and grown to confluency 
(typically 4-5 days). Culture medium was then removed, replenished with 4 ml of fresh 
medium and cells were exposed to laminar shear stress (0 -10 dynes/cm2, 0-24 h) using 
an orbital rotator (Stuart Scientific Mini Orbital Shaker) set to 150 rpm as determined by 
the following equation (Hendrickson et al., 1999). See figure 2.3 for schematic depiction 
of method. 
 
Where: α = radius of rotation (cm) 
  ρ = density of liquid (g/L) 
n = 7.5 x 10-3 (dynes/cm2 at 370C) 
f = rotation per second 
 
 
Fig. 2.3: Orbital Rotation model used in laminar shear stress studies. 
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2.2.5.2 Laminar shear stress by IBIDI® (Integrated BioDiagnostics) flow system 
The IBIDI® pump system is a novel and recently acquired perfused flow system for 
exposing EC’s to shear stress on IBIDI® µ-slides (Figure 2.4). Prior to seeding, slides 
and media were equilibrated overnight at 37°C in a tissue culture incubator. The 
following day, EC’s were plated at a density of 1x105 cells/slide and allowed to adhere. 
After allowing cells to adhere to the flow channel (1 h), 100µl of medium was added to 
each slide reservoir. EC’s were allowed to grow to confluency at which point the µ-
slides were connected to the pump system via its leur connectors in accordance with the 
manufacturer’s instructions. The cells were then exposed to shear stress for the required 
time. This method was used for imaging purposes only and the immunocytochemistry 
(IC) protocol was carried out as described in section 2.5.2  
 
 
Fig. 2.4: IBIDI® flow system for laminar shear studies. (A): depicts the IBIDI® 
pressure pump connected to a fluidic unit containing two media reservoirs, with 
adjoining leur connectors which supply (B): EC’s adhered to IBIDI® µ-slides with 
culture media at a specific shear rate.    
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2.2.6 Transendothelial permeability assay  
 
Two different dextran substrates were employed to monitor BBMvEC transendothelial 
permeability. There preparations are outlined below. 
 
2.2.6.1  Fluorescein isothiocyanate (FITC) – labelled dextran  
For analysis of permeability, BBMvEC’s following treatment were trypsinised and 
replated at high density (1x106 cells/well) into Millicell hanging cell culture inserts (6-
well format, 0.4 µm pore size, 24 mm filter diameter). When cells had reached 
confluency (overnight) transendothelial permeability was monitored as previously 
described (Collins et al., 2006). In brief, fresh culture media was added to the upper 
(abluminal) and lower (sub-luminal) chambers of the Millicell insert within the 6-well 
dish (2 ml: upper, 4 ml: lower). At time (t)=0, FITC-labelled dextran (40 kDa) was 
added to the abluminal chamber (giving a final concentration of 250 µg/ml) and 
transwell diffusion allowed to proceed (Figure 2.5). Media samples (28 µl) were 
collected every 30 min from the sub-luminal compartment (for up to 3 h), diluted to a 
final volume of 400 µl with DMEM complete media, and monitored for FITC-dextran 
fluorescence (as 4x100 µl replicates in a 96-well fluorescence microplate). Using a 
TECAN Safire 2 fluorospectrometer (Tecan Group, Switzerland), excitation and 
emission wavelengths of 490 and 520 nm, respectively, were selected. % Trans 
Endothelial Exchange (%TEE) of FITC-dextran 40 kDa is expressed as the total 
subluminal fluorescence at a given time point (from 0-180 min) expressed as a 
percentage of total abluminal fluorescence at t=0 min.  
 
2.2.6.2 8-Aminopyrene-1,3,6-trisulfonic acid trisodium salt (APTS) – labelled 
dextran 
BBMvEC’s were prepared as described in section 2.2.6.1. At t=0, the APTS dextran 
label, a fluorescent substrate specific to the paracellular space was incorporated in lieu 
of FITC dextran using the labeling reaction method of Neuhaus et al. (Neuhaus et al., 
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2006). Briefly, a mixture consisting of 10 µl of 1 M ATPS, 15 µl of 1 M sodium 
cyanborohydride and 40 µl of dextran (6000 g/mol) was incubated at 85°C for 3.5 h. The 
resulting fluorescently-conjugated dextran was diluted 1:100 with complete culture 
media and added (2 ml) to the abluminal chamber. All remaining aspects of the 
transendothelial permeability assay for performed as described above in section 2.2.6.1.        
 
Fig. 2.5: Transendothelial permeability assay. A depicts the presence of FITC/APTS-
labelled dextran into the upper compartment (abluminal chamber) at t=0, which diffuses 
through the BBMvEC monolayer and semi-permeable membrane, into the lower 
compartment (sub-luminal chamber) (B), from which samples (28 µl) are collected 
every 30 min.  
 
 
2.2.7  Treatment with pharmacological inhibitors  
For these experiments, BBMvEC’s on 6-well plates were grown to confluency, after 
which the culture media was removed and cells were washed twice with sterile PBS. 
Inhibitors were diluted in culture media. For DMSO-soluble compounds, a suitable 
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stock concentration was prepared so that the final concentration of DMSO in working 
solutions was less than 0.5%. 
 
For pharmacological inhibition studies, cells were incubated in culture media with 50 
µM NSC23766 which inhibits Rac1, 10 µM Y-27632 which inhibits Rho-associated 
kinase (ROCK), and 20 µM Dephostatin, a tyrosine phosphatase inhibitor. These 
compounds were added approximately 1 h prior to the initiation of laminar shear stress. 
For Rac1/RhoA GLISA® activation assays, endogenous controls were incorporated to 
activate cellular pools of Rac1 and RhoA. For this procedure, BBMvEC’s were 
incubated in complete media with 5 µM forskolin and 1 U/ml thrombin for 10 min to 
serve as positive controls for Rac1 and RhoA activation respectively (Waschke et al., 
2004, Wojciak-Stothard et al., 2001). 
 
Concentrations used in experiments were taken from recent literature and based on 
manufactures recommendations.      
 
2.2.8  FACS analysis 
Following transfection of BBMvEC’s with a GFP-encoding plasmid construct, cells 
were monitored by fluorescent activating cell sorting (FACS) to detect GFP and assess 
the transfection efficiency. Approximately 24 h after GFP transfection, BBMvEC 
monolayers were washed twice with sterile PBS and harvested by trypsinisation. The 
cells were pelleted by centrifugation at 700 rpm for 5 min at room temperature and the 
resulting supernatant was removed. Cell pellets were then washed with 1 ml of ice-cold 
PBS supplemented with 0.1% w/v bovine serum albumin (BSA) and centrifuged once 
again. Following removal of the supernatant, the cell pellets were resuspended with 1 ml 
of ice-cold PBS (0.1% w/v BSA) and placed on ice. Samples were analysed by flow 
cytometry using a Becton Dickinson FACSCAN flow cytometer (NJ, USA).      
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2.3  Molecular biology techniques 
2.3.1  Plasmid DNA reconstitution  
Plasmid DNA constructs were received as small amounts of DNA (approximately 0.5 
µg) spotted on air dried filter paper, which was stored at 4°C until use. To reconstitute 
the DNA, the small area (~1 cm2) of the filter paper containing the appropriate plasmid 
was cut out using flame sterilized scissors and forceps, and added to a sterile 1.5 ml 
micro-centrifuge tube. Approximately 100 µl of sterile, endotoxin free, TE buffer (10 
mM Tris base, 1 mM EDTA, pH 8.0) was added to the micro-centrifuge tube. This 
mixture was vortexed gently for 5-10 sec, incubated at room temperature for 5min and 
subsequently vortexed again. The tube was then centrifuged for 15 sec at 1000rpm. 
Approximately 1-10 µl of the supernatant was used for subsequent bacterial 
transformations.  
 
2.3.2 Transformation of competent cells 
Chemically modified DH5α Escherichia-Coli bacterial cells were transformed with the 
appropriate plasmid to facilitate rapid replication and subsequent purification of high 
quantities of plasmid DNA to be used for experimental procedures. The transformation 
protocol was as follows: 
 
Approximately 1-10 µl of reconstituted plasmid DNA (10-50 ng) was gently added to 
25-50 µl of competent bacterial cells as supplied in a micro-centrifuge tube. This 
bacterial-plasmid mixture was incubated on ice for 30 min. Following this, the 
competent cells were ‘heat-shocked’ at 42°C for 30 sec and subsequently returned to ice 
for 2 min. At this point, 500 µl of room temperature SOC media (2% w/v Tryptone, 
0.5% w/v Yeast Extract, 10 mM NaCL, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 
and 20 mM Glucose) was added to the mixture and the cells were incubated for a further 
30 min at 37°C on a bacterial culture shaker at 150 rpm. The resulting transformed 
bacterial cells were spread on two Luria-Burtani (L.B) agar plates containing the 
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appropriate selective antibiotics (Table 2.1) in volumes of 50 µl and 500 µl. 
Approximately 5 µl of competent cells (without plasmid DNA) were spread on selective 
agar plates to serve as negative controls for bacterial growth.  The spread plates were 
inverted and incubated at 37°C overnight to facilitate optimal bacterial growth. 
Transformed colonies were isolated the following day.  
 
 
Antibiotic Solvent Final Concentration (µg/ml) 
Ampicillin dH2O 50 ug/ml 
Chloramphenicol EtOH 35 µg/ml 
Kanamycin dH2O 50 µg/ml 
 
Table 2.1: Antibiotic concentrations. Antibiotics dissolved in dH2O were sterile 
filtered using a 0.25 µm filter. 
 
 
2.3.3  Purification of plasmid DNA 
Following bacterial transformation, successfully transformed colonies were isolated 
from the selective agar plates using a flame sterilized inoculating loop. The transformed 
colony was then grown overnight (approximately 16 h) in sterilized baffled flasks 
containing 150 ml of L.B broth (1% w/v Tryptone, 0.5% w/v Yeast Extract and 171 mM 
NaCL) supplemented with the appropriate antibiotics at 37°C with 150 rpm orbital 
shaking. Purification of plasmid DNA was carried out using a Qiagen plasmid midi-prep 
kit as per manufacturer’s instructions.   
 
In brief bacterial cells were pelted by centrifugation at 4000rpm for 15 min at 4°C and 
the resulting supernatant was decanted by tube inversion. The bacterial pellet was 
dissolved by vortexing in 6 ml of chilled P1 buffer. The bacterial suspension was 
subsequently lysed through the addition of 6 ml of P2 buffer and vigorous shaking for 
30 sec followed by an incubation period of 5min at room temperature. The lysis activity 
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of P2 was neutralized by addition of 6 ml of chilled P3 buffer and was thoroughly 
mixed. The resulting cell lysate was poured into the barrel of a Qia midi-cartridge, 
inverted and incubated at room temperature for 10 min allowing cell debris to settle. 
Using a Qia midi-filter, the cell lysate was then filtered into a previously equilibrated hi-
speed midi-prep tip containing a resin column where plasmid DNA binds. The column 
was then washed with 20 ml of QC buffer to flush out any bacterial cell proteins. 
Elution of DNA into a sterile 15 ml tube proceeded through the addition of 5 mls of QF 
buffer to the resin column, which was then followed by a 5 min precipitation period 
involving the addition of 3.5 mls of room temperature isopropanol. This isopropanol 
mixture was then filtered through a Qia-precipitator and the bound plasmid DNA was 
subsequently washed with 2 ml of 70% v/v ethanol. The precipitator was then air dried 
by flushing air through and the bound plasmid DNA eluted into a sterile 1.5 ml micro-
centrifuge tube by the addition of 700 µl of sterile TE-buffer. The eluted DNA was 
flushed through the precipitator once again to remove any unbound DNA and was 
quantified by spectrophotometric analysis. 
 
2.3.4  Spectrophotometric analysis of plasmid DNA 
The concentration and purity of plasmid DNA from the bacterial culture was assessed 
by one of two methods, involving an automated NanoDrop 1000 spectrophotometer 
technique (Thermo Scientific, MA, USA) or measuring the absorbance (A) at 260 nm 
using an Eppendorf BioPhotometer (Eppendorf, Germany. It is assumed that 1 
absorbance unit was equivalent to 50 µg/ml double-stranded DNA. This method 
involved a 1:100 dilution of purified plasmid DNA with TE-buffer in a plastic UVette. 
Plasmid concentration was calculated as follows; 
Abs @260nm x 50 x dilution factor = Concentration of DNA (µg/mL) 
Plasmid purity was assessed by reading the absorbance at 260 nm and at 280 nm and 
then determining the ratio between the two (A260/A280). Pure DNA that has no bound 
protein impurities should have an A260/A280 ratio of 1.8-1.9.  
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2.3.5  Agarose gel electrophoresis 
Agarose gel electrophoresis was employed as a quality control to visualize and assess 
the quality of the purified plasmid. A 1% w/v agarose gel was prepared by adding 1 g of 
ultra pure agarose to a conical flask. This was brought to a volume of 100 ml by adding 
1X Tris Borate EDTA (TBE) (90 mM Tris base, 90 mM Boric Acid, and 4 mM EDTA). 
The solution was boiled to dissolve the agarose until it became clear and transparent. 
Once cooled but still in liquid form, 10 µl (1X) Syber Safe® was added to the solution 
for visualization purposes. The mixture was then poured into a casting plate that had 
already been sealed with masking tape to prevent leakage of the gel. Immediately 
following this, a gel comb was inserted into the agarose gel, and allowed to solidify for 
approximately 20 min. The masking tape was then removed and the solid agarose gel 
was placed in the chamber within a horizontal gel rig and then filled with 1X TBE until 
the buffer overlaid the gel. For plasmid visualization, approximately 1 µg (4-5 µl) of 
plasmid DNA was mixed with 5 µl of 2X loading dye and loaded into the appropriate 
wells generated by comb. Approximately 5 µl of a 10 kilobase (kb) DNA ladder (New 
England BioLabs) was loaded in parallel for relative band size comparison. The gel was 
electrophoresised for 80 min at 40 mA or until the loading buffer appeared to have run 
three quarters of the way down the gel. DNA was visualized using a G-Box fluorescence 
gel documentation and analysis system (Syngene, UK) 
 
2.4  Transfections - electroporation 
Electroporation is a technique that enhances the electrical conductivity and permeability 
of the cell plasma membrane, thus serving as a pivotal tool in molecular biology in the 
delivery of a foreign substance (DNA/RNA) into a cell. Two different commercial 
means of electroporation were assessed for their ability to successfully deliver plasmid 
DNA into BBMvEC’s without compromising overall cell viability (Figure 2.6 and 2.7). 
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2.4.1  Plasmid DNA nucleofection 
Nucleofection is a novel technology that allows transfected DNA to directly enter the 
nucleus. It is a non-viral method that utilizes a unique combination of pre-designed 
electrical parameters and cell-type specific solutions. For BBMvEC’s nucleofector 
transfections, the basic endothelial nucleofector cell kit was used in accordance with 
manufacturer’s instructions. In brief, BBMvEC’s were cultured to 70-80% confluency. 
On the day of transfection, approximately 2.5 ml of culture media without antibiotics 
was added to wells of a 6-well plate and equilibrated to 37°C in a cell culture incubator. 
BBMvEC’s were trypsinised, counted and pelleted as described in section 2.2.2 and 
2.2.4. Residual culture media was removed and the cell pellet was washed once with 
sterile PBS. BBMvEC’s were then centrifuged at 700 rpm for 5 min, residual PBS 
removed by aspiration and cells were resuspended at a final concentration of 
5x105cells/100 µl, in nucleofector solution. Care was taken at this point not to store the 
cell suspension in the nucleofector solution for longer than 15 min as this would reduce 
cell viability and DNA transfer efficiency. For each sample, approximately 1.5 µg of 
DNA was mixed with the 100 µl cell suspension (5x105cells) and carefully transferred 
to a nucleofector cuvette. The cuvette was then checked to be free of air bubbles and 
sealed with a cap. The most appropriate programme to nucleofect BBMvEC’s was U-11. 
Following nucleofection, 500 ul of pre-warmed culture media without antibiotics was 
added to the cuvette containing the sample, which was subsequently transferred to the 
pre-incubated well of the 6-well plate. Nucleofected samples were incubated overnight 
at 37°C and the culture media was replaced the next day.     
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Fig. 2.6: Amaxa nucleofection system. (A) The nucleofector apparatus for conducting 
the electroporation protocol and (B) nucleofector cuvette through which cell suspensions 
are contained during nucleofection (http://www.amaxa.com)  
 
2.4.2  Microporation 
Microporation is another novel method of electroporation but differs from the 
nucleofector as it utilizes a gold-plated tip as an electroporation space. This allows a 
more uniform electric field to be generated with minimal heat generation, metal ion 
dissolution, pH variation and oxide formation that are common problems experienced 
during the electroporation process. Microporation was carried out using a microporation 
kit in accordance with the manufacturer’s instructions. The cell culture steps for 
microporation were performed as described in section 2.4.1 up until the cell counting 
procedure. At this point, BBMvEC’s were pelleted by centrifugation at 700 rpm for 5 
min, from which the supernatant was aspirated off and the cells were washed in sterile 
PBS. This cell suspension was centrifuged at 700 rpm for 5 min and residual PBS 
aspirated, from which the resulting cell pellet was resuspended to give a final 
concentration of 1.1x106 cells/104 µl of transfection buffer-R solution. This cell-buffer 
R suspension was transferred to a sterile 1.5 ml micro-centrifuge tube and was mixed 
with 3.3 µg of plasmid DNA. Also at this point, 3 ml of E-buffer was added to a 
microporation tube and placed into the pipette docking station to form the microporation 
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unit (Figure 2.7). The cell-buffer R-DNA mixture was then pipetted into a 100 µl gold 
tip using the Microporator pipette before been inserted into the microporation docking 
unit. For BBMvEC’s, the desired microporation conditions were set; 1000 pulse voltage, 
30 pulse width (ms) and 2 pulse number. After microporation, the 100 µl sample was 
split between 2 wells of a 6-well plate containing pre-warmed culture media without 
antibiotics, giving approximately 5x105 cells per well. BBMvEC’s were allowed to 
recover overnight and the culture media was changed the following day.      
 
 
Fig. 2.7: Microporation System. (A) Microporation unit that generates the electrical 
parameters necessary for electroporation connected to (B) Microporation pipette 
docking unit consisting of microporation tubes containing electroporation buffer and the 
microporation pipette used to deliver electroporation to the cells through a gold plated 
pipette tip (C) Microporation kit with all the necessary solutions. 
(http://www.microporator.com)  
 
2.5 Immunodetection techniques 
2.5.1  Western blotting 
2.5.1.1 Preparation of whole cell lysate 
Post-treatment, confluent BBMvEC’s were harvested for analysis by western blot or 
immunoprecipitation in the following manner. Either on ice or at 4°C, culture media was 
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removed by aspiration and cells were washed three times in chilled PBS. Following 
complete aspiration of PBS, cells were harvested using a cell scraper in 
radioimmunoprecipitation assay (RIPA) lysis buffer (64 mM HEPES pH 7.5, 192 mM 
NaCL, 1.28% w/v Triton X-100, 0.64% w/v sodium deoxycholate, 0.128% w/v sodium 
dodecyl sulfate SDS, supplemented with 0.5 M sodium fluoride, 0.5 M EDTA pH 8.0, 
0.1 M sodium phosphate, 10 mM sodium orthovanadate, and 1X protease and 
phosphatase inhibitor cocktail) and transferred into a pre-chilled micro-centrifuge tube. 
Continuous lysate rotation persisted for 1 h at 4°C, prior to lysate clarification by 
centrifugation at 10000 rpm for 20 min at 4°C to sediment any triton-insoluble material. 
Subsequently clarified lysates were aliquoted into fresh tubes and were either stored at -
80°C for future analysis or immediately subjected to a BCA assay and used for western 
blot/immunoprecipitation purposes.  
  
2.5.1.2 Bicinchoninic acid (B.C.A) assay 
The BCA assay is a biochemical assay used to quantify the amount of protein in 
solution. This assay is based on the principal that the protein under alkaline conditions 
will reduce copper (Cu2+) ions to Cu1+ and secondly, the bicinchoninic acid (green) will 
chelate to each Cu1+ ion to form a complex (purple) than strongly absorbs at 562 nm. 
Two separate reagents were supplied in this commercially available assay kit (Pierce 
Chemicals), A; an alkaline bicarbonate solution and B; a copper sulphate solution, 
which were mixed at a ratio of 1 part (B) to 49 parts (A). Approximately 200 µL of this 
mixture was added to 10 µL of protein lysate or BSA standards (standard curve in the 
range 0-2 mg/mL) and monitored in triplicate form on a 96-well plate. The plate was 
incubated for 30 min at 37°C and the absorbance read at 562 nm using a ELx800 
microplate reader (BioTek, VT, USA). 
 
2.5.1.3  Immunoprecipitation (IP) 
IP is technique that facilitates the precipitation of a specific protein out of solution by 
forming a stable antigen-antibody complex bound to a resin. This allows investigators to 
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concentrate levels of a target protein, monitor possible binding partners in multimember 
protein complexes and assess post-translational modifications of proteins. For our 
studies, this procedure was performed in conjunction with western blotting to isolate 
occludin protein from a sample of whole cell lysate and monitor changes in occludin 
tyrosine phosphorylation in response to biomechanical stimuli and molecular inhibition 
strategies. 
 
Following preparation of whole cell lysate as described in section 2.5.1.1, lysates were 
monitored by IP analysis according to the method of Ferguson et al. with some minor 
modifications (Ferguson et al., 2000). In brief, lysate containing 200 µg of protein was 
pre-cleared with 20 µl of Protein G Sepharose beads for 1 h to minimize non specific 
binding. Beads were subsequently pelleted at 10000 rpm for 30 sec at 4°C. Pre-cleared 
lysate was transferred to a fresh tube and incubated with 2.5 µg of mouse anti-occludin 
monoclonal IgG, 10 µl of 10% w/v BSA, and 20 µl of fresh Protein G Sepharose beads, 
to give a final reaction volume of 500 µl. Incubation proceeded overnight with 
continuous eppendorf rotation at 4°C. Beads were then pelleted at 10000rpm for 30 sec 
at 4°C and washed extensively; twice in lysis buffer + 1% Triton X and twice in lysis 
buffer alone and resuspended in 2X sample solubilization buffer (2X SSB) (250 mM 
Tris-HCL pH 6.8, 8% SDS w/v, 40% glycerol v/v, 4% β-Mercaptoethanol v/v and 
0.008% Bromophenol blue w/v) and heated for 5 mins at 95°C. Beads were pelleted by 
centrifugation at 10000 rpm for 30 sec at 4°C and supernatant (containing solubilized 
proteins) was transferred to a fresh eppendorf for western blot analysis.  
 
2.5.1.4  Protein precipitation  
Protein precipitation was performed using the organic solvent acetone to concentrate 
protein samples and ensure they could fit into the wells of an SDS-PAGE gel for 
Western blot analysis. In brief, 5 volumes of ice cold acetone were added to 1 volume of 
a known concentration of protein sample. This acetone-sample mixture was gently 
vortexed and centrifuged at 1000 rpm for 15 sec at 4°C. Samples were then incubated at 
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-20°C for 1 h with regular inversion every 10 min to prevent samples from freezing. 
Samples were then centrifuged at 10000 rpm for 5 min at 4°C and acetone-based 
supernatant was discarded. Subsequent protein pellets were allowed to air dry for 15 min 
and once all the acetone was removed, samples were resuspended in 30 µl 1X SSB and 
either stored at -20°C or used for subsequent western blot analysis.  
2.5.1.5  Polyacrylamide gel electrophoresis (SDS-PAGE) 
Sample separation by electrophoresis was carried out according to the method of 
Laemmli et al. (Laemmli, 1970). All components of the Mini-PROTEAN Tetra Cell® 
system (BioRad, CA, USA) were assembled according to the manufacturer’s 
instructions. In brief, 10 x 100 mm glass plates (one short and one long with a 1.0 mm 
spacer; BioRad) were swabbed with 70% v/v ethanol and dried completely. The two 
plates were assembled accordingly and slotted into a casting frame, with the base space 
between the plates sealed by a gasket on a mounting stand. Resolving gels of 7.5% 
(Tiam1), 10% (Rac1, GADPH) and 12% (Occludin) polyacrylamide were prepared as 
described in Table 2.2 below. The TEMED was added last and approximately 5-6 mls of 
the resolving mixture was poured between the two plates. A small layer of 70% v/v 
ethanol was poured on top of the resolving gel to remove any surface air bubbles. The 
gel was then allowed to set for 30 min.  
 7.5% 10% 12% 
Distilled Water 4.85 ml 4.00 ml 4.35 ml 
1.5M Tris HCL pH (8.8) 2.50 ml 2.50 ml 2.50 ml 
Acrylamide/Bis-acrylamide 2.50 ml 3.33 ml 4.00 ml 
10% SDS 100 µl 100 µl 100 µl 
10% Ammonium persulfate 50 µl 50 µl 50 µl 
TEMED 5 µl 5 µl 5 µl 
Total Volume 10 ml 10 ml 10 ml 
          
Table 2.2: SDS-PAGE resolving gel composition. The individual components and 
corresponding volumes of different percentage acrylamide resolving gels are presented.  
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A 4% v/v stacking gel was prepared for all SDS-PAGE experiments and the components 
were compiled in the order documented in Table 2.3 below. 
 
 4% 
Distilled Water 6.10 ml 
1.5M Tris HCL pH (6.8) 2.50 ml 
Acrylamide/Bis-acrylamide 1.30 ml 
10% SDS 100 µl 
10% Ammonium persulfate 100 µl 
TEMED 10 µl 
Total Volume 10sml 
 
Table 2.3 SDS-Page stacking gel components. The individual components and 
corresponding volumes of a 4% acrylamide stacking gel is presented.  
 
When the resolving gel had set, the 70% ethanol at the gel surface was poured off and 
the space in between dried with filter paper. TEMED was then added to the stacking gel 
mixture and poured (approximately 1-2 mls) on top of the polymerized resolving gel. 
Any residing bubbles were removed following which the comb was gently inserted, and 
the stacking gel was allowed to polymerise for 30 min. Upon polymerization, the gels 
were submerged in an electrophoresis tank with approximately 700 mls of running 
buffer (25 mM Tris, 192 mM Glycine, 0.1% SDS) and the combs were then removed. 
The wells in the stacking gel were then flushed using a micro-pipette to remove any 
unpolymerised acrylamide.  
 
Table 2.4 below outlines the appropriate quantity of protein mixed with SSB and lysis 
buffer to give to a total loading volume of 30 µl. Once the samples were prepped, they 
were incubated for 5 min at 95°C on a heating block, before been cooled on ice and 
centrifuged briefly for 20 sec at 1000 rpm to collect any condensation on the lid of the 
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tube. Samples were loaded into the appropriate lanes along with 3 µl of Precision Plus® 
protein molecular weight marker (BioRad). Both samples and protein markers were 
electrophoretically separated for 90-120 min at 100 V.  
 
Protein Name Protein loaded per lane (µg) 
Occludin See section 2.5.1.3 
Rac1 15** 
Tiam1 50* 
GAPDH 15** 
       
Table 2.4: Protein concentrations loaded.  The different proteins and their 
corresponding, optimised loading concentrations for Western blot procedures are 
presented. Asterisk (*) denotes the SSB concentration used, where * = 1XSSB and ** = 
4XSSB. 
 
 
2.5.1.6  Electrotransfer to nitrocellulose membrane 
The wet or tank transfer method of Towbin et al. was utilized for electrotransfer of 
proteins to a gel in all circumstances (Towbin et al., 1979). This was accomplished 
using a Mini PROTEAN® Trans Blot Module (BioRad) according to the manufacturer’s 
instructions. Following SDS-PAGE electrophoresis, gels were removed from glass 
plates and the stacking gel was discarded. The resolved gel was then soaked for 10 min 
in transfer buffer (25 mM Tris, 192 mM Glycine, 20% methanol) to remove any SDS 
complexes bound to the gel that could affect successful protein transfer. At this time, the 
transfer cassette was assembled and nitrocellulose membrane (Pall Biotrace) was cut to 
the exact dimensions of the resolving gel and allowed to soak in transfer buffer for 5-10 
min. Following this the gel was assembled in the transfer cassette as described in Figure 
2.8 below.  
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Fig. 2.8: Wet transfer cassette assembly. Figure describes the layout of the transfer 
cassette used to transfer electrophoresed proteins from an SDS-PAGE gel to 
nitrocellulose membrane. The black colored side is assembled face down, overlaid with 
a fiber pad, filter paper, resolved gel, nitrocellulose membrane, filter paper, and fiber 
pad and sealed on the non-colored side.   
 
Once assembled, the cassette was checked to be free of air bubbles by rolling a 15 ml 
tube over the cassette while submerged in transfer buffer to remove any residual 
bubbles. The cassette was then placed in the Trans Blot Module with the correct 
orientation and subjected to 100 V for 2 h or 40 V overnight at 4°C. Following transfer 
completion, membranes were soaked in Ponceau S solution for 3 min to ensure even 
protein loading. The stain was subsequently removed by gentle washing in 1X PBS, 
0.05% Tween-20® (PBS-Tween).   
 
2.5.1.7  Immunoblotting and chemiluminescence band detection 
Following removal of the Ponceau stain, membranes were blocked for 90 min in tris-
buffered saline/Tween® (TBST: 25 mM Tris-HCL pH7.4, 150 mM NaCL and 0.05% 
Tween) containing 5% w/v BSA. Once membranes were blocked, they were briefly 
rinsed in TBS buffer to remove any excess blocking solution. Subsequently membranes 
were incubated with the appropriate primary antibody (see Table 2.5 below) in TBST 
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(5% BSA w/v) solution overnight at 4°C, with gentle agitation on a rocker (Stuart 
Scientific).       
 
Following completion of primary incubations, membranes were washed 6 times for 5 
min (30 min in total) in wash buffer (0.5% TBST for Rac1, GAPDH and Tiam1 or 1% 
TBST for Occludin or Phosphotyrosine blots). Membranes were subsequently incubated 
with the appropriate secondary antibody in TBST (5% BSA w/v) for 90 min with gentle 
agitation at room temperature. Membranes were then washed again using the same 
conditions described above.  
 
Primary Antibody Primary  
Dilution 
Secondary  
Antibody 
Secondary  
Dilution 
Occludin (Zymed) 0.5 µg/ml Mouse (GE-Healthcare) 1:3000 
Phosphotyrosine (Zymed) 1 µg/ml Mouse 1:3000 
Rac1 (Cytoskeleton) 1 µg/ml Mouse 1:3000 
GAPDH (Santa Cruz) 0.4 µg/ml Rabbit (Cell Signalling) 1:3000 
Tiam1 (Santa Cruz) 0.4 µg/ml Rabbit 1:2000 
 
Table 2.5: Primary and secondary antibody dilutions. This table displays the 
optimised primary and secondary antibody dilutions for proteins monitored by Western 
blot, and the commercial sources of antibodies.   
 
Supersignal® West Pico (Pierce) was the chemiluminescent substrate of choice for 
detection of HRP-conjugated secondary antibodies. This was prepared according to the 
manufacturer’s instructions and incubated with the membranes for 5 min, following 
which excess substrate was removed and the chemiluminescent signal was detected in a 
dark room by autoradiography (GE-Healthcare). Resulting immunoblots were scanned 
and densitometric analysis was performed using NIH Image v1.61 software to obtain 
relative comparisons between bands. 
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2.5.2  Immunocytochemistry 
In order to monitor the expression and/or subcellular localization of proteins, BBMvECs 
were prepared for immunocytochemical (IC) analysis according to the method of 
Groarke et al. with minor modifications (Groarke et al., 2001). Briefly, cells were 
washed twice in PBS and fixed with 3% formaldehyde for 15 mins. Cells were then 
washed, permeabilised with 0.2% Triton X-100 for 15 mins, and blocked in 5% w/v 
BSA for 30 mins. Cells were then incubated at room temperature with the appropriate 
primary antibody or stain as displayed in Table 2.6. Samples were then washed twice in 
PBS and incubated for 1 h in the dark with an Alexa Fluor 488-conjugated goat anti-
mouse IgG (1:400 for Z0-1, 1:400 for claudin-5) (Molecular Probes, OR, USA) and 
Alexa Fluor 488-conjugated goat-anti rabbit IgG (1:400 for FLAG®, Tiam1 and vWF) 
(Molecular Probes). Nuclear DAPI staining was routinely performed by incubating cells 
with 0.5 x 10-6 µg/mL DAPI for 3 min. Following two washes with PBS, BBMvEC’s 
were sealed with DAKO mounting media (DAKO, UK) and coverslips for visualisation 
by fluorescent microscopy (Olympus BX50, Germany). Appropriate controls (such as 
primary antibody omission) were routinely incorporated into all immunocytochemical 
experiments. 
 
1° Antibody/Stain 1° Antibody/Stain Dilution 
ZO-1 (Zymed) 0.5 µg/ml (2 h) 
Claudin-5 (Zymed) 1 µg/ml (3 h) 
Tiam1 (Santa Cruz) 2 µg/ml (2 h) 
FLAG® (DYKDDDDK) (Cell Signalling) 0.4 µg/ml (3 h) 
von Willebrand Factor (DAKO) 1:1000 (2 h) 
Rhodamine-Conjugated Phalloidin (Molecular Probes) 1:80 (40 min) 
 
Table 2.6: Immunocytochemistry primary antibody dilutions. Table 2.6 displays the 
optimised incubations for all primary antibody and stain dilutions of proteins monitored 
by immunocytochemistry. 
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2.6  RhoGTPase G-LISA® activation assays 
2.6.1 Lysate reparation 
Following shear experiments, BBMvEC’s were harvested for analysis of active (GTP) 
levels of Rac1 and RhoA using the Rac1 and/or RhoA G-LISA™ activation assay kits 
(Cytoskeleton Inc., CO, USA). This assay utilizes the p21-binding domain (PDB) of 
p21-activated kinase 1 (Pak1)  for Rac1 and Rho binding domain (RBD) of rhotekin for 
RhoA, coupled to GST as bait to selectively isolate active “GTP-bound” Rac1 and or 
RhoA (Stofega et al., 2006). All aspects of the assay protocol were performed as per the 
manufacturer specifications     
 
In brief, BMvECs were grown to 80% confluence, serum-starved overnight (0.2% FBS) 
and replenished with full-serum culture media immediately prior to the initiation of 
shear stress. Following shear cessation, cells were maintained on ice and rapidly 
processed to reduce GTP hydrolysis. BBMvEC’s were washed twice in ice-cold PBS 
and harvested with a cell scraper in the supplied lysis buffer, and transferred to a pre-
chilled micro-centrifuge tube. Lysate clarification proceeded at 14000 rpm for 2 min at 
4°C, following which the sample protein concentration was assayed within 1 min using 
the supplied Precision Red™ protein assay reagent as per manufacturer’s instructions. 
Sample concentrations were then equalized by diluting the most concentrated sample(s) 
with lysis buffer, aliquoted in 100 µl volumes and ‘flash frozen’ in liquid nitrogen and 
stored at -80°C for subsequent analysis. Typical protein concentrations were in the range 
of 0.7-1 mg/ml.  
 
2.6.2 G-LISA® procedure and immunodetection       
Again all aspects were prepared in accordance with the manufacturer’s instructions. In 
brief samples were rapidly thawed in a room temperature water bath and 60 µl of sample 
was diluted with 60 µl of ice-cold binding buffer. Samples were transferred (in 
duplicate, 50 µl per well) to appropriate wells on a ‘RhoGTPase affinity plate’, pre-
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coated with the respective binding domains for active Rac1 and RhoA. Positive and 
negative controls were routinely incorporated and added to the affinity plate under the 
following conditions; 60 µl of lysis buffer was added to 60 µl of binding buffer 
(negative control) and 12 µl of the supplied Rac1/RhoA control protein added with 108 
µl of binding buffer (positive control). The pulldown of active GTP levels proceeded by 
placing the affinity plate on an orbital shaker at 300 rpm for 30 min at 4°C.   
 
Following this, the solution was removed from the wells and washed twice in the 
supplied wash buffer. Solution removal consisted of a vigorous flick of the plate and 6-7 
hard pats onto paper towels. Then 200 µl of antigen presenting buffer was added to each 
well for 2 min, following which the wells were washed three times with wash buffer. 
Primary antibody incubation proceeded at 300 rpm for 45 min at room temperature in 
antibody dilution buffer (1:250 dilutions for Rac1 and RhoA). Wells were subsequently 
washed three times with wash buffer and incubated at 300 rpm for 45 min at room 
temperature in antibody dilution buffer containing secondary antibodies (1:200 for Rac1 
and 1:62.5 for RhoA). Wells were then washed 3 times with wash buffer, with complete 
solution removal after the final wash before the appropriate substrate was added to the 
samples. Quantification of Rac1 was by luminescence using a Synergy HT Multi-Mode 
Microplate Reader (BioTek) and RhoA was monitored using a TECAN Safire 2 
fluorospectrometer. Figure 2.9 below depicts the principle of the GLISA® assay.        
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Fig. 2.9: G-LISA principle. A 96-well plate is pre-coated with an effector domain for 
particular RhoGTPases forming an affinity plate to selectively isolate active 
RhoGTPases. The assay proceeds with sample addition and a standard primary and 
secondary based immunodetection protocol with subsequent quantification via substrate 
association with the HRP-secondary antibody conjugate.  
 
2.7  Statistical analysis 
Results are expressed as mean±sem. Experimental points were performed in triplicate 
with a minimum of three independent experiments (n=3). Statistical comparisons 
between controls versus treated groups were made by Student’s unpaired t-test and 
Wilcoxon Signed-Rank test (for non-parametric comparisons). A value of *P≤0.05 (or 
ϕP≤0.05) was considered significant.  
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Chapter 3:  
The effects of laminar shear stress and/or flow 
cessation on BBMvEC tight junction assembly and 
barrier function. 
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3.1 Introduction 
Vascular endothelial cells of the cerebral vascular network constitute a highly restrictive 
barrier phenotype forming the blood brain barrier. They establish a dynamic interface 
between cerebral blood flow and the central nervous system, a mechanism essential to 
controlling blood borne fluid and solute flux into the brain microenvironment (Persidsky 
et al., 2006). Surveillance of these BBB specific processes is tightly controlled and 
requires coordinated regulation via specific transcellular and paracellular pathway 
machinery. Indeed, the latter component involves a coordinated interaction of 
intercellular adherens and tight junction protein complexes, which mutually cooperate to 
stabilize barrier properties of the paracellular pathway. An abundance of clinical and 
experimental evidence exists, which implicate perturbations of intercellular junction 
complexes in various CNS disorders such as stroke, meningitis, multiple sclerosis, 
Alzheimer’s disease and epilepsy (Hawkins and Davis, 2005, Persidsky et al., 2006, 
Weiss et al., 2008).    
 
Both in-vivo and in-vitro, the functional BBB phenotype is highly sensitive to 
physiological and pathological variables encompassing both humoral (cytokines, 
immune cells, growth factors and infectious agents) and hemodynamic (shear stress) 
variables. The lateral component, blood flow-associated shear is of crucial importance, 
which through complex mechanosensing mechanisms regulates intracellular signaling, 
cytoskeletal dynamics and differential gene expression with profound consequences for 
vessel integrity and remodeling (del Zoppo, 2008, Schwartz, 2009). Moreover, shear 
stress promotes cerebral homeostasis and is postulated to exert protective effects against 
the pathophysiology of several neurological disorders (Krizanac-Bengez et al., 2004). 
However, a detailed understanding of the cellular mechanisms of shear-induced up-
regulation of BBB function is somewhat lacking. With this in mind, we re-visit the 
previous BBMvEC model of Colgan et al. to further clarify the shear-induced 
upregulation of BBB permeability, with specific relevance to tight junction assembly 
(Colgan et al., 2007). 
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In this chapter we examine the effect of physiological laminar shear stress on 
BBMvEC morphological characteristics, tight junction assembly and barrier function. 
Particular emphasis is also placed on claudin-5 and ZO-1 subcellular localization and 
occludin phosphotyrosine levels. Moreover, the effects of flow cessation following 
shear pre-conditioning of BBMvEC’s are examined with respect to the 
aforementioned barrier indices.                    
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3.2 Results 
 
3.2.1:  Morphology and positive characterization of BBMvEC’s by von Willebrand 
Factor and claudin-5 staining 
 
BBMvEC’s were grown to confluency and monitored by phase-contrast microscopy for 
characteristic growth patterns (doubling time of approximately 24 h) and typical 
‘cobblestone’ shaped morphology (Fig. 3.1 A). BBMvEC’s cultured under similar 
conditions were fixed in situ and monitored by fluorescent microscopy following 
immunocytochemical (IC) staining protocol for expression of two endothelial specific 
markers. BBMvEC’s stained positively for von Willebrand Factor (Fig. 3.1 B i) and 
claudin-5 (Fig. 3.2.1 B iii). Negative controls (Fig. 3.1 B ii, iv) showed no detectable, 
non-specific secondary antibody issues.    
 
3.2.2:  Exposure of BBMvEC’s to laminar shear stress-induced cellular and 
filamentous (F)-actin realignment in the direction of the flow vector 
 
Confluent BBMvEC’s were subjected to laminar shear stress (10 dynes cm-2, 24 h) and 
monitored for cellular realignment by phase-contrast microscopy (Fig. 3.2 i-ii) and 
fluorescent microscopy following IC protocol for F-actin (Fig. 3.2 iii-iv). Under sheared 
conditions, BBMvEC’s and F-actin filaments realigned in the direction of the flow (Fig. 
3.2 ii, iv). Under static (unsheared, 0 dynes cm-2) conditions, BBMvEC’s were randomly 
organised, with high expression levels of F-actin stress fibers exhibiting a random 
pattern of distribution (Fig. 3.2 i, iii).      
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Fig. 3.1: Characterization of BBMvEC’s. (A) Endothelial “cobblestone” morphology: 
(B) BBMvEC’s were grown to confluency and monitored by fluorescent microscopy 
for: (i) Von Willebrand Factor (vWF) expression (green) as indicated by white arrows; 
(ii) vWF negative control – primary antibody exclusion with DAPI stained nuclei; (iii) 
Claudin-5 expression (green) and cell-cell border localization in BBMvEC as indicated 
by red arrows; (iv) Claudin-5 negative control – no primary antibody with DAPI stained 
nuclei. Images are representative.     
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Fig. 3.2: Effect of laminar shear stress on BBMvEC and F-actin re-alignment. 
Confluent BBMvEC’s were exposed to laminar shear stress (10 dynes cm-2, 24 h) and 
monitored for morphological realignment by phase-contrast microscopy (i-ii) and 
fluorescent microscopy (rhodamine phalloidin stain for F-actin) (iii-iv). White arrows 
indicate the direction of the flow vector. DAPI stained nuclei (iii-iv) are clearly visible. 
Images are representative.  
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3.2.3: The impact of laminar shear stress on BBMvEC morphology and barrier 
function is magnitude-dependent 
BBMvEC’s at confluency were investigated for the effect of static (0 dyne cm-2), low (1 
dyne cm-2) and high (10 dyne cm-2) shear (24 h) on BBMvEC morphology and 
permeability as monitored by phase-contrast microscopy (Fig. 3.3 A) and 
transendothelial permeability assay (Fig. 3.3 B, C). Low levels of shear (Fig. 3.3 A ii) 
induced a random pattern of cellular organization as observed in static cultures (Fig. 3.3 
A i) and did not resemble the characteristic BBMvEC realignment as observed 
following high shear exposure (Fig. 3.3 A iii). The trend for permeability, i.e. 
transendothelial exchange (TEE) of FITC-dextran 40 kDa (FD40) between different 
shear rates is depicted by Fig. 3.3 B. Taking the data for a specific time point (e.g. 120 
min), a significant reduction in permeability (i.e. indicative of enhanced barrier 
function) was observed following high shear but not low shear (Fig. 3.3 C). No 
significant difference in permeability between static and low shear conditions were 
detected. All subseqent transendothelial permeability assays presented within this thesis 
will be depicted by a histogram using data from the 120 min time point.    
 
3.2.4: Laminar shear-induced upregulation of BBMvEC barrier function and 
cellular realignment requires prolonged shear exposure 
BBMvEC’s were exposed to varying durations of laminar shear stress (10 dynes cm-2 0-
24 h) and monitored by phase-contrast microscopy for changes in cellular realignment 
(Fig. 3.4 A) and barrier function (Fig. 3.4 B). BBMvEC realignment in the direction of 
the flow only became evident 12 h post shear initiation with full realignment observed 
by 24 h of shear stress (Fig. 3.4 A). The changes in permeability (%TEE of FD40) 
versus shear exposure time is presented in Fig. 3.4 B. Significant reductions in 
transendothelial permeability became evident 6 h post shear initiation, with the most 
significant fold reductions observed at 12 and 24 h respectively.  
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Fig. 3.3 
  
 
113 
 
 
Fig. 3.3: Magnitude-dependent effects of shear stress on BBMvEC permeability 
and morphological realignment. Confluent BBMvEC’s were subjected to non-
physiological (1 dyne cm-2) and physiological (10 dynes cm-2) levels of laminar shear 
stress and monitored by: (A) Phase-contrast microscopy: (B, C) Transendothelial 
permeability. White arrow indicates direction of the flow vector (A iii). Line graph and 
histogram data points show change in permeability (% TEE FD40) at a given time 
point(s) (0-180 min, B), (time (t) =120 min, C). Results are averaged from three 
independent experiments ±SEM; *P≤0.05 vs static, ɸP≤0.05 vs 1 dyne cm-2. Images are 
representative. 
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Fig. 3.4 
                     
 
Fig. 3.4: Time dependent effects of shear stress on BBMvEC permeability and 
morphological realignment. Following laminar shear stress (10 dynes cm-2, 0-24 h), 
BBMvEC’s were monitored for morphological realignment by: (A) phase-contrast 
microscopy: (B) barrier function by transendothelial permeability assay. White arrow  
indicates the direction of the flow vector (A 24 h). (B) Histogram data points show 
change in permeability (% TEE FD40 at t=120 min) Results are averaged from three 
independent experiments ±SEM; *P≤0.05 vs static (0 h) ɸP≤0.05 vs 6h. Images are 
representative. 
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3.2.5: Exposure of BBMvEC’s to laminar shear stress enhances the cell-cell border 
localization of tight junction proteins, ZO-1 and claudin-5  
Confluent BBMvEC’s were exposed to laminar shear stress (10 dynes cm-2, 24 h) and 
fixed in situ to be assessed by fluorescent microcopy following IC protocol for the 
subcellular localization of two pivotal tight junction proteins; ZO-1 and claudin-5 (Fig. 
3.5). For unsheared samples (Fig. 3.5 i, iii), the staining pattern for ZO-1 and claudin-5 
was quite jagged and discontinuous at the cell-cell border. This is in stark contrast to the 
enhanced immunoreactivity and continuous localization pattern of both ZO-1 (Fig. 3.5 
ii) and claudin-5 (Fig. 3.5 iv) at cell-cell borders following shear stress.  
 
Fig. 3.5: Effect of laminar shear stress on ZO-1 and Claudin-5 localization. 
Confluent BBMvEC’s were exposed to laminar shear stress (10 dynes cm-2, 24 h)  and 
monitored for staining patterns of the tight junction proteins ZO-1 (i-ii) and claudin-5 
(iii-iv) by fluorescent microscopy. Red arrows (ii, iv) indicate sharp localization of tight 
junction proteins to cell-cell borders. White arrows (ii, iv) denote the direction of the 
flow vector. DAPI stained nuclei (i-iv) are clearly visible. Images are representative  
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3.2.6: Prolonged exposure of BBMvEC’s to shear stress reduces occludin 
phosphotyrosine levels    
Following exposure to laminar shear stress (10 dynes cm-2, 0-24 h), BBMvEC’s were 
subjected to immunoprecipitation (IP) and immunoblot (IB) analysis for 
phosphotyrosine (pTyr)-occludin levels. PTyr-occludin levels were substantially 
elevated following acute shear exposure to 1.76 fold±0.09 at 30 min shear and 1.39 fold 
±0.10 following 60 min exposure. These values are in stark contrast to the pTyr-
occludin levels observed following chronic shear (24 h), which were significantly below 
static baseline levels (0.38 fold±0.03) (Fig. 3.6 A, B).  
 
 
Fig. 3.6: Effect of laminar shear stress on occludin tyrosine phosphorylation. 
BBMvEC’s were grown to confluence and subjected to laminar shear stress (10 dynes 
cm-2) following which they were harvested at varying time points (0, 30, 60 min and 24 
h) and monitored by IP/IB analysis for pTyr-occludin and total occludin levels. 
Histogram (A) represents relative pTyr-occludin (i.e. pTyr-occludin/total occludin 
derived by scanning densitometry from blots in B). Results are averaged from three 
independent experiments ±SEM; *P ≤0.05 vs 0min. Scanned blots in (B) are 
representative.  
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3.2.7: Laminar shear-induced enhancement of BBMvEC barrier integrity involves 
tyrosine phosphatase activity 
  
BBMvEC’s at confluency were exposed to laminar shear stress (10 dynes cm-2, 24 h) in 
the absence or presence dephostatin and monitored for changes in barrier function via 
transendothelial permeability assay. Shear significantly reduced permeability (%TEE of 
FD40) by 3.61% compared to the static control. However this shear-induced reduction 
in permeability was attenuated by 57.9% when dephostatin was present (following 
correction for the baseline increase with dephostatin under static conditions) (Fig. 3.7).  
 
Fig. 3.7: Effect of dephostatin on laminar shear-induced BBMvEC barrier 
enhancement. Confluent BBMvEC cultures were either maintained under static 
conditions or exposed to laminar shear stress (10 dynes cm-2, 24 h) in the absence and 
presence of the protein tyrosine phosphatase inhibitor, dephostatin and monitored for 
transendothelial permeability. Histogram data points show change in permeability (% 
TEE FD40 at t=120 min). Histogram is averaged from three independent experiments 
±SEM; *P≤0.05 vs unhibited static, ɸP≤0.05 vs unhibited shear.  
118 
 
3.2.8: Flow reduction following shear pre-conditioning of BBMvEC’s leads to a 
reversal of shear-induced barrier stabilization, ZO-1 localization and increase in 
pTyr-occludin level 
 
BBMvEC’s were pre-sheared at 10 dyne cm-2 for 24 h after which, cells were split into 
two groups – those allowed to continue shearing at a sustained rate for 24 h and those 
allowed to continue shearing at a reduced rate of 1 dyne cm-2, in both instances for a 
further 24 h (histogram inset in Fig. 3.8 A). Using an identical shearing protocol, 
BBMvEC’s were monitored for cellular realignment by phase-contrast microscopy (Fig. 
3.8 B i-iii) and fluorescent microscopy following IC protocol for ZO-1 (Fig. 3.8 B iv-
vi). Following flow reduction, BBMvEC morphology reverted from the characteristic 
‘flow-aligned’ phenotype (Fig. 3.8 B ii) to a more cobblestone pattern of cellular 
organization (Fig. 3.8 B iii) similar to observations in static cultures (Fig. 3.8 B i). 
Furthermore, ZO-1 localization at cell-cell borders was abrogated under flow reversal 
conditions (Fig. 3.8 B vi) compared to the characteristic cell-cell border localization of 
ZO-1 observed under sustained shearing conditions at 10 dyne cm-2 (Fig. 3.8 B v).  
BBMvEC’s were then monitored for barrier as assessed by transendothelial permeability 
assay. A significant increase in permeability (%TEE FD40) was observed as pre-sheared 
BBMvEC’s were reduced to 1 dyne cm-2 (Fig. 3.8 C). Finally this shear regime was 
employed to monitor pTyr-occludin levels. The characteristic decrease in pTyr-occludin 
levels (0.20 fold±0.04) in response to sustained shear at 10 dynes cm-2 relative to static 
control was substantially reversed (to 0.71 fold±0.054) by flow reduction to 1 dyne cm-2 
(Fig. 3.8 D i-ii).   
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Fig. 3.8 
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Fig. 3.8: Effect of flow reduction on the barrier properties of shear-preconditioned 
BBMvEC’s. (A) In confluent cultures of laminar shear-preconditioned BBMvEC’s (10 
dynes cm-2, 24 h), flow was either sustained at 10 dynes cm-2 for a further 24 h or 
reduced to 1 dyne cm-2 (24 h) as shown by schematic inset. (B): Following flow 
reduction protocol, BBMvEC’s were monitored for morphological realignment by 
phase- contrast microscopy (i-iii) and ZO-1 staining by fluorescent microscopy (iv-vi). 
Red arrows (v) indicate localization of ZO-1 to cell-cell borders. White arrows (ii and v) 
denote direction of the flow vector. DAPI stained nuclei (iv-vi) are clearly visible. 
Images are representative. (C): BBMvEC’s were then monitored for barrier function by 
transendothelial permeability assay. Histogram data points show change in permeability 
(% TEE FD40 at t=120 min). Histogram is averaged from three independent 
experiments ±SEM; *P≤0.05 vs 0 dynes cm-2 (static) ɸP≤0.05 vs 10 dynes cm-2 
(sustained). (D): Illustrates the effect of shear pre-conditioning (10 dynes cm-2, 24 h) 
followed by sustained flow (10 dynes cm-2, 24 h) or flow reduction (1 dyne cm-2, 24 h) 
on pTyr-occludin and total occludin levels. Histogram represents relative pTyr-occludin 
(i.e. pTyr-occludin/total occludin as derived by scanning densitometry from blots in D 
ii). Results are averaged from three independent experiments ±SEM; *P ≤0.05 vs static, 
ɸP≤0.05 vs shear 10 dynes cm-2. Blots are representative (D ii). 
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3.2.9: Shear-dependent enhancement of BBMvEC barrier function occurs via 
paracellular mechanisms 
 
A control study was conducted in which BBMvEC’s at confluency were exposed to 
laminar shear stress (10 dynes cm-2 24 h) and monitored for changes in paracellular 
permeability using APTS-dextran. This molecule has been previously validated to be a 
paracellular specific marker (Neuhaus et al., 2006). Using ATPS-dextran, shear reduced 
permeability (%TEE FD40) from 23.1% to 18.35%, (i.e. 0.21±0.03 fold reduction), 
which is very similar to the fold reduction in permeability observed with FITC-dextran 
(Fig. 3.9).  
 
 
Fig. 3.9: Effect of shear stress on BBMvEC permeability using the “paracellular” 
marker, APTS-dextran. Confluent BBMvEC were exposed to laminar shear stress (10 
dynes cm-2, 24 h), and monitored for transendothelial permeability using the 
paracellular-specific label APTS-dextran. Histogram data points show change in 
permeability (% TEE FD40 at t=120 min). Histogram is averaged from three 
independent experiments ±SEM; *P≤0.05 vs 0 dynes cm-2.     
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3.3 Discussion. 
EC’s of the BBB in-vivo are physiologically regulated by a multitude of signaling 
mediators that encompass both humoral and hemodynamic stimuli. A further dimension 
to BBB regulation involves local, chemical input from the surrounding neurovascular 
unit. Together these contribute to a functional BBB phenotype that protects the CNS 
from fluctuations in changes in concentrations of ions, neurotransmitters, blood-borne 
factors and various toxins/pathogens that could affect neuronal and/or glial function. 
Traditionally, the majority of experimental evidence from in-vitro studies has utilized 
various co-culture or tri-culture model systems consisting of brain EC’s, astrocytes 
and/or pericytes to recapture the in situ ‘conditioning’ of brain EC’s (for comprehensive 
review see Deli et al. 2005). These models have proved to be invaluable tools in 
expanding our understanding in the induction of BBB specific properties, such as high 
TEER, expression of BBB-specific transporters and ion channels and thus serve as more 
viable methods to study BBB function. However, the major disadvantage of some of 
these models is that they lack the input of flow-associated shear stress.  
Efforts in more recent years have sought to overcome this, with the establishment of the 
DIV-BBB (dynamic in-vitro) model, which allows real time monitoring of barrier 
function (Cucullo et al., 2002). Notwithstanding this there is still a genuine lack of 
knowledge regarding the cellular signaling processes involved in the flow-induced 
regulation of BBB function. Previous work conducted in this laboratory by Colgan et al. 
investigated the regulation of brain microvascular endothelial tight junction assembly 
and barrier function by laminar shear stress using a mono-culture BBMvEC model 
(Colgan et al., 2007). With this particular chapter, we sought to expand on these basic 
findings and further develop our insight into the cellular phenomenology regarding 
shear-dependent enhancement of BBB function.  
Throughout the course of this project, BBMvEC’s were routinely monitored for 
endothelial specific markers vWF and claudin-5, to ensure they retained their properties 
in-vitro. Furthermore we observed the characteristic shear-induced realignment of EC’s 
in the direction of the flow following laminar shear stress (10 dynes cm-2, 24 h) relative 
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to static (unsheared) controls, findings consistent with the parallel organization of F-
actin stress fibers in the direction of flow. This cellular adaptation to blood flow is an 
essential process EC’s undergo to reduce mechanical loading and subsequent injury. 
Moreover, based on the immunocytochemical staining pattern of F-actin, there was 
enhanced cortical actin localization at the cell-cell borders suggesting increased 
association with intercellular junction components, i.e. adherens and tight junctions. 
This morphological feature of EC’s is frequently associated with vessel homeostasis and 
indicative of an upregulated barrier phenotype (Lai et al., 2005, Jacobson et al., 2006, 
Spindler et al., 2010).  
Although the preliminary BBMvEC experimental work discussed above was performed 
using the static (unsheared/0 dyne cm-2) condition as control, we also sought to 
investigate the effect of a more physiologically relevant control within the context of 
vascular flow patterns to assess any possible discrepancies in using static cultures. To 
this end, we used low shear stress (1 dyne cm-2), which falls within a non-physiological 
paradigm and is prevalent in atherosclerotic-prone and flow compromised regions of the 
vasculature (Krizanac-Bengez et al., 2004, Davies, 2009). There was however no 
detectable difference in BBMvEC permeability between static and low shear protocols. 
Furthermore, BBMvEC’s under low shear were unable to realign with the flow, clearly 
exhibiting a morphological resemblance to static BBMvEC cultures. In view of this, 
subsequent experiments routinely employed the static condition as control.  
As a control to ensure our permeability assay with FITC-dextran was indeed measuring 
paracellular (not transcellular) flux, we prepared a fluorescent ATPS-dextran conjugated 
label from first principles. This molecule is extremely hydrophilic with 3 negatively 
charged sulfonic acid groups and its structural characteristics hamper its binding to 
transcellular active transport systems, thus making it a paracellular specific marker 
(Neuhaus et al., 2006). Our experiments demonstrated that the shear-induced fold 
decrease in permeability was very similar with either APTS-dextran (paracellular only) 
or FITC-dextran, suggesting that the latter marker is principally recording paracellular 
transport.                  
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Studies have previously shown that prolonged (> 24 h) exposure of physiological levels 
of shear stress enhances the barrier properties of brain endothelial monolayers (Colgan 
et al., 2007, Siddharthan et al., 2007). We sought to expand on this knowledge and 
temporally monitor shear-induced enhancement of BBMvEC barrier integrity. In this 
regard, significant decreases in permeability became evident 6 h post shear initiation, 
however the most noticeable responses observed following chronic shear exposure at 12 
and 24 h. In a subsequent control experiment, no detectable difference in permeability 
between 24 and 48 h was detected (data not shown). Furthermore, the pattern of cellular 
realignment under shear stress appeared to mimic these functional responses as the most 
noticeable changes in BBMvEC realignment with flow were observed at the 12 and 24 h 
points. Interestingly, shear initiation (1 h) did not significantly alter BBMvEC barrier 
function. This period of flow onset is associated with dramatic cytoskeletal remodeling 
and pro-inflammatory conditions, which would imply that the endothelial barrier would 
be compromised and permeability increased (Hahn and Schwartz, 2009). Perhaps a 
more sensitive model which allows for real-time monitoring of barrier integrity by 
transendothelial electrical resistance would refine such a possible discrepancy.  
Having established a reliable model of shear-induced (10 dynes cm-2, 24 h) regulation of 
BBMvEC barrier function, our focus shifted to the tight junction components likely 
mediating these effects. Apically located tight junctions represent the primary form of 
maintenance to paracellular permeability, and alterations in their regulation contribute to 
permeability changes in a variety of disease states (Harhaj and Antonetti, 2004, Lee et 
al., 2004, Liu et al., 2008). Consistent with our findings of enhanced barrier function 
following shear (10 dynes cm-2, 24 h), we observed enhanced immunoreactivity of 
claudin-5 and ZO-1 at intercellular junctions. ZO-1 presents a structural anchor for the 
insertion of other tight junction proteins such as claudin-5 and occludin, which provide 
the physical barrier to solute flux via homo/heterophilic interaction with partners from 
adjacent EC’s. Unsheared BBMvEC’s exhibited a substantially decreased 
immunoreactivity of both ZO-1 and claudin-5 at cell borders with a discontinuous, 
broken staining pattern.  
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We further extended our understanding of the mechano-regulation of BBB function by 
assessing post-translational modifications of the tight junction component occludin, on 
tyrosine residues. The significance of phosphotyrosine (pTyr) occludin levels to barrier 
integrity has been frequently cited in the literature. Following shear onset (0-60 min), 
we observed a significant increase in pTyr-occludin above static levels, a finding 
consistent with previous work using a similar shear regimen in bovine aortic endothelial 
cells (DeMaio et al., 2001). However, this acute increase is in complete contrast to the 
profound reduction in pTyr-occludin observed following chronic shear exposure (24 h) 
suggesting pTyr-occludin is essential for BBB adaptation to, and function under flow. 
This somewhat paradoxical shift in pTyr-occludin levels could be explained by the 
profound remodeling processes that EC’s undergo during the acute phase of shear 
initiation (Hahn and Schwartz, 2009). Furthermore, tyrosine phosphorylation of 
occludin is known to lead to reduced association with ZO-1, which likely explains the 
scattered ZO-1 localization observed in static BBMvEC’s (Kale et al., 2003). In 
addition, the two extracellular loops of occludin are rich in tyrosine residues and their 
phosphorylation status could possibly dictate the strength of the homophilic binding 
between opposing occludin strands, or its interlocking with ZO-1, either of which would 
have a significant impact on paracellular permeability. In a further development of this 
finding, we assessed the effect of protein tyrosine phosphatase (PTP) inhibition on 
shear-induced regulation of barrier function using dephostatin (Imoto et al., 1993). 
Molecular inhibition of PTP significantly attenuated the shear-induced increase in 
barrier integrity by 57.9% suggesting a putative role for PTP’s in maintaining barrier 
function.  
Cerebral ischemia is an irreversible neurodegenerative disorder of which decreased 
shear stress is believed to be one of three major initiating components of ‘Virchow’s 
Triad’ (along with thrombosis and loss of microvascular barrier function) (Krizanac-
Bengez et al., 2006b, Krizanac-Bengez et al., 2006a, del Zoppo, 2008). We therefore 
sought to investigate the effect of decreased flow on BBMvEC barrier function. Our 
findings demonstrate that when flow is reduced (1 dyne cm-2, 24 h) following 
preconditioning at 10 dyne cm-2 (24 h), both BBMvEC permeability and 
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phosphotyrosine occludin levels return to pre-shear levels, in parallel with a complete 
loss of shear-induced cellular realignment. Moreover, ZO-1 cell border 
immunoreactivity was abrogated as inter-endothelial gaps between cells became 
apparent. Molecular alterations of tight junction proteins during ischemic stroke 
progression have previously been reported in the literature. Kago and colleagues showed 
a reduced expression of occludin and ZO-1, in addition to increased pTyr-occludin 
levels following cerebral ischemia, whilst more recent experiments by Takenaga et al. 
implicating the protein tyrosine kinase (PTK) Src as a putative mediator of this post-
translational phosphorylation state of occludin (Kago et al., 2006, Takenaga et al., 
2009). Interestingly, recent work by Salle and Burrdige implicated a specific role for the 
tyrosine phosphatase DEP-1 (density enhanced phosphatase-1) in dephosphorylating 
occludin and ZO-1, consistent with increased barrier function, albeit in epithelial cells 
(Sallee and Burridge, 2009). It seems apparent that a coordinated activation/de-
activation of PTK’s and PTP’s is crucial to tight junction assembly, and thus barrier 
function, including BBB function in response to flow. As a complete attenuation of 
shear-induced barrier regulation with PTP was not achieved within our model using 
dephostatin, it is plausible that PTK’s are also involved in regulating pTyr-occludin 
levels. Future work could address this issue and also attempt to identify the specific 
phosphatase(s) and kinase(s) involved.  
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Chapter 4: 
The contribution of RhoGTPases, Rac1 and 
RhoA, to shear-induced adaptation of BBMvEC 
tight junction assembly and barrier function. 
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4.1 Introduction 
Maintenance of a dynamic yet stable BBB is a prerequisite for CNS homeostasis. In this 
regard, physiological levels of blood flow-associated laminar shear stress are of crucial 
importance, and have been extensively documented to control the structural integrity of 
the endothelial monolayer (Stanness et al., 1999, Krizanac-Bengez et al., 2004, Colgan 
et al., 2007, Siddharthan et al., 2007). Vascular EC’s responding to such physiological 
conditions undergo dramatic actin-cytoskeletal remodeling, which induces an elongated 
cellular phenotype aligned in the direction of the flow, aswell as enhanced cortical actin 
accumulation at the cell periphery. Most notably, tight and adherens junction complexes 
are associated with the cortical actin cytoskeleton through associations with adaptor 
molecules ZO-1 and catenin (α-, β-, p120-) family members respectively. It is widely 
accepted that these associations enhance the ‘stiffness’ of the cell periphery, thus 
stabilizing the endothelial barrier (Jacobson et al., 2006, Waschke et al., 2006). 
Conversely, breakdown of endothelial integrity is believed to be a consequence of 
increased centripetal tension created by actomyosin contractility, thus destabilizing 
intercellular adhesion (Wojciak-Stothard and Ridley, 2002).  
The RhoGTPases, and in particular its family members RhoA, Rac1 and Cdc42 have 
been extensively documented for their ability to profoundly influence cytoskeletal 
dynamics. There is a wealth of evidence from in-vivo and in-vitro studies incorporating 
EC’s predominantly of macrovascular origin, culminating in a generally well-accepted 
view that RhoA disrupts the endothelial barrier, whereas Rac1 serves to 
strengthen/stabilize cell-cell junctions (Spindler et al., 2010, Beckers et al., 2010). 
Studies on Cdc42 have shown that its activation is essential to barrier restoration 
subsequent to injury (Kouklis et al., 2004, Waschke et al., 2006). Moreover, these 
GTPases have been shown to be hemodynamically sensitive. However, coupled to the 
fact that there is genuine lack of knowledge regarding laminar shear-induced 
upregulation of tight junction assembly at the BBB, there is little or no evidence of 
studies that have assessed signaling mechanisms pertaining to such effects in the 
cerebral microvasculature.                   
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In this chapter we examine the potential role of the RhoGTPases, Rac1 and RhoA in 
the shear-dependent regulation of BBMvEC tight junction assembly and barrier 
function.   
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4.2 Results 
4.2.1: Post-transfection efficiency/viability: Microporation versus Amaxa 
Nucleofection.  
BBMvEC’s were monitored by two different electroporation mechanisms (Amaxa 
nucleofection and microporation) to determine the most appropriate method of plasmid 
DNA delivery for genetic manipulation studies. Initial optimization of each system 
required fine tuning of electrical parameters, plasmid DNA concentration and cell 
number. Once this was achieved, the two systems were compared for cell viability and 
transfection efficiency. BBMvEC’s monitored by phase-contrast microscopy 24 h post 
transfection revealed noticeably better cell viability (and morphology) with 
microporation compared to nucleofection (Fig. 4.1 A i-ii). Analysis of enhanced Green 
Fluorescent Protein (eGFP) expression by fluorescent microscopy revealed a negligible 
difference in eGFP uptake between the two methods (Fig. 4.1 A iii-iv), although 
quantitative evaluation of eGFP by FACS analysis revealed a transfection efficiency of 
52.92% compared to 35.05% in favour of microporation (Fig. 4.1 B). As a result, all 
subsequent transfections were performed using microporation.  
 
4.2.2: Laminar shear stress regulates BBMvEC Rac1-GTP activity. 
BBMvEC’s subjected to laminar shear stress (10 dynes cm-2, 0-24 h), were monitored 
for acute (0-60 min) and chronic (24 h) effects on Rac1 total protein and Rac1-GTP 
levels. Acute and chronic shear exposure did not alter Rac1 protein levels (Fig. 4.2 A i). 
Interestingly, shear onset (within 1 min) triggered a small decrease (to 0.74±0.09 fold) 
in Rac1-GTP followed by a 1.54±0.06 fold increase of Rac1-GTP above static levels at 
60 min shear. Levels of Rac1-GTP following chronic exposure of shear stress were 
1.75±0.08 fold above static values. Forskolin and NSC23766 exerted their respective 
positive (1.31±0.01 fold) and negative (0.72±0.07 fold) control effects on Rac1-GTP 
levels (Fig. 4.2 A ii).  
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Fig. 4.1: Assessment of plasmid DNA transfection viability and efficiency via 
Amaxa nucleofection and microporation. BBMvEC’s were grown to 70-80% 
confluency and subjected to electroporation protocols described in sections 2.4.1 and 
2.4.2. The following day, BBMvEC’s were monitored for cell viability by: (A i-ii) 
phase-contrast microscopy, and eGFP transfection efficiency via: (A iii-iv) fluorescent 
microscopy and: (B) FACS analysis. Scatter plots in (B iii-iv) show the regions of non-
transfected cells (R2) vs. the region of transfected cells (R3), which represent the gate 
statistics generated (B i-ii) and the overall transfection efficiency encircled in red. 
Images shown are representative.   
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Fig. 4.2: Effect of laminar shear stress on Rac1 activation.  BBMvEC’s were 
cultured as described in section 2.6.1 and exposed to laminar shear stress (10 dynes 
cm2), following which they were harvested at varying time points (0-60 min and 24 h) 
and monitored by: (A i) IB analysis for total Rac1 levels and (A ii) Rac1-GLISA® 
activation assay for Rac1 GTP levels. Forskolin (5 µM, 10 min treatment) and 
NSC23766 (50 µM, 24 h treatment) were included as positive and negative controls, 
respectively, for Rac1 activation. Results are averaged from three independent 
experiments ±SEM; *P≤0.05 vs. 0 min. Blots are representative.         
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4.2.3: Laminar shear stress-induced BBMvEC morphological/cytoskeletal 
realignment is Rac1-dependent.  
As observed in section 3.2.2, the common characteristic response of EC’s to prolonged 
laminar shear stress (10 dynes cm-2, 24 h) is their morphological and F-actin realignment 
in the direction of the flow vector in tandem with cortical actin accumulation at the cell 
periphery. These responses were found to be Rac1-dependent as blockade of Rac1 
activation via NSC23766 strongly attenuated shear-induced BBMvEC morphological 
(Fig. 4.3 A iv) and F-actin (Fig. 4.3 B iv) realignment, and diminished cortical actin 
assembly. Treatment with NSC23766 had no observable impact on static BBMvEC 
morphology as observed by phase-contrast microscopy (Fig. 4.3 A ii).  
 
4.2.4: Laminar shear stress-induced upregulation of BBMvEC barrier function is 
Rac1 dependent.  
As observed in section 3.2.4, laminar shear stress (10 dynes cm-2, 24 h) reduces 
BBMvEC permeability (i.e. upregulates barrier function). We therefore employed two 
methods of Rac1 inhibition using NSC23766 and T17N (dominant negative mutant) to 
assess the potential role of Rac1 in the shear-dependent enhancement of BBMvEC 
barrier function. At t =120 min, shear significantly reduced permeability (%TEE of 
FD40), however the shear-induced reduction in permeability was attenuated by 88.7% 
and 76.6% with NSC23766 and T17N respectively (following correction for the baseline 
increase with NSC23766/T17N under static conditions) (Fig. 4.4 A/B i). Overexpression 
of T17N was confirmed by IB analysis for total Rac1 levels (Fig. 4.4 B ii). 
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Fig. 4.3: Effect of Rac1 inhibition on laminar shear-induced BBMvEC 
morphological and F-actin realignment. Following exposure to laminar shear (10 
dynes cm-2 24 h) in the absence and presence of 50 µM NSC23766, BBMvEC 
realignment was monitored by: (A) phase-contrast microscopy and (B) fluorescent 
microscopy (rhodamine-phalloidin stain for F-actin). White arrows indicate direction of 
the flow vector (A/B iii). Yellow arrows indicate cortical actin (B iii). DAPI stained 
nuclei (blue) are clearly visible (Bi-iv). Images are representative. 
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Fig. 4.4: Effect of Rac1 blockade on laminar shear-induced regulation of BBMvEC 
permeability. Confluent BBMvEC cultures were either maintained under static 
conditions or exposed to laminar shear stress (10 dynes cm-2, 24 h) in the absence and 
presence of NSC23766 and T17N monitored for transendothelial permeability. 
Histogram data points show change in permeability (% TEE FD40 at t=120 min) (A/B 
i). Histogram is averaged from three independent experiments ±SEM; *P≤0.05 vs 
uninhibited static, ɸP≤0.05 vs uninhibited shear. Overexpression of Rac1 in tandem 
with GAPDH (as loading control) was assessed by IB (B ii). Blots are representative.   
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4.2.5: Laminar shear stress-induced localization of ZO-1 requires Rac1 activation. 
Consistent with an intact endothelial barrier, ZO-1 immunoreactivity in response to 
laminar shear stress (10 dynes cm-2, 24 h) displays a continuous, well-defined 
localization pattern along cell-cell borders (section 3.2.5). Two methods of Rac1 
inhibition (NSC23766 and T17N) were incorporated to assess their potential 
involvement in this shear-dependent process. Both molecular and pharmacological 
inhibition strategies abrogated shear-induced ZO-1 alignment at cell-cell junctions (Fig. 
4.5 i-vi). Baseline effects of both NSC23766 and T17N (i.e. relative to untreated static 
BBMvEC’s) were not apparent.  
4.2.6: Laminar shear stress-induced tyrosine dephosphorylation of occludin is Rac1 
dependent. 
Having already established that prolonged shear exposure (10 dynes cm-2, 24 h) induces 
a significant reduction in occludin phosphotyrosine (pTyr-occludin) levels (section 
3.2.6), we next investigated the potential involvement of Rac1 in this process. In this 
regard, laminar shear induced a substantial reduction in pTyr-occludin levels, which 
could be substantially attenuated (65.1%) by pretreatment of BBMvEC’s with 
NSC23766 (following correction for the baseline decrease with NSC23766 under static 
conditions) (Fig. 4.6 A i-ii).     
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Fig. 4.5: Effect of Rac1 blockade on laminar shear-induced localization of ZO-1. 
Following transfection with (or without) T17N or pre-treatment with (or without) 
NSC23766, BBMvEC’s at confluency were either maintained under static conditions or 
exposed to laminar shear stress (10 dyne cm-2, 24 h) and monitored for ZO-1 
localization by fluorescent microscopy. Red arrows denote sharp, continuous 
localization of ZO-1 to cell-cell borders (iv). White arrow indicates direction of the flow 
vector (iv). DAPI stained nuclei (blue) are clearly visible (i-vi). Images are 
representative. 
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Fig. 4.6: Effect of Rac1 inhibition on laminar shear stress-induced occludin 
tyrosine dephosphorylation. Confluent BBMvEC cultures were either maintained 
under static conditions or exposed to laminar shear stress (10 dyne cm-2, 24 h) in the 
absence and presence of NSC23766 and monitored for pTyr-occludin and total occludin 
levels. Histogram (A i) represents relative pTyr-occludin (i.e. pTyr-occludin/total 
occludin derived by scanning densitometry from blots in A ii). Results are averaged 
from three independent experiments ±SEM; *P ≤0.05 vs unihibited static. ϕP≤0.05 vs. 
uninhibited shear. Blots are representative.    
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4.2.7: Laminar shear stress regulates BBMvEC RhoA-GTP activity.  
BBMvEC’s were subjected to laminar shear stress (10 dyne cm-2) and monitored for 
acute (0-60 min) and chronic (24 h) effects on RhoA-GTP levels. Shear onset (within 1 
min), triggered a 1.32±0.02 fold increase in RhoA-GTP followed by a return to baseline 
(static) levels at 60 min shear. Levels of RhoA-GTP following chronic shear were 
significantly reduced to 0.57±0.05 fold below baseline values. Thrombin was included 
as a positive control on RhoA activation (Fig. 4.7).   
      
Fig. 4.7: Effect of laminar shear stress on RhoA activation.  BBMvEC’s were 
cultured as described in section 2.6.1 and exposed to laminar shear stress (10 dynes cm2) 
following which they were harvested at varying time points (0-60 min and 24 h) and 
monitored by RhoA-GLISA®. Thrombin (1 U/ml, 10 min treatment) was included as a 
positive control for RhoA activation. Results are averaged from two independent 
experiments ±SEM; *P≤0.05 vs. 0 min.      
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4.2.8:  Rho-associated kinase (ROCK) inhibition attenuates shear-induced 
BBMvEC morphological realignment and diminishes actin stress fiber formation. 
The effect of ROCK inhibition (downstream effector of RhoA) on the shear-induced 
realignment of BBMvEC’s was investigated. Pretreatment with Y-27632 
(pharmacological inhibitor of ROCK) abolished the characteristic realignment of 
BBMvEC’s to laminar flow with no noticeable baseline effects on static cells (Fig. 4.8 A 
i-iv). ROCK inhibition severely diminished cytoskeletal F-actin stress fiber formation, 
but retained cortical actin at cell peripheries in both static and sheared BBMvEC’s (Fig. 
4.8 B i-iv).  
 
4.2.9: Laminar shear-induced upregulation of BBMvEC permeability involves 
ROCK activity. 
BBMvEC’s were monitored for transendothelial permeability to assess the potential 
involvement of ROCK in the shear-dependent (10 dynes cm-2, 24 h) enhancement of 
barrier function. At t =120 min, static BBMvEC’s treated with Y-27632 had 
significantly reduced permeability (%TEE FD40) compared to untreated static 
BBMvEC’s. The shear-induced reduction in permeability yielded similar findings in 
BBMvEC’s sheared in the presence of Y-27632, however restoration of the baseline 
effect of Y-27632 in static BBMvEC’s reveals that the shear-induced reduction in 
permeability is attenuated by 74.1% in the presence of Y-27632 (Fig. 4.9).      
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Fig. 4.8: Effect ROCK inhibition on shear-induced BBMvEC morphological and F-
actin realignment. Following exposure to laminar shear (10 dynes cm-2, 24 h) in the 
absence and presence of 10 µM Y-27632 (ROCK inhibitor), BBMvEC realignment was 
monitored by: (A) phase-contrast microscopy and (B) fluorescent microscopy 
(rhodamine-phalloidin stain for F-actin). White arrows indicate direction of the flow 
vector (A/B iii). Yellow arrows indicate cortical actin (B ii-iv). DAPI stained nuclei 
(blue) are clearly visible (B i-iv). Images are representative. 
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Fig. 4.9: Effect of ROCK inhibition on shear-induced regulation of BBMvEC 
permeability. Confluent BBMvEC cultures were either maintained under static 
conditions or exposed to laminar shear stress (10 dyne cm-2, 24 h) in the absence and 
presence of 10 µM Y-27632 and monitored for transendothelial permeability. Histogram 
data points show change in permeability (% TEE FD40 at t=120 min). Histogram is 
averaged from three independent experiments ±SEM; *P≤0.05 vs uninhibited static.   
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4.2.10: Shear-induced localization of ZO-1 does not involve ROCK activity. 
Following BBMvEC exposure to laminar shear stress (10 dynes cm-2, 24 h) in the 
absence and presence of Y-27632, subcellular localization of ZO-1 was monitored. 
Findings show that static BBMvEC’s cultured in the presence of Y-27632 (ii) displayed 
enhanced ZO-1 immunoreactivity at the cell-cell border compared to untreated static 
controls (i). Shear-induced cell-cell localization of ZO-1 (iii) did not appear to be 
affected by pre-treatment with Y-27632 (iv) (Fig. 4.10 i-iv).     
 
Fig 4.10: Effect of ROCK inhibition on shear-induced regulation of ZO-1 
localization. Confluent BBMvEC cultures were either maintained under static 
conditions or exposed to laminar shear stress (10 dynes cm-2, 24 h) in the absence and 
presence of 10 µM Y-27632 and monitored for ZO-1 localization by fluorescent 
microscopy. Red arrows denote sharp, continuous localization of ZO-1 to cell-cell 
borders (ii-iv). White arrow indicates direction of the flow vector (iii). DAPI stained 
nuclei (blue) are clearly visible (i-iv). Images are representative.  
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4.3 Discussion 
Transport across the BBB occurs via two distinct pathways; directly through the cell 
(transcellular) or between adjacent cells linked by intercellular junction complexes 
(paracellular). The latter mechanism is of specific interest to this report. It is commonly 
accepted that paracellular permeability is regulated by a finely tuned balance between 
pro-adhesive forces generated by intercellular junction complexes on the one hand, and 
pro-contractile forces generated by the actin cytoskeleton on the other. Moreover, shear 
stress is well known to alter both the organization of the actin cytoskeleton and 
intercellular junctions (Birukov et al., 2002, Mehta and Malik, 2006). Given the fact that 
a wealth of knowledge implicates the RhoGTPases RhoA and Rac1 in actin-cytoskeletal 
dynamics, we sought to investigate their potential role in the shear-dependent regulation 
of tight junction assembly and barrier function within the BBB context. 
Our first objective was to monitor the shear-induced activation of RhoGTPases in 
BBMvEC’s following acute and chronic shear exposure. Previous authors have 
addressed the acute effects of shear on RhoGTPase activity in EC’s of macrovascular 
origin, however data from the microvasculature is scarce (Tzima, 2006). Our results 
show that shear onset triggers a rapid (1 min) activation of RhoA, concomitant with a 
significant reduction of Rac1 activation below basal levels. By 60 mins however, an 
inverse shift in this trend indicated significantly elevated Rac1 activity while RhoA 
activation returned to baseline levels. This reciprocating trend in RhoGTPase activation 
suggests that the initial activation of RhoA following shear onset triggers a transient 
phase of cell contraction followed by Rac-1 mediated lamellipodia formation and 
extension in the direction of the flow. This two-stage mechanism has previously been 
suggested to be important for cellular reorientation in response to flow onset (Wojciak-
Stothard and Ridley, 2003).  
Most work to-date on shear-induced RhoGTPase activity has monitored acute responses 
(< 2 h shear), during which Rac1 activity returns to basal levels (Tzima et al., 2002, 
Wojciak-Stothard and Ridley, 2003). However, a recent report by Liu et al. showed that 
pulmonary artery EC’s exposed to more prolonged hemodynamic stimuli (6 h cyclic 
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strain) retained significantly elevated levels of Rac1-GTP relative to static cells (Liu et 
al., 2007). Consistent with this, we observed Rac1GTP levels were significantly 
elevated 24 h post-shear, while RhoA-GTP was significantly below basal levels after 
similar shear duration. In the case of Rac1-GTP, it would be reasonable to speculate that 
shear-dependent regulation of Rac1 activation undergoes a biphasic response, whereby 
Rac1-GTP peaks and returns to baseline during the acute shear phase, followed by a 
later increase in Rac1-GTP during the chronic shear phase. This would be consistent 
with the notion of RhoGTPases functioning as molecular switches capable of sensing 
and activating in response to cell shape and morphology (Takai et al., 2001, Etienne-
Manneville and Hall, 2002). Furthermore, as described in section 3.2.3, full BBMvEC 
realignment was only observed between 12 and 24 h, implying that dynamic cellular 
remodeling events are still evident in the chronic phase. The observation that RhoA-
GTP levels were substantially below basal levels at 24 h (in conjunction with elevated 
Rac1) emphasizes the decreased state of cell contractility at this point that would favour 
intercellular junctional assembly, and thus stabilize barrier integrity (Wojciak-Stothard 
and Ridley, 2002). 
In order to dissect the putative role of RhoGTPase signaling in our BBB model, 
selective RhoGTPase inhibition strategies were employed in shearing experiments 
following which cells were monitored for various indices of barrier integrity. 
Pharmacological inhibitors NSC23766 and Y-27632 have been extensively cited 
throughout the scientific literature for their respective blockade capabilities of the Rac1 
and RhoA-ROCK signaling pathways (Gao et al., 2004, Sun et al., 2006, Yamamoto et 
al., 2008). Moreover, we achieved very good transfection efficiency (>50%) with T17N, 
a Rac1 dominant negative mutant (Jou et al., 1998).  
Using these inhibitory approaches, we sought to investigate the involvement of 
RhoGTPases in the shear-dependent barrier improvements observed. In this regard, 
Rac1 has been previously implicated in shear-mediated cytoskeletal realignment (Tzima 
et al., 2002, Tzima et al., 2001). Consistent with this, pre-treatment of BBMvEC’s with 
NSC23766 prevented the shear-induced cellular morphology realignment. The 
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corresponding shear-induced realignment of F-actin stress fibers was also disorientated 
with Rac1 inhibition, concurrent with a complete loss of cortical actin accumulation at 
cell-cell borders. The enhancement of cortical accumulation has been frequently 
associated with improvements in barrier function (Waschke et al., 2006, Dudek et al., 
2004, Jacobson et al., 2006) We extended these inhibition strategies to our model of 
transendothelial permeability, to determine functional consequences of Rac1 inhibition 
on shear-dependent enhancement of barrier function. Initial experiments with 
NSC23766 revealed a significant attenuation of the shear-induced reduction in 
permeability. To undoubtedly confirm Rac1 participation in this effect, we repeated 
these experiments using a Rac1 T17N dominant negative mutant, which yielded a 
relatively similar inhibitory effect. This mutant contains a threonine (T) to asparagine 
(N) substitution at amino acid 17 within the Rac core effector domain, which cannot 
bind downstream effectors and also competes with endogenous Rac1 for guanine 
exchange factor (GEF) binding (Feig, 1999).  
We extended our investigations with Rac1 to assess potential involvement in the shear-
induced regulation of tight junction assembly. Previous reports have shown that 
constitutively active or dominant negative mutants of both Rac1 and RhoA can 
adversely affect junctional localization of occludin and ZO-1(Wojciak-Stothard et al., 
2001). By blocking shear-dependent Rac1 activation with NSC23766 and T17N, we 
observed a reduced ZO-1 immunoreactivity at cell-cell borders, thus adding further 
weight to a role for Rac1 in shear-induced enhancement of barrier function.  
We next revisited our earlier finding that prolonged shear exposure reduces pTyr-
occludin levels and we found that pre-treatment with NSC23766 significantly attenuated 
this shear-dependent response. Recent work by Peng et al. showed VEGF-induced 
hyperpermeability in glomerular EC’s was acting through a Rac1-pTyr-occludin 
mechanism (Peng et al., 2009), while Benson and Burridge using a similar mechanism 
of VEGF stimulation in pulmonary EC’s uncovered a Rac1-ROS (reactive oxygen 
species)-pTyr-VE-Cadherin-dependent pathway of barrier disruption (Monaghan-
Benson and Burridge, 2009). Consistent with our results was the observation that 
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elevated pTyr-occludin correlates with weaker endothelial barrier, however Peng et al. 
showed that Rac1 elevates pTyr-occludin, whereas shear-induced activation of Rac1 in 
our model reduces pTyr-occludin. These somewhat contradictory findings are most 
likely attributable to the specificity of the upstream stimulus, i.e. ligand-dependent 
activation of VEGFR2 via VEGF has been shown to induce a divergent intracellular 
signaling cascade compared to shear-induced (ligand-independent) activation of 
VEGFR2 (Shay-Salit et al., 2002). This effect could determine Rho guanine nucleotide 
exchange factor (RhoGEF) recruitment and also the specificity of the downstream 
effectors of Rac1. Collectively, these findings implicate Rac1 activation in the shear-
dependent upregulation of BBMvEC barrier function and tight junction assembly at 
multiple levels. 
It is a well-accepted notion that RhoA and Rac1 have antagonizing effects with respect 
to barrier function, where Rac1 promotes barrier stabilization and RhoA destabilizes 
barrier integrity (Wojciak-Stothard and Ridley, 2002, Wojciak-Stothard et al., 2001, 
Jacobson et al., 2006). Having clarified a definitive shear-dependent role for Rac1, we 
sought to investigate a potential reciprocal role for RhoA in our BBMvEC model. Under 
static conditions, pretreatment with Y-27632 had no observable effect on BBMvEC 
morphology, however it significantly diminished actin stress fiber formation, with 
BBMvEC’s retaining a dense band of cortical actin at cell-cell junctions. In a further 
series of experiments, ROCK inhibition significantly reduced permeability under basal 
conditions, and displayed an enhanced junctional immunoreactivity of ZO-1 to cell-cell 
border. Under shearing conditions, pretreatment with Y-27632 prevented shear-induced 
cellular morphology realignment, which is consistent with previous findings using a 
dominant negative mutant of RhoA (Tzima et al., 2001). Moreover, the data implicates 
that ROCK inhibition attenuates the shear-induced regulation of BBMvEC permeability, 
following correction of the baseline effect with Y-27632 under static conditions. 
BBMvEC’s sheared in the presence of Y-27632 also displayed decreased stress fiber 
formation, but retained a band of cortical actin and ZO-1 immunolocalization at the cell-
cell junction similar to static conditions,          
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We can interpret these results on a number of levels. Firstly, our initial finding that 
ROCK inhibition blocked the shear-induced morphology realignment led us to 
hypothesize that the initial increase of Rho-GTP in the acute shear-onset phase is a 
significant factor necessary for BBMvEC morphological realignment in the chronic 
shear phase. It would appear that this initial phase of cell contraction ‘primes’ the EC for 
a cascade of signaling events associated with morphology realignment under sustained 
shear conditions (Wojciak-Stothard and Ridley, 2003). The finding that Y-27632 
severely diminished actin stress fiber assembly under both static and shearing conditions 
supports the concept of weakening cell contraction. Moreover, the observation of 
enhanced cortical actin accumulation under these conditions would provide a favourable 
environment for stabilizing intercellular adhesion (Sun et al., 2006). Interestingly, 
previous reports have shown that ROCK inhibition can stimulate Rac1 activation, which 
could potentially explain the observed enhancement of cortical actin under such 
conditions (Desai et al., 2004, Tsuji et al., 2002, Wang and Dudek, 2009). 
Our observation that Y-27632 treatment reduces BBMvEC permeability under static 
conditions, yet attenuates the shear-induced reduction in permeability may initially seem 
ambiguous. It would appear that under static conditions, basal levels of RhoA-GTP are 
sufficient to contribute to barrier disassembly, such that inhibition of RhoA signaling 
with Y-27632 disrupts this mechanism, possibly via enhanced cortical actin 
accumulation. A large amount of experimental evidence exists to show that Y-27632 
exerts barrier-stabilizing effects when EC’s are challenged with hyperpermeability 
mediators that initiate their effects through modulation of RhoA-ROCK activity 
(Birukova et al., 2004, Sun et al., 2006, Miyazaki et al., 2010). With prolonged shear 
exposure we observed a significant drop in RhoA activity below basal values 
(concomitant with elevated Rac1 activity). We hypothesize that shearing in the presence 
of Y-27632 blocks the early contraction phase necessary for barrier establishment; 
hence the reversal of shear induced permeability but would also further 
reduce/completely diminish RhoA-ROCK signaling to non-physiological levels. 
Moreover, this effect could potentially elevate Rac1-GTP above physiological levels 
normally observed following prolonged shear. When interpreting findings on 
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RhoGTPase activity, it is important to recognize that these molecules are spatially and 
temporally regulated (as under shearing conditions), thus any inappropriate 
induction/changes of their GTPase activities would alter the homeostatic balance and 
thus compromise the functional response, i.e. barrier stability (Tzima, 2006, Connolly et 
al., 2002).  
Following pretreatment with Y-27632 we observed enhanced junctional localization of 
ZO-1 under static conditions, thus offering further explanation for the reduction in 
BBMvEC permeability under such conditions. Interestingly, ROCK inhibition did not 
disrupt the shear-induced junctional localization of ZO-1, a result seemingly at odds 
with the effect of Y-27632 on permeability under shear conditions. However, our 
observation that BBMvEC’s sheared in the presence of Y-27632 retained a dense band 
of cortical actin would suggest that this likely facilitated the retention of ZO-1 
localization to the cell periphery (Fanning et al., 2002, Van Itallie et al., 2009). Thus, Y-
27632 likely blocks shear-dependent permeability reduction in BBMvEC’s by a ZO-1 
independent mechanism. In this regard, recent findings by van Nieuw et al. showed that 
basal levels of ROCK activity were essential for barrier maintenance by regulating 
expression levels of VE-Cadherin, thus offering a possible alternative mechanism for 
barrier disassembly (van Nieuw Amerongen et al., 2007).  
To summarize, blockade of RhoA signaling via ROCK inhibition enhances junctional 
stability in BBMvEC’s under static conditions. However, from a shear context, RhoA 
activity appears crucial to the upregulation of BBMvEC barrier function during the early 
shear-onset phase/adaptation. An inverse shift in RhoGTPase activity towards Rac1 
predominates during the chronic shear phase, after necessary Rho-dependent cellular 
morphological adaptations have occurred. This response is more closely associated with 
the in-vivo condition of EC’s in undisturbed, laminar regions of the vasculature, thus 
placing a greater emphasis on Rac1 in shear-dependent maintenance of barrier function 
(Noria et al., 2004, Hahn and Schwartz, 2009).  
The signaling mechanisms connecting RhoGTPase activation to post-translational 
modification of junctional proteins is poorly understood. Given the fact that post-
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translational modifications of tight and adherens junction proteins (elevated tyrosine 
phosphorylation in particular) can have such a profound effect on endothelial 
permeability, it would be logical to imply a role for protein tyrosine phosphatases 
(PTP’s) and protein tyrosine kinases (PTK’s) as downstream effectors of RhoGTPase 
activity. Furthermore, our initial studies showing that shear-induced activation of Rac1 
regulates both ZO-1 localization and pTyr-occludin comply with a notion that Rac1 is 
targeting the tight junction, albeit through unknown mechanisms. Evidence from the 
literature on upstream regulators and/or downstream effectors (e.g. PTP’s) of Rac1 
within endothelium is currently lacking, however recent findings from epithelial cells 
suggest that the tight junction imbedded protein paracingulin (homologous to cingulin) 
can associate with and regulate RhoA and Rac1 GEF’s, GEF-H1 and Tiam1 respectively 
(Guillemot et al., 2008). The RhoA effector ROCK has already been implicated in direct 
association and modulation of tight junction components (Yamamoto et al., 2008). Thus, 
identification of targets modulating tight function assembly could not only be of genuine 
therapeutic benefit to pathologies exhibiting vascular leakiness, but also in the delivery 
of therapeutic compounds to the underlying interstitium via temporal manipulation of 
the tight junction ‘seal’ to facilitate paracellular delivery of the compound.     
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Chapter 5: 
The role of VE-Cadherin and Tiam1 in shear-
induced upregulation of BBMvEC tight junction 
assembly and barrier function. 
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5.1 Introduction 
Understanding the mechanosensory and intracellular signaling mechanism mediating the 
physiological/pathological consequences of hemodynamic force stimulation of the 
endothelium has been the subject of intense investigation over recent decades, with the 
intention of identifying key molecular targets in health and disease. Adding to the 
complexity of this matter are findings demonstrating that a host of apical, lateral and 
basolaterally situated EC mechanosensors in tandem with the actin cytoskeleton can all 
instigate profound shear-induced consequences on EC functions (Chen et al., 1999, Deli 
et al., 2005, Hahn and Schwartz, 2009). This would imply that no single 
mechanosensing mechanism exits, but possibly requires a synchronous activation of 
several mechanosensory systems, as evidenced by the signaling triad involving 
PECAM-1, VE-Cadherin and VEGFR2 (Tzima et al., 2005).       
Within our model of shear-induced enhancement of BBMvEC barrier function, our 
attention turned to VE-Cadherin as a possible mechanosensory adaptor protein 
participating in the shear-dependent induction of these events. The contribution of VE-
Cadherin in the adaptation of EC’s to flow is well established in compliance with its 
multifaceted role in other EC functions, including barrier maintenance and RhoGTPase 
regulation. Moreover, recent evidence has demonstrated that VE-Cadherin can regulate 
claudin-5 expression, by preventing nuclear accumulation of Fox01 and β-Catenin 
(repressors of claudin-5 expression), thereby alluding to a functional cross-talk 
mechanism between endothelial adherens and tight junction structures (Taddei et al., 
2008). Furthermore, VE-Cadherin is also known to regulate membrane association of 
the guanine nucleotide exchange factor (GEF) Tiam1, a known activator of Rac1 
(Lampugnani et al., 2002). Increasing evidence has suggested a putative role for Tiam1-
mediated activation of Rac1 in models of barrier enhancement (Birukova et al., 2007a, 
Birukova et al., 2008). However, to the best of our knowledge no group has examined 
the contribution of intercellular junctions (VE-Cadherin) to shear-mediated changes in 
RhoGTPase activity, particularly at the BBB.  
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In this chapter we examine the contribution of VE-Cadherin and Tiam1 to laminar 
shear-induced changes in Rac1 activity, with downstream consequences for tight 
junction assembly and barrier function. For these studies we used VE-Cad ∆EXD 
(extracellular domain deletion mutant) and Tiam1 C580 (mutant lacking PHn and 
DHR domains) plasmid constructs to inhibit VE-Cadherin and Tiam1 function. 
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5.2 Results 
5.2.1:  Illustration of VE-Cadherin WT and ∆EXD mutant and confirmation of 
∆EXD expression in BBMvEC’s. 
Fig. 5.1 A depicts the core domains of wild type (WT) VE-Cadherin compared to VE-
Cad ∆EXD lacking the extracellular cadherin repeats (1-5), which are essential for 
homophilic cell-cell adhesion. This ‘non-junctional’ mutant form of VE-Cadherin has 
the external repeats replaced by a FLAG® (octapeptide) tag. Following transfection of 
BBMvEC’s with and without (mock) VE-Cad ∆EXD, mutant over-expression was 
confirmed by immunocytochemistry (IC) using an anti-FLAG® antibody (Fig. 5.1 B ii). 
 
Fig. 5.1: Illustration and overexpression of VE-Cad ∆EXD in BBMvEC’s. (A): 
Illustration of VE-Cadherin wild type and ∆EXD mutant. SP, signal peptide; PP, pre-
peptide; CR, cadherin repeat; TM, transmembrane domain; CD, cytoplasmic domain; F, 
FLAG® epitope. (B): Following transfection of BBMvEC’s, VE-Cad ∆EXD expression 
was monitored by IC. Arrows in red indicate FLAG® epitope staining (ii). DAPI stained 
nuclei (blue) are clearly visible (i-ii). Images are representative.  
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5.2.2: Laminar shear stress-induced activation of Rac1 is VE-Cadherin-dependent. 
In section 4.2.2 we observed that acute exposure of laminar shear stress (10 dynes cm-2, 
60 min) induced a significant increase in Rac1-GTP. We therefore monitored the effects 
of VE-Cadherin inhibition on shear-dependent Rac1 activation following 60 min shear 
exposure. No detectable changes in Rac1 protein levels were observed following 
treatment (Fig 5.2 A i). However, sheared BBMvEC’s caused a 1.89±0.08 fold increase 
in Rac1-GTP, a response that was significantly attenuated by 73.03% in the presence of 
VE-Cad ∆EXD (following correction for the baseline increase with VE-Cad ∆EXD 
under static conditions) (Fig. 5.2 A ii). 
 
Fig. 5.2: Effect of VE-Cadherin inhibition on laminar shear induced-Rac1 
activation. Cultures of BBMvEC’s were either maintained under static conditions or 
exposed to laminar shear stress (10 dynes cm-2, 60 min) in the absence and presence of 
VE-Cad ∆EXD, following which they were harvested and monitored by: (A i) IB 
analysis for total Rac1 levels and (A ii) Rac1-GLISA® for Rac1-GTP. Results are 
averaged from three independent experiments ±SEM; *P≤0.05 vs. uninhibited static, 
ϕP≤0.05 vs. uninhibited shear. Blots are representative.  
156 
 
5.2.3: Laminar shear stress-induced upregulation of BBMvEC barrier function is 
VE-Cadherin-dependent. 
BBMvEC’s transfected in the absence (mock) or presence of VE-Cad ∆EXD were 
monitored for their effects on shear-dependent enhancement of barrier function. As 
expected, shear significantly reduced permeability (%TEE of FD40) compared to the 
static control. However, this shear-induced reduction in permeability was attenuated by 
79.8% in the presence of VE-Cad ∆EXD (following correction for the baseline increase 
with VE-Cad ∆EXD under static conditions) (Fig. 5.3).  
            
 
Fig. 5.3: Effect of VE-Cadherin inhibition on laminar shear-induced regulation of 
BBMvEC permeability. Confluent BBMvEC’s transfected with or without (mock) VE-
Cad ∆EXD were either maintained under static conditions or exposed to laminar shear 
stress (10 dynes cm-2, 24 h) and monitored for transendothelial permeability. Histogram 
data points show change in permeability (%TEE FD40 at t=120 min). Histogram is 
averaged from three independent experiments ±SEM; *P≤0.05 vs uninhibited static, 
ɸP≤0.05 vs uninhibited shear.  
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5.2.4: Laminar shear-induced localization of ZO-1 is VE-Cadherin dependent. 
Following BBMvEC exposure to laminar shear stress (10 dynes cm-2, 24 h) in the 
absence (mock) or presence of VE-Cad ∆EXD, subcellular localization of ZO-1 was 
monitored. Results indicate that the typical shear-induced re-localization of ZO-1 
immunoreactivity to the cell-cell borders was completely abrogated following 
transfection with VE-Cad ∆EXD, leaving a broken, discontinuous pattern of ZO-1 
staining at cell peripheries (Fig. 5.4 i-iv).  
 
 
Fig. 5.4: Effect of VE-Cadherin inhibition on laminar shear-induced ZO-1 
localization. Transfected BBMvEC’s with or without (mock) VE-Cad ∆EXD were 
grown to confluency and either maintained under static conditions or exposed to laminar 
shear stress (10 dyne cm-2, 24 h) and monitored for ZO-1 localization by fluorescent 
microscopy. Red arrows denote sharp, continuous localization of ZO-1 to cell-cell 
borders (iii). White arrow indicates direction of the flow vector (iii). DAPI stained 
nuclei (blue) are clearly visible (i-iv). Images are representative. 
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5.2.5: Laminar shear-induced localization of claudin-5 is VE-Cadherin dependent.  
Following BBMvEC exposure to laminar shear stress (10 dynes cm-2, 24 h) in the 
absence (mock) or presence of VE-Cad ∆EXD, subcellular localization of claudin-5 was 
monitored. Results indicate that the continuous and well-defined organization of 
claudin-5 immunoreactivity initially observed along the plasma membrane in response 
to laminar shear stress was completely ablated by treatment with VE-Cad ∆EXD, 
reverting to a jagged and somewhat diminished pattern of claudin-5 along the cell-cell 
border (Fig. 5.5 i-iv).     
 
 
Fig. 5.5: Effect of VE-Cadherin inhibition on laminar shear-induced claudin-5 
localization. Transfected BBMvEC’s with or without (mock) VE-Cad ∆EXD were 
grown to confluency and either maintained under static conditions or exposed to laminar 
shear stress (10 dyne cm-2, 24 h) and monitored for claudin-5 localization by fluorescent 
microscopy. Red arrows denote sharp, continuous localization of claudin-5 to cell-cell 
borders (iii). White arrow indicates direction of the flow vector (iii). DAPI stained 
nuclei (blue) are clearly visible (i-iv). Images are representative. 
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5.2.6: Laminar shear-induced tyrosine dephosphorylation of occludin is VE-
Cadherin-dependent. 
We extended our investigations of the shear-induced (10 dynes cm-2, 24 h) reduction in 
phosphotyrosine (pTyr)-occludin levels to assess potential involvement of VE-Cadherin. 
Following transfection in the absence and presence (mock) of VE-Cad ∆EXD, 
BBMvEC’s were harvested and monitored for changes in pTyr-occludin level by IP and 
IB. The shear-induced reduction in pTyr-occludin (to 0.08±0.01 fold of control) was 
attenuated by 89.13% in the presence of VE-Cad ∆EXD (following correction for the 
baseline decrease with VE-Cad ∆EXD under static conditions) (Fig. 5.6). 
 
Fig. 5.6: Effect of VE-Cadherin inhibition on laminar shear-induced occludin 
tyrosine dephosphorylation. Transfected BBMvEC’s with or without (mock) VE-Cad 
∆EXD were grown to confluency and either maintained under static conditions or 
exposed to laminar shear stress (10 dyne cm-2, 24 h) and monitored for pTyr-occludin 
and total occludin levels. Histogram (A i) represents relative pTyr-occludin (i.e. pTyr-
occludin/total occludin derived by scanning densitometry from blots in A ii). Results are 
averaged from three independent experiments ±SEM; *P ≤0.05 vs uninhibited static, 
ϕP≤0.05 vs. uninhibited shear. Blots are representative.    
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5.2.7: Illustration of Tima1 WT and C580 mutant and confirmation of C580 
expression in BBMvEC’s. 
Fig. 5.7 A depicts the core domains of the guanine nucleotide exchange factor Tiam1 
WT compared to Tiam1 C580 (lacking the PHn and DHR domains, which are 
responsible for membrane trafficking of Tiam1). Following transfection of BBMvEC’s 
with and without (mock) Tiam1 C580, overexpression of Tiam1 was confirmed by IC 
using an anti-Tiam1 C16 antibody specific to an epitope on the C-terminus of Tiam1 
(Fig. 5.7 B ii). 
 
 
Fig. 5.7: Illustration and overexpression of Tiam1 C580 in BBMvEC’s. (A) 
Illustration of Tiam1 WT and C580 mutant.  PHn, N-terminal pleckstrin homology 
domain; DHR, disc homology region; DH, Dbl-homology domain; PHc, C-terminal 
pleckstrin homology domain. (B) Following transfection of BBMvEC’s with and 
without (mock) Tiam1 C580, Tiam1 expression (green) was monitored by IC. DAPI 
stained nuclei (blue) are clearly visible (i-ii). Images are representative. 
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5.2.8: Laminar shear stress-induced activation of Rac1 is Tiam1-dependent 
We assessed the potential upstream signaling role of Tiam1 using Tiam1 C580. Initially, 
the effects of Tiam1 inhibition on shear-dependent Rac1 activation following 60 min 
shear was monitored. No detectable changes in Rac1 protein levels were observed 
following treatment (Fig 5.8 A i). However sheared BBMvEC’s caused a 1.69±0.11 fold 
increase in Rac1-GTP, a response that was significantly attenuated by 60.87% in the 
presence of Tiam1 C580 (following correction for the baseline decrease with Tiam1 
C580 under static conditions) (Fig. 5.8 A ii). 
 
 
Fig. 5.8: Effect of Tiam1 inhibition on laminar shear-induced Rac1 activation. 
Cultures of BBMvEC’s were either maintained under static conditions or exposed to 
laminar shear stress in the absence and presence of Tiam1 C580, following which they 
were harvested and monitored by: (A i) IB analysis for total Rac1 levels and (A ii) 
Rac1-GLISA® for Rac1-GTP. Results are averaged from three independent experiments 
±SEM; *P≤0.05 vs. uninhibited static, ϕP≤0.05 vs. uninhibited shear. Blots are 
representative.  
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5.2.9: Laminar shear stress-induced BBMvEC cellular realignment is Tiam1-
dependent.  
Following transfection in the absence (mock) or presence of Tiam1 C580, BBMvEC’s 
were left static or exposed to laminar shear stress (10 dynes cm-2, 24 h) and monitored 
for cellular realignment by phase-contrast microscopy. Inhibition of Tiam1 signaling 
severely abrogated the typical shear-induced realignment of BBMvEC’s (Fig. 5.9 i-iv). 
 
Fig. 5.9: Effect of Tiam1 inhibition on laminar shear-induced cellular realignment. 
BBMvEC’s transfected with or without (mock) Tiam1 C580 were either maintained 
under static conditions or exposed to laminar shear stress (10 dynes cm-2, 24 h) and 
monitored for cellular realignment by phase-contrast microscopy. White arrow indicates 
the direction of the flow vector (iii). Images are representative. 
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5.2.10: Laminar shear stress-induced upregulation of BBMvEC barrier function is 
Tiam1-dependent. 
BBMvEC’s transfected in the absence (mock) and presence of Tiam1 C580 were 
monitored for their effects on shear-dependent enhancement of barrier function. As 
expected, shear significantly reduced permeability (%TEE of FD40) compared to the 
static control. However, this shear-induced reduction in permeability was attenuated by 
76.4% in the presence of Tiam1 C580 (following correction for the baseline decrease 
with Tiam1 C580 under static conditions) (Fig. 5.10).   
                         
Fig. 5.10: Effect of Tiam1 inhibition on laminar shear-induced regulation of 
BBMvEC permeability. Transfected BBMvEC’s with or without (mock) Tiam1 C580 
were either maintained under static conditions or exposed to laminar shear stress (10 
dynes cm-2, 24 h) and monitored for transendothelial permeability. Histogram data 
points show change in permeability (%TEE FD40 at t=120 min). Histogram is averaged 
from three independent experiments ±SEM; *P≤0.05 vs uninhibited static, ɸP≤0.05 vs 
uninhibited shear.  
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5.2.11: Laminar shear-induced localization of ZO-1 is Tiam1 dependent. 
Following BBMvEC exposure to laminar shear stress (10 dynes cm-2, 24 h) in the 
absence (mock) or presence of Tiam1 C580, subcellular localization of ZO-1 was 
monitored. As previously described, undisturbed laminar flow induced a profound 
immunoreactivity of ZO-1 along the plasma membrane, which was completely disrupted 
with Tiam1 C580 treatment, exhibiting a more discontinuous, broken pattern of ZO-1 at 
cell-cell borders (Fig. 5.11 i-iv).   
 
Fig. 5.11: Effect of Tiam1 inhibition on laminar shear-induced ZO-1 localization. 
Transfected BBMvEC’s with or without (mock) Tiam1 C580 were grown to confluency 
and either maintained under static conditions or exposed to laminar shear stress (10 dyne 
cm-2, 24 h) to be monitored for ZO-1 localization by fluorescent microscopy. Red 
arrows denote sharp, continuous localization of ZO-1 to cell-cell borders (iii). White 
arrow indicates direction of the flow vector (iii). DAPI stained nuclei (blue) are clearly 
visible (i-iv). Images are representative. 
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5.2.12: Laminar shear-induced tyrosine dephosphorylation of occludin is Tiam1-
dependent. 
Following transfection in the absence (mock) or presence of Tiam1 C580, BBMvEC’s 
were harvested and monitored for changes in pTyr-occludin level by IP and IB. The 
shear-induced reduction in pTyr-occludin (to 0.09±0.06 fold of control) was 
significantly attenuated by 37.36% in the presence of Tiam1 C580 (following correction 
for the baseline increase with Tiam1 C580 under static conditions) (Fig. 5.12 A i-ii).  
 
 
Fig. 5.12: Effect of Tiam1 C580 inhibition on laminar shear-induced occludin 
tyrosine dephosphorylation. Transfected BBMvEC’s with or without (mock) Tiam1 
C580 were grown to confluency and either maintained under static conditions or 
exposed to laminar shear stress (10 dyne cm-2, 24 h) and monitored for pTyr-occludin 
and total occludin levels. Histogram (A i) represents relative pTyr-occludin (i.e. pTyr-
occludin/total occludin derived by scanning densitometry from blots in A ii). Results are 
averaged from three independent experiments ±SEM; *P≤0.05 vs uninhibited static, 
ϕP≤0.05 vs. uninhibited shear. Blots are representative.    
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5.3 Discussion 
In-vitro models of blood flow have yielded a comprehensive insight into potential in-
vivo mechanostransduction processes that might mediate responses to flow-associated 
shear stress and uncover mechanisms that contribute to disease progression. Chapters 3 
and 4 clearly demonstrate the role of laminar shear stress in the assembly of tight 
junction proteins, consistent with an enhancement of BBMvEC barrier function. 
Furthermore, putative intracellular signaling roles for the GTPase Rac1 (and to an 
extent, RhoA) in the shear-induced regulation of BBMvEC barrier function was 
clarified. We now extend these findings to examine potential upstream regulators of 
shear-induced Rac1 activity and BBMvEC barrier function, specifically monitoring the 
mechanosensory adaptor protein, VE-Cadherin and the Rho GEF, Tiam1.   
In order to block VE-Cadherin function, BBMvEC’s were transfected with a VE-Cad 
∆EXD plasmid construct (mutant form of VE-Cadherin lacking extracellular cadherin 
repeat domains 1-5). Thus, whilst VE-Cad ∆EXD can localize to adherens junctions and 
associate as normal with cytoplasmic binding partners, homotypic intercellular adhesion 
with wild type VE-Cadherin is completely disrupted (Kouklis et al., 2003, Orrington-
Myers et al., 2006). Furthermore it has been shown that over-expressing VE-Cadherin 
cytoplasmic domains (lacking EC repeat domains) titrates β-Catenin from its 
downstream effectors and suppresses the endogenous expression of VE-Cadherin 
(Venkiteswaran et al., 2002). Following transfection of BBMvEC’s with VE-Cad 
∆EXD, the shear-induced activation of Rac1 following 60 min shear exposure was 
significantly attenuated suggesting a plausible role for VE-Cadherin mechano-signaling 
in our model. Consistent with our findings, a recent report by Liu et al. showed that VE-
Cadherin engagement (i.e. homotypic binding of adjacent EC domains) was necessary 
for cyclic strain-induced activation of Rac1, by using blocking antibodies specific to EC 
domains of VE-Cadherin. The authors proposed a model whereby a primary junctional 
structure (PECAM-1?) transduces the hemodynamic stimuli, which alters the 
engagement of cadherins and in turn leads to Rac1 signaling, i.e. outside-in signaling 
(Liu et al., 2007). Also, as discussed in section 1.5.1, VE-Cadherin is organised through 
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cis dimerization/trimerization of EC domains, a mechanism that would potentially be 
disrupted through VE-Cad ∆EXD expression.  
Downstream of VE-Cadherin mechano-signaling, we sought to investigate the potential 
role of Tiam1 in shear-induced activation of Rac1 in BBMvEC’s. It has been previously 
demonstrated that VE-cadherin engagement can activate Rac1 via recruitment of Tiam1 
(Lampugnani et al., 2002). In order to block Tiam1 function, BBMvEC’s were 
transfected with a Tiam1 C580 plasmid construct (mutant form lacking PHn; pleckstrin 
homology N-terminus domain and DHR; discs-large homology region). Although 
endogenous Tiam1 contains two PH domains (PHn and PHc), the PHn domain has been 
specifically shown to be critical for the membrane localization of Tiam1 and 
downstream signaling through Rac1 (Hordijk et al., 1997). In our model, shear-induced 
Rac1 activation was significantly attenuated following Tiam1 C580 expression 
suggesting a definitive role for Tiam1 in this process. Furthermore, Tiam1 inhibition 
disrupted the shear-induced realignment of BBMvEC’s, consistent with findings 
observed with the Rac1 inhibitor NSC23766 in section 4.2.3, confirming Tiam1 as a 
critical GEF regulating shear-mediated activation of Rac1. The molecular linkage of 
VE-Cadherin to Tiam1 activation is unknown, however an attractive linkage is proposed 
herein. Shear-induced activation of the ‘PECAM-1/VE-Cadherin/VEGFR2’ 
mechanosensory complex is known to regulate PI3K activity, which can lead to the 
production of the membrane-associated lipid product, phosphatidylinositol 3,4,5-
triphosphate (PIP3). PIP3 has been shown to bind to at least 3 GEFs (Tiam1, Vav and 
Sos) through associations with their PH domains, which would relieve their inhibitory 
effect and elicit the conformational changes necessary to activate the GEF, thus 
signaling to their respective GTPases (Kjoller and Hall, 1999, Tzima et al., 2005). This 
mechanism would however appear somewhat controversial as it ‘bypasses’ integrin-
mediated mechanosensing processes, which have also been implicated in shear-induced 
activation of Rac1 (discussed further in chapter 6) (Tzima et al., 2002).  
The specificity of the upstream signal activating a particular RhoGTPase is essential for 
specific downstream effector activation and functional response. Thus, having 
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confirmed that both VE-Cadherin and Tiam1 were acting upstream of shear-induced 
Rac1 signaling, we employed similar inhibition strategies to monitor for potential effects 
on downstream indices of barrier function. Both VE-Cadherin and Tiam1 inhibition 
significantly attenuated the shear-induced enhancement of barrier function (79.8% and 
76.4% respectively) as measured by transendothelial permeability assay, alluding to a 
coupled signaling relationship between the two molecules. Previous in-vitro and in-vitro 
findings have shown that VE-Cad ∆EXD expression induces junctional disassembly 
(Orrington-Myers et al., 2006, Broman et al., 2006). Interestingly though, expression of 
VE-Cad ∆EXD in BBMvEC’s didn’t provoke a statistically significant increase in 
permeability relative to static, mock-transfected BBMvEC’s, but was pivotal to shear-
induced responses. One possible explanation is that under static conditions tight 
junctions are able to compensate for the reduction in VE-Cadherin homotypic adhesion 
experienced with VE-Cad ∆EXD. Furthermore, the observed modifications 
(localization, phosphorylation) in tight junction proteins following prolonged, 
physiological levels of shear appear to explain the concomitant reduction in 
permeability, thus placing tight junctions at the hub of paracellular permeability 
regulation at the BBB. This is consistent with the well-accepted view that tight junction 
proteins at the BBB are of the highest complexity and best equipped to limit paracellular 
flux compared to endothelial tight junctions of non-BBB origin (Kniesel and Wolburg, 
2000, Wolburg and Lippoldt, 2002).     
To this end, we extended our inhibition studies with VE-Cad ∆EXD and Tiam1 C580 to 
examine biochemical changes in tight junction proteins with respect to ZO-1 and/or 
claudin-5 localization. Both inhibition strategies clearly abrogated the shear-induced 
immunoreactivity of ZO-1 at cell-cell borders. ZO-1 is an essential adaptor protein that 
facilitates correct spatial organization of tight junction proteins and associations with 
cortical actin, and is thus crucial to stability of the endothelial barrier (Umeda et al., 
2006, Fanning and Anderson, 2009). The loss of shear-induced ZO-1 localization at the 
cell membrane would offer in part, an explanation for the observed increase in 
BBMvEC permeability under conditions of VE-Cadherin and Tiam1 inhibition. The 
specific finding that VE-Cadherin could influence shear-induced ZO-1 organization 
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adds further weight to the recently established concept of a functional “cross-talk” 
mechanism between adherens and tight junction complexes. Taddei et al. identified this 
concept by showing that VE-Cadherin inhibition represses claudin-5 expression, which 
paralleled with increases in permeability, thereby offering a novel mechanism of barrier 
disruption via VE-Cadherin ablation (Taddei et al., 2008). With this in mind, we 
examined the effect of shear-induced claudin-5 subcellular localization following VE-
Cad ∆EXD expression. Similar to ZO-1, the shear-mediated cell-cell border 
immunoreactivity of claudin-5 was completely disrupted with VE-Cad ∆EXD, thus 
confirming that shear stress promotes a junctional cross-talk within BBMvEC’s. 
Although quantification of claudin-5 expression was not assessed with VE-Cad ∆EXD 
treatment, the immunocytochemical staining pattern appeared to reveal a diminished 
expression of claudin-5, in tandem with a discontinuity along the plasma membrane.             
Finally, we observed that both VE-Cadherin and Tiam1 inhibition significantly 
attenuated the shear-induced reduction in pTyr-occludin by 89.13% and 37.36% 
respectively. This finding with VE-Cad ∆EXD on pTyr-occludin confirmed that shear-
induced regulation of VE-Cadherin was able to target all three tight junction 
components (occludin, claudin-5 and ZO-1), placing the mechanosensory adaptor 
molecule as a core mediator of shear-induced regulation of BBMvEC barrier function, 
possibly through a Tiam1-Rac1 signaling axis. Interestingly, the shear-induced 
attenuation of pTyr-occludin with Tiam1 inhibition only represented 57.38% of the 
shear-induced attenuation of pTyr-occludin observed with NSC23766 (Rac1 inhibition). 
Consistent with this was the finding that Tiam1 inhibition attenuated the shear-induced 
activation of Rac1 by 60.87%. Not owing to possible discrepancies in transfection 
efficiency, this observation could suggest the involvement of integrins or even the 
possibility of other GEF’(s) in shear-mediated Rac1 activation and barrier function. In 
this regard, the RhoGEF Vav2 has been shown to promote Rac1 activity consistent with 
an enhancement of barrier integrity (Birukova et al., 2007b, Birukova et al., 2008). 
Future work using a molecular knockout of Vav2 would help clarify this issue. 
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In concluding, our findings build substantially on the earlier work of Colgan et al. and  
establish a series of shear-induced changes in tight junction proteins that are consistent 
with an upregulated BBMvEC barrier phenotype (Colgan et al., 2007). This includes 
shear-induced enhancement of occludin and ZO-1 expression levels (mRNA and 
protein); enhanced localization of occludin, ZO-1 and claudin-5 to the cell-cell border; 
reduction in pTyr-occludin and increased occludin-ZO-1 association. Our recent 
findings have shed some light on possible mechanosensing (VE-Cadherin) and 
intracellular signaling mechanisms (Tiam1, Rac1) putatively mediating these effects. 
Future work will attempt to expand on the molecular link between VE-Cadherin and 
GEF and/or integrin-mediated activation of Rac1. Furthermore, the events downstream 
of Rac1-mediated regulation of tight junction proteins will need to be assessed, with a 
specific emphasis on the tyrosine kinase and phosphatase mechanisms involved in tight 
junction protein modification.   
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Chapter 6: 
Final Summary 
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6.1 Final Summary 
Physiological maintenance of cerebral homeostasis and thus neuronal/glial function is 
governed by the blood brain barrier (BBB). This highly stringent barrier is formed by 
cerebral microvascular endothelial cells (EC’s), which shield the brain from blood-borne 
toxins, supplies the brain with essential nutrients and filters harmful compounds from 
the brain back into the bloodstream. Crucial to regulation of these processes are the 
transcellular and paracellular pathways. The former contains multiple transport systems 
and enzymatic barriers to control molecular traffic through the cell.  The latter describes 
a continuum of intercellular tight and adherens junction complexes between adjacent 
cerebral microvascular endothelial cells (EC’s), generating a relatively impermeable 
barrier to the flow of ions, proteins, hydrophilic molecules and hormones between EC’s, 
thereby protecting the brain from harmful fluctuations in these molecules. Together, 
both pathways establish a highly restrictive barrier phenotype, and as a consequence 
make the BBB the rate limiting step in the delivery of therapeutic agents to the CNS 
(Pardridge, 2007). Conversely, BBB disruption has been associated with the 
pathophysiology of various neurological disorders, including HIV-encephalitis, 
ischemia, tumors, Parkinson’s disease, multiple sclerosis and Alzheimer’s disease 
(Persidsky et al., 2006). 
Of particular interest to the present thesis is the paracellular pathway. It is a well-
accepted concept that tight junctions are the primary structures responsible for the 
paracellular barrier properties present at the BBB (Wolburg and Lippoldt, 2002, 
Vorbrodt and Dobrogowska, 2003, Engelhardt, 2003). Much effort in recent decades has 
been made to indentify the molecular composition of the tight junction complex, the 
interaction with adaptor/peripheral proteins and their regulation by adhesion molecules, 
extracellular matrix components and signal transduction pathways. Understanding the 
mechanisms by which intercellular junction complexes (tight junctions) are regulated in 
physiology and/or pathology will be essential to the development of 
pharmacotherapeutic strategies modulating BBB function. Unfortunately, most of the 
findings to date have been gathered in epithelial cells or endothelial cells of non-
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neuronal origin thus making accurate inferences about tight junction permeability 
regulation at the BBB more difficult. The probable reasons for this are direct 
investigation of BBB in-vivo is hindered because of anatomical and topographic 
obstacles, and furthermore it is challenging for in-vitro models to encompass all 
essential surrounding influences such as astrocytes, pericytes, neurons, extracellular 
matrix and flow-associated shear-stress. Indeed, the latter component, laminar shear 
stress is widely considered to be a principal differentiative stimulus influencing 
endothelial phenotype at multiple levels, with profound consequences for blood vessel 
integrity and remodeling (Krizanac-Bengez et al., 2004, del Zoppo, 2008, Hahn and 
Schwartz, 2009). 
With this in mind, the aim of this study was to examine the effects of shear stress (acute 
vs. chronic) on endothelial tight junction assembly at both the molecular and functional 
level in an in-vitro BBMvEC model. We hypothesised that physiological shear stress 
would induce BBMvEC barrier phenotypes as assessed by various responses, including 
changes in BBMvEC cellular and F-actin morphology, biochemical changes in tight 
junction proteins (occludin, ZO-1 and claudin-5) and functional changes in permeability. 
Furthermore, we investigated the effects of flow reduction following an initial pre-
conditioning phase of high shear and monitored for changes in BBMvEC barrier 
phenotype.  
In an effort to delineate the signaling pathways mediating shear-dependent changes in 
BBMvEC barrier function, we employed a series of pharmacological and molecular 
inhibition strategies specifically targeting the RhoGTPases, RhoA and Rac1, the guanine 
nucleotide exchange factor (GEF) Tiam1, and the mechanosensory adaptor protein VE-
Cadherin. It was anticipated that the latter studies elucidating signal transduction 
pathways would identify potential molecular targets involved in tight junction regulation 
at the BBB, which would be invaluable in CNS disorders exhibiting a dysfunctional 
barrier. Figure 6.1 below schematically depicts the experimental approach used in this 
body of research.  
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Fig. 6.1: Schematic depiction of experimental approach. Bovine brain microvascular 
endothelial cells (BBMvEC’s) were subjected to different experimental paradigms; 
pathological shear conditions (blue) and physiological shear (red), and monitored for 
structural changes in morphology, functional alterations in permeability and biochemical 
changes in tight junction proteins. Various molecular and pharmacological inhibition 
strategies (green) were incorporated to assess potential involvement under physiological 
conditions.   
Hemodynamic forces are a functionally relevant stimulus, which have previously been 
described as critical regulators of BBB induction and regulation (Stanness et al., 1997, 
Siddharthan et al., 2007, Cucullo et al., 2008). Furthermore, recent findings from our 
laboratory have implicated hemodynamic forces as a putative stimulus regulating 
endothelial tight junction assembly and barrier function (Collins et al., 2006, Colgan et 
al., 2007). With this in mind, we sought to re-visit and expand on the basic findings of 
Colgan et al. using physiological and non-physiological paradigms of blood flow-
associated shear stress and examine the cellular signaling mechanism regulating 
BBMvEC function under shear. Our initial experiments revealed that non-physiological 
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levels of laminar shear stress (1 dyne cm-2 24 h) correlated with findings from unsheared 
BBMvEC’s with respect to cellular morphology and transendothelial permeability, thus 
strengthening the applicability of the static condition as a suitable control when 
comparing to physiological levels of shear (10 dynes cm-2). In a parallel series of 
experiments we temporally monitored shear-enhanced barrier function at 10 dynes/cm-2 
over a 24 h period. The most significant shear-induced reductions in permeability only 
became evident in the latter chronic stages (12-24 h), which paralleled with the pattern 
of cellular realignment in the direction of the flow. EC realignment to flow involves a 
complex process of actin-cytoskeletal remodeling that spans a rapid (within mins) to 
prolonged (up to 24 h) time course of events (Rizzo, 2007, Noria et al., 2004). Thus, 
although shear-onset initiates a rapid phase of cytoskeletal adaptations, it appears that 
the cellular elongation and realignment processes that accompany extended shear 
exposure necessitate/facilitate appropriate assembly of intercellular junction components 
that stabilize barrier integrity.  
To further extend our physiological flow paradigm, we monitored the effects of chronic 
shear on biochemical alterations in tight junction proteins. The tight junction-associated 
adaptor molecule ZO-1 plays a multifunctional role at the intercellular junction by 
facilitating protein-protein interactions, membrane trafficking of other tight junction 
proteins and bridging associations with the cortical based actin-cytoskeleton (Fanning 
and Anderson, 2009). The tight junction protein claudin-5 plays a more physical role in 
barrier maintenance through the ‘sealing’ properties of its extracellular domains within 
the intercellular cleft (Krause et al., 2008). We therefore hypothesized that membrane 
localization of ZO-1 and claudin-5 would be crucial to the structural assembly and/or 
associations of the tight junction complex. Within our BBMvEC model, we observed 
that chronic shear exposure induced significant enhancements of both ZO-1 and claudin-
5 immunoreactivity at cell-cell borders, which is consistent with the observed decrease 
in permeability at similar time points. Moreover, loss of these junctional structures has 
been frequently associated with various pathological conditions at the BBB, thereby 
strengthening the functional relevance of these molecules at the tight junction following 
shear exposure (Dallasta et al., 1999, Andras et al., 2003, Liu et al., 2008a, Chen et al., 
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2009). Furthermore, these events coincided with the shear-induced re-arrangement of 
the actin cytoskeleton, as F-actin staining revealed an enhanced assembly of cortical 
actin.  This forms an important structural association with ZO-1 and thus, indirect 
association with other tight junction components and has been frequently associated 
with enhanced barrier integrity (Birukova et al., 2007a). Consistent with this was the 
observation by Colgan et al. that shear exposure enhanced the co-association of ZO-1 
with occludin in BBMvEC’s (Colgan et al., 2007). Thus, it appears that prolonged shear 
enhances the structural assembly and integrity of tight complexes, but the mechanistic 
link mediating these shear-induced structural alterations in tight junction components 
needs to be deciphered.    
Recent findings from our laboratory indicated that inhibition of de-novo protein 
synthesis (by cycloheximide) could only partially attenuate the shear-induced increase in 
ZO-1-occludin co-association, thereby suggesting that post-translation modifications of 
the tight junction pool were essential for enhanced tight junction co-association, in 
tandem with increased protein expression (Collins et al., 2006, Colgan et al., 2007). We 
found that shear exposure in BBMvEC’s triggers a shift in pTyr-occludin levels, from 
being initially elevated in the acute shear phase (1 h) to being significantly attenuated 
well below basal levels in the chronic shear phase (24 h). Indeed, the latter finding on 
pTyr-occludin status (i.e. tyrosine dephosphorylated) is consistent with previous reports 
showing that pTyr-occludin levels are essential for barrier maintenance (Kago et al., 
2006, Peng et al., 2009). To further confirm the hypothesis that this post-translational 
state was imperative to tight junction assembly and barrier function, we observed that 
protein tyrosine phosphatase (PTP) inhibition with dephostatin significantly attenuated 
the shear-induced reduction with permeability. Recent work by Elias et al. identified 
specific pTyr-residues on occludin that were essential for its interaction with ZO-1 (at 
the C-terminus), a process which was regulated by the tyrosine kinase c-Src (Elias et al., 
2009). Based on all these findings it would imply that possibly other PTP’s (not 
inhibited by dephostatin) and protein tyrosine kinases (PTK’s) are mechano-regulated to 
target the tight junction, albeit through unknown mechanisms. Importantly though, these 
findings are consistent with previous reports by Lohmann et al. and Wachtel et al. who 
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showed that pharmacological blockade of tyrosine phosphatases alters barrier function at 
the BBB and peripheral vasculature respectively (Lohmann et al., 2004, Wachtel et al., 
1999). Identifying the molecular link(s) and specific PTP’s and PTK’s regulating these 
functions would be of genuine therapeutic relevance.        
Having established a series of structural and biochemical responses in BBMvEC’s to 
physiological shear, our attention turned towards potential signaling molecules 
mediating such effects. The RhoGTPases RhoA and Rac1 have been implicated as 
definitive regulators of cytoskeletal dynamics and vascular permeability, and as such we 
hypothesized that these molecules would participate in shear-dependent barrier 
regulation within BBMvEC’s (Hall, 1998, Spindler et al., 2010). GTPases function like 
molecular switches in response to upstream stimuli (i.e. shear stress) that propagate 
downstream signaling pathways through appropriate effector binding. In this regard, 
RhoA has been extensively linked with barrier dysfunction through its effector Rho-
associated kinase (ROCK) which drives actin-mediated cell contractility and 
intercellular junction disassembly (Birukova et al., 2004, Sun et al., 2006). By contrast, 
Rac1 has been well documented for its barrier-stabilizing effects by promoting cortical 
actin accumulation and intercellular junction assembly (Jacobson et al., 2006, Baumer et 
al., 2009).  
Both GTPases were shown to be mechanosensitive in BBMvEC’s, albeit with 
significant temporal disparity between their activation states. RhoA was rapidly 
activated following shear-onset (while Rac1-GTP was decreased), and we hypothesize 
that this initial, acute shear-phase response is essential to the cellular morphological 
adaptations and barrier enhancement observed following prolonged shear exposure 
(Wojciak-Stothard and Ridley, 2003). However, as the time course of shear exposure 
advances, a reciprocating trend towards Rac1 activity became more prominent, 
particularly in the chronic shear phase (24 h) as levels of Rac1-GTP at this stage were 
significantly elevated above basal levels whereas RhoA activity was significantly below 
baseline levels. This suggests a more central role for Rac1 in the maintenance of barrier 
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integrity under continued shear exposure, and as result, we decided to look more closely 
at the Rac1 participation in our shear-dependent model.  
To test this hypothesis further, we used two different strategies of Rac1 inhibition 
(NSC23766 and T17N), and we confirmed that Rac1 activity is essential to shear-
induced BBMvEC morphological realignment, enhancement of barrier function, cell-
cell border localization of ZO-1 and reduction in pTyr-occludin levels following 
prolonged shear exposure. Significantly though, these findings show that within 
BBMvEC’s, RhoGTPases can target the tight junction, which is consistent with previous 
findings (Wojciak-Stothard et al., 2001, Yamamoto et al., 2008). Thus, from this point 
on our primary focus was to expand on the signaling events linking shear-induced 
activation of Rac1 to changes in tight junction assembly and barrier function. 
Moving upstream of shear-mediated Rac1 activity, our focus shifted toward the 
mechanosensory adaptor protein VE-Cadherin which has been previously implicated in 
endothelial mechanotransduction processes (Shay-Salit et al., 2002, Tzima et al., 2005). 
Inhibition of VE-Cadherin by over-expressing VE-Cad∆EXD significantly abrogated 
the shear-induced activation of Rac1. VE-Cadherin has been previously shown to 
regulate RhoGTPase activity, to our knowledge however, no group has investigated the 
contribution of intercellular junctions to shear-dependent changes in Rac1 activity (Liu 
et al., 2007, Wallez and Huber, 2008). Moreover, we extended this inhibition strategy 
with VE-Cad ∆EXD to indices of BBMvEC barrier function and observed that shear-
induced membrane localization of ZO-1 and claudin-5, reduction in pTyr-occludin and 
enhancement of barrier function was significantly disrupted following VE-Cadherin 
inhibition. Thus, we confirm that under shear conditions, VE-Cadherin is targeting the 
tight junction, possibly via Rac1. This conforms to recent findings by Taddei et al. who 
identified a functional crosstalk mechanism between adherens and tight junctions, 
whereby VE-Cadherin was able to regulate claudin-5 expression (Taddei et al., 2008). 
Previous work by Orrington Myers et al. confirmed that VE-Cad ∆EXD disrupts lung 
endothelial barrier function in-vivo (Orrington-Myers et al., 2006). We anticipate that by 
restoring VE-Cadherin adhesion and function may not only alleviate vascular leakage, 
179 
 
but could rescue BBB function in associated pathologies by providing positive feedback 
on tight junction proteins. Thus, future work should focus on further clarification of the 
molecular mechanisms by which shear-induced regulation of VE-Cadherin regulates 
tight junction assembly.   
In an effort to further delineate this shear-induced signaling network, we assessed the 
participation of the Rho guanine nucleotide exchange factor (GEF) Tiam1 in our model. 
Tiam1 is Rac1-specific RhoGEF that is regulated by diverse signaling pathways 
including PI3K-dependent, protein-kinase A-dependent, tyrosine-kinase dependent and 
Epac-Rap1-dependent pathways (Arthur et al., 2004, O'Connor and Mercurio, 2001, 
Servitja et al., 2003, Welch et al., 2003). Furthermore, VE-Cadherin mediated cell-cell 
adhesion has been shown to activate Tiam1, thus forming our hypothesis that shear-
mediated activation of Rac1 via VE-Cadherin requires Tiam1 (Lampugnani et al., 2002). 
Indeed, shear-induced activation of Rac1 in BBMvEC’s was significantly attenuated by 
Tiam1 C580. When this inhibition strategy was incorporated into indices of barrier 
function, we noticed that the shear-mediated immunoreactivity of ZO-1 at cell-cell 
borders, reduction in pTyr-occludin and enhancement of barrier function was 
significantly disrupted following Tiam1 inhibition. We conclude that Tiam1 is essential 
to shear-mediated responses in our BBMvEC model, however as complete attenuation 
of shear-induced activation of Rac1 was not achieved with Tiam1 inhibition, we suspect 
that other GEF’s may be involved. Given the fact that Rac1 can regulate such diverse 
cellular processes, identification of these specific upstream mediators of shear-induced 
Rac1 activity will help identify appropriate molecular targets (Bosco et al., 2009).  
Based on our observations in BBMvEC’s and accepted findings throughout the 
literature, we now propose a signaling model by which shear stress upregulates barrier 
function and tight junction assembly (Figure 6.2). In brief, shear stress activates the 
mechanosensory complex (PECAM-1-VE-Cadherin-VEGFR2), which induces Tiam1 
and/or integrin-mediated Rac1 activation via PI3K (Tzima et al., 2005). Downstream 
effector(s) activation by Rac1 promotes the assembly of cortical actin, and the 
regulation of PTK’s and PTP’s, which together control pTyr-occludin levels and cell-
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cell border localization of ZO-1 and claudin-5 thus promoting tight junction assembly 
and barrier stability. 
 
 
Fig. 6.2: Signaling mechanisms mediating the barrier-stabilizing influence of shear 
stress in BBMvEC’s. PECAM-1, platelet endothelial cell adhesion molecule 1; 
VEGFR2, vascular endothelial growth factor receptor 2; p120/α/β-catenins; PI3K, 
phosphoinisotide 3-OH-kinsae; Shc, Src-homology SH2 domain adaptor protein; PTP, 
protein tyrosine phosphatase; PTK, protein tyrosine kinase; ZO-1, zonula occludens 1.          
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Although not examined in this body of research, we acknowledge the possible 
contribution of integrins to the barrier stabilizing influence of shear in BBMvEC’s. 
Integrins comprise a family of transmembrane receptors that facilitate cell-matrix 
adhesion but have been implicated in flow-mediated responses. In this regard, shear-
dependent activation of the mechanosensory complex has been shown to activate PI3K, 
consequently leading to integrin (αvβ3) activation, which imply a degree of cross talk of 
mechanosensing mechanisms originating from cell-cell and cell-matrix contacts (Tzima 
et al., 2005). Furthermore, Rac1 activation has been shown to occur downstream of 
shear-induced integrin activation (Tzima et al., 2002). Crucial to the integration of both 
signaling mechanisms is Shc, an SH2 adaptor protein which orchestrates signals from 
both cell-cell and cell-matrix adhesions to elicit flow-induced signaling (Liu et al., 
2008b, Sweet and Tzima, 2009). Future work should therefore clarify the contribution of 
integrins (and Shc), in conjunction with VE-Cadherin, to the shear signaling cascade 
during BBB stabilization.  
In an attempt to mimic the evolution of cerebrovascular injury experienced during 
cerebral ischemia, we investigated the effect of flow reduction on BBMvEC barrier 
function (Krizanac-Bengez et al., 2004, del Zoppo, 2008). This experimental paradigm 
involved a “pre-conditioning” phase under physiological conditions (10 dynes cm-2, 24 
h) followed by a sustained (10 dynes cm-2, for a further 24 h) or reduced (1 dyne cm-2, 
24 h) flow phase. Significantly, flow reduction attenuated the shear-induced BBMvEC 
morphological realignment, enhancement of barrier function, ZO-1 cell-cell border 
localization and reduction in pTyr-occludin. Indeed, the latter finding is consistent with 
recent findings from in-vivo BBB models showing that cerebral ischemia enhances 
pTyr-occludin levels, therefore supporting the applicability of our model (Kago et al., 
2006, Takenaga et al., 2009). Therefore, future work should explore the signaling 
mechanisms pertaining to these effects. In this regard, we hypothesize that decreased 
shear would alter cytoskeletal machinery leading to barrier disassembly, possibly via 
RhoA. Moreover, this pathological state is associated with increased levels of reactive 
oxygen species (ROS) which have been previously shown to disrupt barrier integrity, 
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and their participation within this context should also be addressed (Lee et al., 2004, 
Monaghan-Benson and Burridge, 2009).  
Although our shearing model of orbital rotation has been previously validated and was 
suitable for generating substantive quantities of sheared cells for IB, IP and IC analyses,   
BBMvEC permeability via transendothelial permeability assay could be not monitored 
in real time (Pearce et al., 1996, Fitzpatrick et al., 2009, Colgan et al., 2007, 
Hendrickson et al., 1999). Shearing of BBMvEC’s in transwell inserts was not feasible 
as cells would be exposed to basolateral turbulence, and thus would not reflect the in-
situ condition of apical shear exposure. As a consequence, BBMvEC’s following 
shearing protocols had to be replated and left to adhere overnight on transwell inserts 
before permeability could be monitored. In this regard, EC’s have previously 
demonstrated ‘mechanical memory’ capabilities under a similar protocol following 
prolonged exposure of cyclic strain in bovine aortic endothelial cells (Collins et al., 
2006). The dynamic in-vitro (DIV)-BBB model would be a suitable alternative as it 
allows for real-time monitoring of BBB function under flow conditions by direct 
quantification of transendothelial electrical resistance (TEER) (Flocel Inc., Cleveland, 
Ohio). DIV-BBB is a novel, tri-dimensional, perfused trans-capillary apparatus 
consisting of an enclosed bundle of 19 semi-permeable (0.2µm) Pronectin®-coated 
capillaries within a DIV-BBB cartridge, through which medium from a reservoir is 
pumped at a chosen flow rate.  (Figure 6.3). Each cartridge contains built in electrodes 
which connect to a computer controlled device for monitoring TEER. Moreover, the 
DIV-BBB allows for co-culturing of cell-types within spatially distinct compartments 
i.e. intralumenial space (EC’s) and extralumenial space (astrocytes) whilst facilitating 
solute diffusion via 0.2µm trans-capillary pores, giving a closer representation of the in-
vivo brain micro-environment and an accurate in-vitro model to study BBB function 
(Krizanac-Bengez et al., 2006, Santaguida et al., 2006). Thus, acquiring such a multi-
dimensional model would be invaluable for future cell modeling work assessing 
molecular/pharmacological based inhibition strategies targeting BBB permeability. 
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Fig. 6.3: Representation of DIV-BBB model and computer controlled TEER 
monitoring device. (A): Schematic representation of the DIV-BBB module cartridge 
and model set-up, (B): actual set-up of DIV-BBB with flow path and medium reservoir, 
(C): DIV-BBB cartridges contain electrodes in the lower half of the module and are 
connected to the TEER measurement system (Flocel Inc.) allowing for computer 
controlled monitoring of BBB function in real time. 
 
Finally, although bovine models are a suitable surrogate system for biological research, 
proof-of-concept experiments on BBB function should be replicated in human primary 
cells. In this regard, we recently acquired primary, human brain microvascular 
endothelial cells (HBMvEC’s), from which we hypothesize that future experiments on 
BBB function will yield similar findings to those observed within our BBMvEC model. 
Indeed, initial findings with HBMvEC’s demonstrating shear-induced (10 dyne cm-2, 24 
h) morphological realignment and enhanced ZO-1 immunoreactivity at cell-cell borders 
184 
 
are consistent with our observations from the BBMvEC model (Figure 6.4). Future work 
should expand on these basic findings and monitor the role of various signaling 
mediators, i.e. Rac1, integrins, RhoGEF’s in shear-dependent regulation. Moreover, the 
RasGTPase ‘Rap1’ has received much recent attention for its role in regulating cell-cell 
adhesion and as an upstream mediator of Rac1-induced barrier stability, however its 
participation in shear-mediated processes remains to investigated (Adamson et al., 2008, 
Birukova et al., 2007b, Birukova et al., 2008, Spindler et al., 2010).  
 
Fig. 6.4: Effect of laminar shear stress on HBMvEC re-alignment, F-actin 
organization and ZO-1 localization. Confluent HBMvEC’s were exposed to laminar 
shear stress (10 dynes cm-2, 24 h) using a novel IBIDI® perfusion flow system and 
monitored for morphological realignment by phase-contrast microscopy (i-ii) and 
fluorescent microscopy (Olympus, FV10i confocal microscope) using a double-stain 
procedure for F-actin (red) and ZO-1 (green) (iii-iv). White arrow indicates direction of 
the flow (iii). Blue arrow indicates ZO-1 cell-cell border localization (iv). Images are 
representative.        
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In conclusion, it was demonstrated that laminar shear stress is a dynamic regulator of 
tight junction assembly and barrier function within BBMvEC’s. Our findings implicate a 
putative link between shear-induced regulation of tight junction proteins (ZO-1, 
occludin, claudin-5) and endothelial permeability. Furthermore, we partially elucidated 
the signaling mechanism mediating the shear-dependent induction of tight junction 
assembly, which involved a VE-Cadherin-Tiam1-Rac1 signaling axis. Multiple 
signaling pathways (including RhoGTPases) have been previously implicated in tight 
junction regulation, including heterotrimeric G-proteins, serine-, threonine-, and tyrosine 
kinases, intracellular calcium levels, cytokines and extracellular matrix proteins 
(Wolburg et al., 1994, Schulze et al., 1997, Lu et al., 2000, Wolburg and Lippoldt, 
2002). However it is our belief that we are the first group to specifically investigate the 
signaling mechanism(s) mediating shear-induced regulation of tight junctions 
specifically within the BBB, thus establishing molecular targets of genuine relevance to 
neurological diseases manifesting through manipulations of BBB tight junctions. It is 
anticipated that these findings may also transfer to other areas of the vasculature, and 
thus impact on non-neurological diseases associated with endothelial barrier dysfunction 
in peripheral vasculature, e.g. atherosclerosis in coronary arteries leading to myocardial 
infarction.     
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